WO2010151879A1 - Photolabile compounds - Google Patents
Photolabile compounds Download PDFInfo
- Publication number
- WO2010151879A1 WO2010151879A1 PCT/US2010/040220 US2010040220W WO2010151879A1 WO 2010151879 A1 WO2010151879 A1 WO 2010151879A1 US 2010040220 W US2010040220 W US 2010040220W WO 2010151879 A1 WO2010151879 A1 WO 2010151879A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- bond
- forms
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 337
- 238000000034 method Methods 0.000 claims abstract description 81
- 238000002372 labelling Methods 0.000 claims abstract description 75
- 239000012472 biological sample Substances 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 179
- 125000003118 aryl group Chemical group 0.000 claims description 131
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 101
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims description 85
- 229960004979 fampridine Drugs 0.000 claims description 77
- 229910052757 nitrogen Inorganic materials 0.000 claims description 72
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 125000002619 bicyclic group Chemical group 0.000 claims description 42
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 41
- -1 -C3-C8 cycloalkyl Chemical group 0.000 claims description 39
- 125000002950 monocyclic group Chemical group 0.000 claims description 37
- 125000004437 phosphorous atom Chemical group 0.000 claims description 33
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 31
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 29
- 125000004122 cyclic group Chemical group 0.000 claims description 27
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 26
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 22
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 210000002569 neuron Anatomy 0.000 claims description 19
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 18
- 229960002715 nicotine Drugs 0.000 claims description 18
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 18
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 17
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000004076 pyridyl group Chemical group 0.000 claims description 17
- 125000004434 sulfur atom Chemical group 0.000 claims description 17
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 16
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 16
- 229950006790 adenosine phosphate Drugs 0.000 claims description 16
- 125000002837 carbocyclic group Chemical group 0.000 claims description 16
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- 230000001537 neural effect Effects 0.000 claims description 15
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 14
- 150000002825 nitriles Chemical class 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 13
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 11
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 11
- 229960001948 caffeine Drugs 0.000 claims description 11
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 229940076279 serotonin Drugs 0.000 claims description 11
- 229960002989 glutamic acid Drugs 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 9
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 9
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 229960003638 dopamine Drugs 0.000 claims description 9
- 229960005139 epinephrine Drugs 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 229960002748 norepinephrine Drugs 0.000 claims description 9
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 9
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 8
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 8
- 229960001456 adenosine triphosphate Drugs 0.000 claims description 8
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 8
- 229940124277 aminobutyric acid Drugs 0.000 claims description 8
- 230000000926 neurological effect Effects 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 208000018360 neuromuscular disease Diseases 0.000 claims description 5
- UKBRUIZWQZHXFL-UHFFFAOYSA-N Tet-glycine Chemical group OC(=O)C(N)C=1N=NNN=1 UKBRUIZWQZHXFL-UHFFFAOYSA-N 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 208000019838 Blood disease Diseases 0.000 claims description 3
- 231100001015 blood dyscrasias Toxicity 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 claims description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 2
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 230000000536 complexating effect Effects 0.000 claims description 2
- 208000013219 diaphoresis Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 231100000640 hair analysis Toxicity 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 25
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000000975 bioactive effect Effects 0.000 abstract description 6
- 230000001627 detrimental effect Effects 0.000 abstract description 4
- 230000035899 viability Effects 0.000 abstract 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 127
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 43
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 230000000694 effects Effects 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000003814 drug Substances 0.000 description 20
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 17
- 238000001228 spectrum Methods 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 229940049906 glutamate Drugs 0.000 description 15
- 229930195712 glutamate Natural products 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- SJNALLRHIVGIBI-UHFFFAOYSA-N allyl cyanide Chemical compound C=CCC#N SJNALLRHIVGIBI-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000006862 quantum yield reaction Methods 0.000 description 13
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
- 239000007850 fluorescent dye Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 230000007170 pathology Effects 0.000 description 10
- 238000006303 photolysis reaction Methods 0.000 description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 230000015843 photosynthesis, light reaction Effects 0.000 description 9
- 229940043267 rhodamine b Drugs 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 208000003098 Ganglion Cysts Diseases 0.000 description 8
- 241000237902 Hirudo medicinalis Species 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 208000005400 Synovial Cyst Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 8
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 150000003841 chloride salts Chemical class 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 229960005305 adenosine Drugs 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 5
- 101100242814 Caenorhabditis elegans parg-1 gene Proteins 0.000 description 5
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000011369 resultant mixture Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 241000545744 Hirudinea Species 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002484 cyclic voltammetry Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000000295 emission spectrum Methods 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 210000000609 ganglia Anatomy 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 108010069934 methionyl-aspartyl-phenylalaninamide Proteins 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- GWOGSJALVLHACY-UHFFFAOYSA-N 2-pyridin-2-ylpyridine;ruthenium Chemical group [Ru].N1=CC=CC=C1C1=CC=CC=N1 GWOGSJALVLHACY-UHFFFAOYSA-N 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical group Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000005281 excited state Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000012421 spiking Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- SIWKJSQISPNWDG-IHRRRGAJSA-N (3s)-3-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-4-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SIWKJSQISPNWDG-IHRRRGAJSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- 229920002972 Acrylic fiber Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910017673 NH4PF6 Inorganic materials 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- GKKWUSPPIQURFM-IGDGGSTLSA-N Prostaglandin E2 ethanolamide Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)NCCO GKKWUSPPIQURFM-IGDGGSTLSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 210000003520 dendritic spine Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000003473 flash photolysis reaction Methods 0.000 description 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 150000003017 phosphorus Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003463 sulfur Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 2
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 2
- PLQQKRPSINJWTK-VNMBDIRDSA-N (2s,3r,4s,5r)-2-[[(6ar,8r,9r,9as)-8-(6-amino-8-bromopurin-9-yl)-4,9-dihydroxy-2,4-dioxo-6a,8,9,9a-tetrahydro-6h-furo[3,2-f][1,3,5,2,4]trioxadiphosphocin-2-yl]oxy]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O1)O)N2C=3N=CN=C(C=3N=C2Br)N)OP(O)(=O)OP1(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O PLQQKRPSINJWTK-VNMBDIRDSA-N 0.000 description 1
- CLLFEJLEDNXZNR-UUOKFMHZSA-N (4ar,6r,7r,7as)-6-(6-amino-8-chloropurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Cl CLLFEJLEDNXZNR-UUOKFMHZSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 description 1
- 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- YUFCOOWNNHGGOD-UMMCILCDSA-N 8-bromo-3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1Br YUFCOOWNNHGGOD-UMMCILCDSA-N 0.000 description 1
- ZJYIMUUTYALQDP-UHFFFAOYSA-N 9,10,11-trihydroxynonadecane-8,12-dione Chemical compound CCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCC ZJYIMUUTYALQDP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100478297 Arabidopsis thaliana SR45 gene Proteins 0.000 description 1
- FOXXZZGDIAQPQI-XKNYDFJKSA-N Asp-Pro-Ser-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FOXXZZGDIAQPQI-XKNYDFJKSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229910001200 Ferrotitanium Inorganic materials 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CIPFCGZLFXVXBG-FTSGZOCFSA-N Inositol 1,3,4,5-tetraphosphate Chemical compound O[C@H]1C(OP(O)(O)=O)[C@H](O)[C@@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H]1OP(O)(O)=O CIPFCGZLFXVXBG-FTSGZOCFSA-N 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 229910021135 KPF6 Inorganic materials 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027462 Metastases to ovary Diseases 0.000 description 1
- 241000078511 Microtome Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001715 Osteoblastoma Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 150000003999 cyclitols Chemical class 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical class CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
- JGUQDUKBUKFFRO-CIIODKQPSA-N dimethylglyoxime Chemical compound O/N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-CIIODKQPSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 1
- 125000006086 furo[3,2-b]pyridinyl] group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000011858 nanopowder Substances 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000008906 neuronal response Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000006223 plastic coating Substances 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 125000004424 polypyridyl Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- OCQZXMCGTAWGEQ-UHFFFAOYSA-N prop-2-enamide;n-[(prop-2-enoylamino)methyl]prop-2-enamide Chemical compound NC(=O)C=C.C=CC(=O)NCNC(=O)C=C OCQZXMCGTAWGEQ-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003115 supporting electrolyte Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates generally to novel Photolabile Compounds and methods for uncaging an organic molecule, such as a bioactive molecule, which can have a variety of uses both in vitro and in vivo.
- Photolabile protecting groups which are also called caging groups, are classes of protecting groups that are particularly useful in the biological sciences. Because light can be controlled with precision both spatially and temporally, cleaving a protecting group from a bioactive molecule allows release, or uncaging, of the molecule. Protecting groups typically mask or conceal charged (for example, carboxylate or phosphate) or polar (for example, amine, hydroxyl, or sulfhydryl) groups on the compounds. Frequently such functionalities increase the hydrophobicity and membrane permeability of the protected molecules. Prior to photolysis, the Photolabile Compounds are typically chemically or biologically inactive because at least one of the compounds' main functionalities is blocked.
- the activity of the molecule can be triggered by a pulse of light, thereby releasing the molecule from the photoreleasable compound.
- photolabile protecting groups can be removed from a protected compound by irradiation, for example, to control the release of the compound when and where desired, either in vivo or in vitro.
- Photolabile Compounds typically require ultraviolet (UV) light to remove the compounds from the cage.
- UV light can cause damage to organs, tissues and cells, thus making UV light detrimental for in vivo use.
- the present invention provides novel Photolabile Compounds and methods for using the compounds, which provide advantages over currently available compounds that are photolabile using only UV light.
- the present invention provides compounds of Formula I:
- R'-R 8 are independently -H, -Ci-C 18 alkyl, -NH 2 , -COOH, -(Ci-Ci 8 alkyl)-O-(Ci-Ci 8 alkyl), or -OC(OXC-C 8 alkyl); and
- X is CI ' , F, Br ⁇ I “ , PF 6 “ , CF 3 SO 3 " , (Ci-Ci 8 alkyl)-CO 2 " , or (Ci-Ci 8 alkyl)-SO 3 " .
- L 2 is (R 9 ) 3 P, (R 9 O) 3 P, or L 1 and m is 2; or L 2 is -CN and m is 1 ;
- R'-R 8 are independently -H, -Ci-Ci 8 alkyl, -NH 2 , -COOH, -(Ci-Ci 8 alkyl)-O-(Ci-Ci 8 alkyl), or -OC(O)(C, -C ) 8 alkyl); and X is Cl “ , F, Br “ , I “ , PF 6 “ , CF 3 SO 3 " , (Ci-C 18 alkyl)-CO 2 ' , or (Ci-C 18 alkyl)-SO 3 " .
- each phenyl is not substituted with methyl.
- each L 1 is independently an organic molecule having:
- R'-R 8 are independently -H, -C 1 -Ci 8 alkyl, -NH 2 , -COOH, -(Ci-Ci 8 alkyl)-O-(Ci-C, 8 alkyl), or -OC(O)(C-C 8 alkyl); and
- X is Cl “ , F, Br “ , I ⁇ PF 6 “ , CF 3 SO 3 ' , (Ci-C 8 alkyl)-CO 2 " , Or (C-C 8 alkyl)-SO 3 " .
- L 2 is (R 9 ) 3 P, (R 9 O) 3 P, or L 1 and m is 2; or L 2 is -CN and m is 1 ;
- R'-R 8 are independently -H, -C-C 8 alkyl, -NH 2 , -COOH, -(Ci-C 18 alkyl)-O-(C,-C 8 alkyl), Or -OC(O)(C-C 8 alkyl); and X is Cl “ , F, Br “ , T, PF 6 " , CF 3 SO 3 -, (C-C 8 alkyl)-CO 2 " , or (C,-C, 8 alkyl)-SO 3 " .
- each R 9 is different from each other.
- each phenyl is not substituted with methyl.
- the present invention provides compounds of Formula III:
- L 1 is 4-aminopyridine (4-AP), whose pyridyl nitrogen atom forms a bond with Ru;
- R'-R 8 are independently -H, -Ci-Ci 8 alkyl, -NH 2 , -COOH, -(Ci-C 18 alkyl)-O-(C,-C, 8 alkyl), or -OC(O)(Ci-Ci 8 alkyl);
- X is Cl ⁇ F, Br ⁇ T, PF 6 ' , CF 3 SO 3 -, (Ci-C 8 alkyl)-CO 2 ⁇ or (C 1 -Ci 8 alkyl)-SO 3 ⁇
- R'-R 8 are independently -H, -Ci-Ci 8 alkyl, -NH 2 , -COOH, -(C 1 -Ci 8 alkyl)-O-(Ci-C ) 8 alkyl), or -OC(O)(C-C 18 alkyl); and X is Cl ⁇ F, Br “ , I ⁇ PF 6 " , CF 3 SO 3 " , (C 1 -C 8 alkyl)-CO 2 -, or (C-C 18 alkyl)-SO 3 ⁇
- each R 9 is different from each other.
- two R 9 are the same and different from the remaining R .
- each phenyl is not substituted with methyl.
- the present invention provides compounds of Formula FV:
- M 1 is Li + , Na + , or K + ;
- M 2 is Ru; and L 1 is independently an organic molecule having:
- the present invention provides compounds of Formula V:
- each L 1 is independently an organic molecule having:
- X is Cl “ , F, Br “ , I “ , PF 6 “ , CF 3 SO 3 “ , (Ci-C 18 alkyl)-CO 2 " , or (Ci-C 18 alkyl)-SO 3 " ;
- Y is selected from the group consisting of -H, -Ci-C] 8 alkyl, aryl, -(Ci-Ci 8 alkyl)-aryl, -C 3 -C 8 cycloalkyl, heteroaryl, and heterocyclyl.
- each L 1 is independently an organic molecule having:
- X is Cl “ , F, Br “ , I ⁇ PF 6 “ , CF 3 SO 3 " , (Ci-Ci 8 alkyl)-CO 2 " , or (C-Ci 8 alkyl)-SO 3 " ;
- each R 9 is different from each other.
- each phenyl is not substituted with methyl.
- each L 1 is independently an organic molecule having:
- X is Cl “ , F, Br “ , I “ , PF 6 “ , CF 3 SO 3 “ , (C-C 8 alkyl)-CO 2 ⁇ or (C-C 8 alkyl)-SO 3 " ;
- Y is selected from the group consisting of -H, -C-C) 8 alkyl, aryl, -(C-Ci 8 alkyl)-aryl, -C 3 -C 8 cycloalkyl, heteroaryl, and heterocyclyl.
- each L 1 is independently an organic molecule having:
- X is Cl “ , F, Br “ , I ⁇ PF 6 “ , CF 3 SO 3 " , (C,-C, 8 alkyl)-CO 2 " , or (C 1 -Ci 8 alkyl)-SO 3 " ;
- Y is selected from the group consisting of -H, -Ci-Ci 8 alkyl, aryl, -(Ci-Ci 8 alkyl)-aryl, -C 3 -C 8 cycloalkyl, heteroaryl, and heterocyclyl.
- each R 9 is different from each other.
- each phenyl is not substituted with methyl.
- each L 1 is independently an organic molecule having:
- X is Cl “ , F, Br ⁇ I " , PF 6 ' , CF 3 SO 3 ' , (Ci-C )8 alkyl)-CO 2 ⁇ , or (C 1 -C 18 alkyl)-SO 3 " ;
- Y is selected from the group consisting of -H, -Ci-Ci 8 alkyl, aryl, -(Ci-Ci 8 alkyl)-aryl, -C 3 -C 8 cycloalkyl, heteroaryl, and heterocyclyl.
- each L 1 is independently an organic molecule having:
- L 2 is (R 9 )3P, (R 9 O) 3 P, or L 1 , wherein each R 5 is independently -Ci-Ci 8 alkyl, -C 3 -C 8 cycloalkyl, or phenyl, m is 2, and L 2 is not P(phenyl) 3 ; or L 2 is -CN and m is 1 ;
- X is Cl “ , F, Br ⁇ I “ , PF 6 ⁇ CF 3 SO 3 " , (C I -C I 8 alkyl)-CO 2 ⁇ or (C 1 -C, 8 alkyl)-SO 3 " ;
- Y is selected from the group consisting of -H, -Ci-Ci 8 alkyl, aryl, -(Ci-Ci 8 alkyl)-aryl, -C 3 -C 8 cycloalkyl, heteroaryl, and heterocyclyl.
- each R 9 is different from each other.
- X is Cl “ , F, Br ⁇ I ⁇ PF 6 ' , CF 3 SO 3 ' , (C 1 -C 18 alkyl)-CO 2 " , or (C 1 -C 18 alkyl)-SO 3 " ;
- Y is selected from the group consisting of -H, -Ci-C] 8 alkyl, aryl, -(C 1 -Ci 8 alkyl)-aryl, -C 3 -C 8 cycloalkyl, heteroaryl, and heterocyclyl.
- each L is independently a labeling molecule
- X is Cl “ , F, Br “ , I “ , PF 6 “ , CF 3 SO 3 “ , (Ci-C 18 alkyl)-CO 2 " , or (C 1 -Ci 8 alkyl)-SO 3 " ;
- Y is selected from the group consisting of -H, -Ci-Ci 8 alkyl, aryl, -(Ci-Ci 8 alkyl)-aryl, -C 3 -C 8 cycloalkyl, heteroaryl, and heterocyclyl.
- each R 9 is different from each other.
- each phenyl is not substituted with methyl.
- L 2 is Rhodamine B-Methylaminopropionitrileamide (RhodB-MAPN).
- RhodG-MAPN Rhodamine G- Methylaminopropionitrileamide
- L 2 is:
- L 2 is:
- the labeling molecule is rhodamine B. In some embodiments of the compounds of Formula I-III and V-VIII, the labeling molecule is rhodamine 6G.
- the present invention provides a composition comprising an effective amount of a Photolabile Compound and a physiologically acceptable carrier, vehicle, diluent, or excipient.
- the present invention provides a vessel containing a Photolabile Compound.
- the present invention provides a kit comprising a Photolabile Compound and instructions for use.
- Another aspect of the present invention provides methods for releasing an organic molecule or a labeling molecule from a Photolabile Compound, comprising exposing a Photolabile Compound to light under conditions sufficient to release the organic molecule or labeling molecule.
- the present invention provides a method for making an organic molecule bioavailable to a subject in need of the organic molecule, comprising administering a Photolabile Compound to the subject; and exposing the compound to light under conditions sufficient to release the organic molecule from the compound.
- the present invention provides methods for treating diseases and disorders in a subject, comprising: (a) administering a Photolabile Compound to the subject; and (b) exposing the Photolabile Compound to light under conditions sufficient to release the organic molecule from the Photolabile Compound.
- the diseases and disorders treated by the methods of the invention include neurological, neurophysiological, or neuromuscular diseases and conditions, such as epilepsy and multiple sclerosis; cancers; diaphoresis; and blood dyscrasias.
- the present invention provides methods for assaying an organic molecule, comprising: (a) exposing a Photolabile Compound and a biological sample to light under conditions sufficient to release the organic molecule from the Photolabile Compound, and (b) determining an effect of the organic molecule on the biological sample.
- the invention provides a compound selected from the group consisting of: [Ru(bpy)2(RhodB-MAPN)Cl]Cl, [Ru(bpy)2(Rhod6G-MAPN)Cl]Cl, [Ru(bpy)2(RhodB-MAMePy)Cl]Cl.
- the invention provides a compound selected from the group consisting of: [Ru(bpy)2(RhodB-MAPN)Cl]Z, [Ru(bpy)2(Rhod6G-MAPN)Cl]Z, [Ru(bpy)2(RhodB-MAMePy)Cl]Z, wherein Z is an anion.
- Fig. 2 shows action potentials (spikes) recorded in a medicinal leech ⁇ Hirudo medicinalis) neuron for saline and solutions of [Ru(bpy) 3 ]Cl 2 and [Ru(bpy) 2 (4 AP) 2 ]Cl 2 (Bottom): Frequency of the spikes. Arrows indicate irradiation with Xe flashlamp. (Middle): Composition of the extracellular medium.
- Fig. 3 shows cyclic voltammetry (CV) profile of [Ru(bpy) 2 (4AP) 2 ]Cl 2 in water.
- the supporting electrolyte was KNO3 (1 M).
- dE/dt 100 mV/s in glassy carbon electrode.
- Figs. 4A and 4B show NMR spectra of [Ru(bpy) 2 (4AP) 2 ]Cl 2 in D 2 O before (Fig. 4A) and after (Fig. 4B)irradiation. Bruker 500 MHz.
- Fig. 5 shows the UV-visible (UV-vis) spectra of Ru(bpy) 2 (4AP) 2 before and after complete photolysis.
- the photoproducts after exposure to light were Ru(bpy) 2 (4AP)(H 2 O) and free 4AP.
- the complex did not undergo dark decomposition for more than 20 hours. After 7 hours in the dark, the irradiated solution showed less than 4% of 4AP recombination.
- Fig. 6 shows a UV-vis spectrum of the filter used for the ganglion irradiation experiments as described in Example 3.
- Figs. 7 A and 7B show action potentials and frequency of the spikes obtained in studies of medicinal leech ⁇ Hirudo medicinalis) ganglia.
- Fig. 7A shows a recording of Retzius neuron voltage activity during perfusion of free 4AP on the leech ganglia.
- [4AP] 0, 10, 20 and 50 mM.
- Flow rate lml/min.
- Fig. 7B shows the recording of Retzius neuron activity during exposure to a 0.1 msec flash of green light through the filter of FIG. 6.
- Flow rate l ml/min.
- Carrier saline solution, as described in Example 3. Pulse energy: 0.5 J.
- Figs. 8A and 8B relate to spectra changes of [Ru(bpy) 2 (4AP) 2 ]Cl 2 during exposure to light.
- Fig. 8B Fraction of [Ru(bpy) 2 (4AP)(H 2 ⁇ )] 2+ as a function of irradiation time obtained from the spectra depicted in FIG. 8A.
- Fig. 11 depicts a graph of total two-photon fluorescence versus excitation wavelength of [Ru(bpy) 2 (4AP) 2 ]Cl 2 .
- Fig. 12 presents a UV-vis spectrum of TzGIy before and after irradiation with 400-600 nm light.
- Figs. 14A-G relate to experiments performed on neurons contacted with [Ru(bpy) 2 (TzGly)(py )]C1 2 .
- Figs. 14A, B and C show fluorescent-image micrographs of a neuron, including magnified views of dendritic spines.
- Fig. 14D shows the effect of laser irradiation ( ⁇ 40 mW) on the spiking of a single neuron in the presence of [Ru(bpy) 2 (TzGly) 2 ]Cl 2 .
- Figs. 14E-G relate to experiments carried out as controls to the experiments of Figs. 14A-D.
- Figs. 14E and F show magnified views of the dendritic spines of a neuron.
- Fig. 14G' presents a plot showing the effect of laser irradiation on a control neuron in the absence of [Ru(bpy) 2 (TzGIy) 2 ]Cl 2 . No increased activity is observed. Pulse length: 10 ms; Power: 40 mW; Wavelength: 720 nm.
- FIG. 15 depicts a cyclic voltammetry (CV) profile of native [Ru(bpy) 2 (PMe 3 )Glu] at 100 mV/s on Pt wire electrode in CH 3 CN containing 100 mM TBAPF 6 .
- Fig. 17 shows the aromatic section of the 1 H-NMR spectra of [Ru(bpy) 2 (PMe 3 )Glu] in D 2 O before (upper trace) and after (lower trace) photolysis, showing the aromatics signals of [Ru(bpy) 2 (PMe 3 )H 2 O] 2+ .
- Fig. 18 shows the aliphatic section of the 1 H-NMR spectrum of [Ru(bpy) 2 (PMe 3 )Glu] in D 2 O before (upper trace) and after (lower trace) photolysis. In the last case, the signals at 3.50, 2.30, 2.04 and 1.94 ppm correspond to free glutamate.
- Fig. 19 shows 1 H NMR aliphatic region spectra of the complex [Ru(bpy) 2 (RhodB-MAPN)Cl] + (A) before irradiation. (B) after 5 min irradiation. (C) free RhodB-MAPN spectrum. Note in B that the signals of the free ligand a, b, and c are apparent, indicating its photorelease. The signals d and e, corresponding to the ethyl groups in RhodB-MAPN, are far from the coordination center and therefore do not suffer big changes. A photolysis reaction schematic is added for clarity.
- Fig. 20 shows emission spectra of a 10 ⁇ M aqueous solution of the complex [Ru(bpy) 2 (RhodB-M APN)Cl] + during irradiation of the cuvette with a 473 nm laser diode. A spectrum was measured every 10 s. Inset shows emission maxima during irradiation.
- the present invention relates generally to Photolabile Compounds comprising organic molecules or labeling molecules and methods for using the Photolabile Compounds.
- the organic molecules can be biologically active.
- an organic molecule e.g., a biologically active molecule, is protected and subsequently released upon exposure to light, advantageously, visible light.
- visible light e.g., a visible light pulse
- samples e.g., organs, tissues or cells, or subjects to which a Photolabile Compound is administered, undergo only minimal, if ' any, exposure to UV radiation, which has detrimental effects on cellular components and, ultimately, on cell growth and viability.
- the Ru-organic molecule bond or Ru-labeling molecule bond is normally weaker than a covalent ⁇ bond, and therefore can be broken using a lower energy irradiation. Further in accordance with this invention, and without wishing to be bound by theory, the energy required for the release of an organic molecule or a labeling molecule by exposure to light is relatively low.
- the organic molecule or labeling molecule is photoreleased by irradiation of the Photolabile Compound using light as described herein.
- Photolabile Compounds are also suitable for use in non-biological systems, such as in solar cells, photocells, or an optical memory, e.g., a three dimensional optical memory.
- the invention encompasses a compound of Formula I:
- R'-R 8 , L'_ L 2 , X, M and m are as defined above for the compounds of Formula I.
- the invention encompasses a compound of Formula II:
- R'-R 8 , L 1 , L 2 , X and m are as defined above for the compounds of Formula II.
- the invention encompasses a compound of Formula III:
- R -R , L L , X and m are as defined above for the compounds of Formula III.
- the invention encompasses a compound of Formula IV:
- the invention encompasses compounds of Formula V:
- R'-R 4 , L 2 , X and m are as defined above for the compounds of Formula V.
- the invention encompasses a compound of Formula VI:
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl) 3 and each phenyl is independently substituted at the 3 or 4 position.
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl) 3 and at least one phenyl is substituted with -(C
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl) 3 and each phenyl is substituted with -(Ci-Ci 8 alkyl)-OH.
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl)3 and at least one phenyl is substituted with -COOH.
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl) 3 and each phenyl is substituted with -OH.
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl) 3 and at least one phenyl is substituted with -NH 2 .
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl)3 and each phenyl is substituted with -NH 2 .
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl)3 and at least one phenyl is substituted with -NO 2 .
- the invention encompasses a compound of Formula VI, wherein L 2 is P(phenyl)3 and each phenyl is substituted with -NO 2 .
- the invention encompasses a compound of
- L 1 is an organic molecule comprising PMe 2 whose phosphorus atom forms a bond with Ru.
- the invention encompasses a compound of
- L 1 is an organic molecule comprising P(phenyl) 2 whose phosphorus atom forms a bond with Ru.
- the invention encompasses a compound of
- R'-R 4 , L 1 , L 2 , X and m are as defined above for the compounds of Formula VII.
- the invention encompasses a compound of
- the invention encompasses a compound of
- the invention encompasses a compound of
- L 1 is an organic molecule comprising PMe 2 whose phosphorus atom forms a bond with Ru.
- the invention encompasses a compound of
- L 1 is an organic molecule comprising P(phenyl) 2 whose phosphorus atom forms a bond with Ru.
- the invention encompasses a compound of
- the Photolabile Compounds of Formulas I-VIII can exist in a cis or trans configuration. Accordingly, Formulas I-VIII encompass both cis and trans forms of the Photolabile Compounds.
- the term "-(Ci-Ci 8 ) alkyl" refers to a saturated straight or branched non-cyclic hydrocarbon having 1 to 18 carbon atoms.
- Representative saturated straight chain -(Ci-Ci 8 ) alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonyl, -n-decyl, -n- undecyl, -n-dodecyl, -n-tridecyl, -n-tetradecyl, -n-pentadecyl, -n-hexadecyl, -n- heptadecyl and -n-octadecyl.
- Representative saturated branched -(Ci-Ci 8 ) alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -2-methylbutyl, -3- methylbutyl, -2,2-dimethylbutyl, -2,3-dimethylbutyl, -2-methylpentyl, -3-methylpentyl, -4-methylpentyl, -2-methylhexyl, -3-methylhexyl, -4-methylhexyl, -5-methylhexyl, - 2,3-dimethylbutyl, -2,3-dimethylpentyl, -2,4-dimethylpentyl, -2,2-dimethylhexyl, -2,3- dimethylhexyl, -2,4-dimethylhexyl, -2,5-dimethylhexyl,
- aryl refers to an aromatic group containing 1 to 3 aromatic rings, either fused or linked.
- heterocyclic group or “heterocyclic” or “heterocyclyl” or “heterocyclo” as used herein refers to fully saturated, or partially or fully unsaturated, including aromatic (i.e., “heteroaryl”) cyclic groups (for example, 4 to 7 membered monocyclic, 7 to 1 1 membered bicyclic, or 10 to 16 membered tricyclic ring systems) which have at least one heteroatom in at least one carbon atom-containing ring.
- aromatic i.e., "heteroaryl”
- Each ring of the heterocyclic group containing a heteroatom may have 1 , 2, 3, or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized.
- the heterocyclic group may be attached to the remainder of the molecule at any heteroatom or carbon atom of the ring or ring system.
- heterocyclic groups include, but are not limited to, azepanyl, azetidinyl, aziridinyl, dioxolanyl, furanyl, furazanyl, homo piperazinyl, imidazolidinyl, imidazolinyl, isothiazolyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl,
- cyclic aliphatic amine or "cyclic aliphatic amine group” as used herein refers to a non-aromatic secondary amine or tertiary cyclic amine group.
- examples of cyclic aliphatic amines include, but are not limited to, aziridine and piperidine.
- active derivative refers to a chemical derivative of a labeling molecule, which retains the labeling function of the labeling molecule (e.g., its fluorescence properties).
- active derivative offers superior properties for attachment to Ru atom through a phosphine group, an aliphatic amine group, an imine group, a pyridyl group, or a nitrile group.
- a specific example of an active derivative of rhodamine (a labeling molecule) is B-Methylaminopropionitrileamide (RhodB- MAPN).
- RhodB- MAPN B-Methylaminopropionitrileamide
- An amino acid group such as an ⁇ -amino acid
- An amino acid is an organic molecule having an amino group (-NH 2 ) and a carboxylic acid group.
- An amino acid can be one of the 20 common ⁇ -amino acids (GIy, Ala, VaI, Leu, He, Ser, Thr, Asp, Asn, Lys, GIu, GIn, Arg, His, Phe, Cys, Trp, Tyr, Met and Pro), or another naturally occurring amino acid, such as norleucine, ethylglycine, ornithine, gamma-amino butyric acid, and phenylglycine.
- Examples of a 6-membered monocyclic aromatic ring, wherein one of the ring's members is a nitrogen atom, include a pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl ring.
- Examples of a 5-membered monocyclic aromatic ring, wherein one of the ring's members is a nitrogen atom, include a pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, thiazolyl and thiadiazolyl ring.
- Examples of an 8-10-membered bicyclic aromatic ring, wherein one of the rings is aromatic and has a nitrogen atom member include an indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, l ,3,7-trimethyl-2,6-dioxopurinyl, quinazolinyl, cinnolinyl, pteridinyl, 6-amino-l H-purinyl and 2-aminohypoxanthinyl bicyclic aromatic ring.
- Illustrative organic molecules can further include luciferin, enzyme inhibitors, fatty acids (e.g., arachidonic acid), protein kinase C activators (e.g., dioctanoylglycerol), tubulin assembly promoters (e.g., paclitaxel), antibiotics (e.g., penicillins or A23187), neurotransmitters (e.g., L-glutamic acid, aspartic acid, carbamylcholine, dopamine, epinephrine, GABA, glutamic acid, glycine, haloperidol, isoproterenol, kainic acid, NMDA, NMDA receptor antagonist MK-801, norepinephrine, phenylephrine, propranolol), 4-aminopyridine (4AP), serotonin (5 hydroxy triptamine, 5HT), (RS)-(tetrazol-5-yl) glycine (Tz
- organic molecules include adenosine 5'- diphosphate ADP; adenosine 5'-triphosphate ATP; adenosine 5'-monophosphate AMP; aminobutyric acid; L-glutamic acid; cyclic adenosine 5'-diphosphate ribose; adenosine 3', S'-cyclicmonophosphate; fluorescein; methyl-D-aspartic acid; tyramine; tryptophan; 4-aminopyridine (4AP); epinephrine; norepinephrine; dopamine; serotonin (5 hydroxy triptamine, 5HT); (RS)-(tetrazol-5-yl) glycine (TzGIy), which is a potent N- methyl-D-aspartate receptor (NMDA) agonist; tetrazolyl- ⁇ -amino-3-hydroxy-5- methyl-4-iso
- NMDA N-
- the organic molecule ligands glutamate, gamma aminobutyric acid (GABA), alaninate, glycinate and the like have been demonstrated to photorelease from a Photolabile Compound after exposure to visible light; such Photolabile Compounds are stable in solutions in addition to water.
- Organic molecules having an -NH 2 group or an -COOH group may be released in solvents other than water, for example, alcohol (e.g., methanol, ethanol), acetone, etc.
- the organic molecule of the invention include phosphorus derivatives with a -PR. 2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci ⁇ alkyl, or aryl.
- exemplary phosphorus derivatives include dimethylphosphinyl, diethylphosphinyl, and diphenylphosphinyl.
- the organic molecule of the invention include sulfur derivatives with an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently - H, -Ci-C] 8 alkyl, or aryl.
- Exemplary sulfur derivatives include isopropyl beta-D-1- thiogalactopyranoside (IPTG), thioethers, thiolates, methylthio, ethylthio, and phenylthio.
- a fluorescent molecule can be selected from bodipy, dansyl, fluorescein, rhodamine, Texas red, cyanine dyes, pyrene, coumarins, Cascade BlueTM, Pacific Blue, Marina Blue, Oregon Green, 4',6-Diamidino-2-phenylindole (DAPI), indopyra dyes, lucifer yellow, propidium iodide, porphyrins, arginine, and variants and derivatives thereof.
- DAPI 6-Diamidino-2-phenylindole
- fluorescent label moieties and fluorescence techniques see, e.g., Handbook of Fluorescent Probes and Research Chemicals, by Richard P. Haughland, Sixth Edition, Molecular Probes, (1996), which is hereby incorporated by reference in its entirety.
- the Photolabile Compounds of Formulas I-I1I and V-VIII where L 2 is other than Li can be made by allowing about a molar equivalent of Ru(bdt) 2 Cl 2 , where bdt is bipyridine or phenanthroline substituted with an Ri-Rs group as defined in Formulas I- III or R 1 -R 4 group as defined in Formulas V- VIII, to react with about a molar equivalent of an organic or labeling molecule in water, ethanol, methanol, isopropyl alcohol, ethylene glycol, acetone, methylene chloride or a mixture thereof at reflux under nitrogen.
- the resultant solution is cooled and to it is added at least about an equivalent of L 2 .
- the resultant mixture is heated at reflux for about 4 to about 20 h.
- the resultant solution is diluted with water, and to it is added excess NH 4 PF O .
- the resultant precipitate is filtered, purified via silica-gel chromatography, dried and dissolved in acetone. (H-Bu) 4 NH 4 + X, wherein X is defined in Formula I-III and V-VIII, is added to the acetone solution, and the resultant Photolabile Compound of Formula I-III and V- VIII where L 2 is other than L] is filtered.
- Li can be made by allowing about a molar equivalent of Ru(bdt) 2 Cl 2 , where bdt is bipyridine or phenanthroline substituted with an Ri-R 8 group as defined in Formulas I- IUI or Ri-R 4 group as defined in Formulas V- VIII, to react with an excess amount of an organic or labeling molecule in water, ethanol, methanol, isopropyl alcohol, ethylene glycol, acetone, methylene chloride or a mixture thereof at reflux under nitrogen. After about 4 to about 8 hours, the resultant solution is cooled to room temperature. The resultant mixture is diluted with water, and to it is added excess NH 4 PF O .
- the Photolabile Compounds of Formula IV where M 2 is Ru can be obtained by dissolving about 1 molar equivalent of (M')3[M 2 (CN)sNH 3 ] 2H 2 O, where M 1 is defined in Formula IV, in about 15 mL of argon-deoxygenated 1 :1 ethanol:water containing about 10 molar equivalents of the organic molecule.
- the resultant mixture is maintained at about room temperature under argon for about 1 hour and concentrated in vacuo at about room temperature to a volume of about 1 mL.
- To the resultant concentrate is added a cold, saturated ethanol solution of M 1 I, resulting in a precipitation of the Photolabile Compounds of Formula IV where M 2 is Ru, which are washed with ethanol and diethyl ether.
- photorelease can generally occur rapidly, e.g., after about a few nanoseconds to about 500 milliseconds ( See Salierno et al., J Inorg Biochem. 2010 104(4):418-22) following exposure to visible light of the appropriate wavelength.
- Suitable wavelengths of light for effective photorelease of an organic molecule or a labeling molecule from a Photolabile Compound range from about 300 to about 500 nm, or from about 300 to about 360 nm, or from about 450 to about 500 nm, e.g., 473 nm and may be extended up to 700nm.
- Suitable light sources include those which are capable of irradiating light of the appropriate wavelengths, for example and without limitation, commercially available tungsten lamps (Cole-Parmer), arc lamps, xenon continuous lamps, lasers, e.g., blue or green lasers or photooptic light sources.
- Such light sources are commercially available (CrystaLaser, Reno, Nevada; Lasever, Jiangdong, Ningbo, China).
- Other forms of light such as sunlight, infrared light, pulsed infrared light, or UV radiation can also be used for the invention, as necessary or desired.
- Devices and systems suitable for exposing the Photolabile Compounds to light further include imaging probes, imaging catheters and fiber optic probes, particularly those containing gradient index, or graded-index, (GRTN) lenses, which are described in U. Utzinger et al., 2003, J. Biomed. Optics, 8(1): 121-147; and Fujimoto et al., Photonic Materials, Devices and Systems - Laser Medicine and Medical Imaging Group, RLE Progress Report 144, pp 27-1 to 27-35, and which are commercially available. (Sp3 plus, UK).
- GRTN gradient index, or graded-index,
- the light suitable for exposing the Photolabile Compounds to photorelease an organic molecule or a labeling molecule comprises a wavelength of about 300 to about 500 nm, or about 300 to about 360 nm, or about 450 to about 500 nm.
- Suitable light includes visible or infrared light.
- the organic molecules or labeling molecules can also be released from the Photolabile Compounds via one- photon or two-photon photolysis.
- Optical memories that utilize a two-photon excitation are described, for example, by Strickler and Webb, 1991 , Optics Letters, 16: 1780-1782.
- a feature of two-photon excitation is the elimination of out-of-focus background. ⁇ See, e.g., W. Denk et al., 1990, Science, 248:73-76).
- two-photon uncaging can release an organic molecule or a labeling molecule only in the plane of focus. (See, e.g., W. Denk et al., 1994, Proc Natl. Acad Sci. USA, 91 :6629-6633).
- the present invention encompasses a compound of
- the invention encompasses a compound of Formula I, wherein the organic molecule is 4-AP. In another embodiment, the invention encompasses a compound of Formula I, wherein the organic molecule is TzGIy. In another embodiment, the invention encompasses a compound of Formula I, wherein the organic molecule is (tetrazol-5-yl) AMPA. In another embodiment, the invention encompasses a compound of Formula I, wherein the organic molecule is nicotine or caffeine. In another embodiment, the invention encompasses a compound of Formula I, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine.
- the present invention encompasses a compound of Formula I, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', 5'-cyclicmonophosphate.
- the invention encompasses a compound of Formula I wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D-aspartic acid.
- the present invention encompasses a compound of
- the invention encompasses a compound of Formula II, wherein the organic molecule is 4-AP.
- the invention encompasses a compound of Formula II, wherein the organic molecule is TzGIy.
- the invention encompasses a compound of Formula II, wherein the organic molecule is (tetrazol-5-yl) AMPA.
- the invention encompasses a compound of Formula II, wherein the organic molecule is nicotine or caffeine.
- the invention encompasses a compound of Formula II, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine.
- the present invention encompasses a compound of Formula II, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5 '-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate.
- the invention encompasses a compound of Formula II, wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D-aspartic acid.
- the present invention encompasses a compound of
- Formula IV wherein the organic molecule is 4-AP.
- the invention encompasses a compound of Formula IV, wherein the organic molecule TzGIy.
- the invention encompasses a compound of Formula IV, wherein the organic molecule is (tetrazol-5-yl) AMPA.
- the invention encompasses a compound of Formula IV, wherein the organic molecule is nicotine or caffeine.
- the invention encompasses a compound of Formula IV, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine.
- the present invention encompasses a compound of Formula IV, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate.
- the invention encompasses a compound of Formula IV, wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D- aspartic acid.
- the present invention encompasses a compound of
- the invention encompasses a compound of Formula V, wherein the organic molecule 4-AP.
- the invention encompasses a compound of Formula V, wherein the organic molecule is TzGIy.
- the invention encompasses a compound of Formula V, wherein the organic molecule is (tetrazol-5-yl) AMPA.
- the invention encompasses a compound of Formula V, wherein the organic molecule is nicotine or caffeine.
- the invention encompasses a compound of Formula V, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine.
- the present invention encompasses a compound of Formula V, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'- diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate.
- the invention encompasses a compound of Formula V wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D-aspartic acid.
- the present invention encompasses a compound of
- Formula VI wherein the organic molecule is 4-AP.
- the invention encompasses a compound of Formula VI, wherein the organic molecule is TzGIy.
- the invention encompasses a compound of Formula
- the organic molecule is (tetrazol-5-yl) AMPA.
- the invention encompasses a compound of Formula VI, wherein the organic molecule is nicotine or caffeine.
- the invention encompasses a compound of Formula VI, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine.
- the present invention encompasses a compound of Formula VI, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate.
- the invention encompasses a compound of Formula VI wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D- aspartic acid.
- the present invention encompasses a compound of
- Formula VII wherein the organic molecule is 4-AP.
- the invention encompasses a compound of Formula VII, wherein the organic molecule is TzGIy.
- the invention encompasses a compound of Formula
- the organic molecule is (tetrazol-5-yl) AMPA.
- the invention encompasses a compound of Formula VII, wherein the organic molecule is nicotine or caffeine.
- the invention encompasses a compound of Formula VII, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine.
- the present invention encompasses a compound of Formula VII, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate.
- the invention encompasses a compound of Formula VII wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D- aspartic acid.
- the present invention encompasses a compound of
- the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is fluorescein. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is iodeosin. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is a fluorescent molecule containing a -CN group whose nitrogen atom forms a bond with Ru.
- the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is a fluorescent molecule containing a pyridyl group whose nitrogen atom forms a bond with Ru.
- the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is a fluorescent molecule containing an amino group whose nitrogen atom forms a bond with Ru.
- the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is a fluorescent molecule containing a phosphine group whose nitrogen atom forms a bond with Ru.
- the invention encompasses a compound of
- the labeling molecule is rhodamine containing a -CN group whose nitrogen atom forms a bond with Ru.
- the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine containing a pyridyl group whose nitrogen atom forms a bond with Ru.
- the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine containing an amino group whose nitrogen atom forms a bond with Ru.
- the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine containing a phosphine group whose nitrogen atom forms a bond with Ru.
- the labeling molecule is rhodamine containing a phosphine group whose nitrogen atom forms a bond with Ru.
- the labeling molecule or an active derivative thereof is bonded to Ru to Ru through other coordinating groups: -NH2, pyridyl, or a phosphine group.
- L 2 comprises a labeling molecule or an active derivative thereof, which can serve as a light antenna and can transfer energy to the portion of the compound that effects photorelease of moiety L 1 .
- a Photolabile Compound has a dual functional ization, one being a light antenna and second being a photorelease entity.
- a Photolabile Compound can be used in combinatorial chemistry strategies. For example, one could generate a systematic series of derivatives in the photorelease part of the molecule and perform large-scale screening with them. Alternatively or in addition, one could fix the photorelease part of the molecule while derivatizing the light antenna moiety.
- Photolabile Compound are used as a means of indentifying it or manipulating it in living cells.
- Photolabile Compounds are used as MRI (Magnetic Resonance Imaging) contrast agents.
- L 2 comprises a labeling molecule such as a fluorophore or a derivative thereof
- L 2 can servean antenna, to extend the irradiation spectrum to lower energies with very high absorption and efficiency.
- the fluorescent dye is linked through a derivatization using a non-releasable ligand, i.e., a phosphine ( :P(R) 2 -fluorophore).
- a non-releasable ligand i.e., a phosphine ( :P(R) 2 -fluorophore).
- the light is collected by the fluorescent moiety acting as an antenna, and transferred to the Ru center, populating the MLCT or d-d excited states. Once the excited state is reached, the other ligand (i.e., L 1 , which can be a biomolecule or drug) is released.
- the active wavelength is not determined by the Ru center but by the high absorption of the fluorescent dye (-100,000 M 1 Cm " ') allows the tuning of different complexes having different photouncageable drugs at different wavelengths, from 400 to 600 nm, providing orthogonality.
- a suitable organic dye coordinated to the ruthenium next to the coordinated fluorescent dye permits the selective quenching of the fluorescence due to its proximity.
- the absorption of light via the Ru- bpy MLCT band without antenna effect, the fluorescent being quenched by the nearby nonfluorescent dye
- can photorelease either the fluorescent dye increasing dramatically the fluorescence and "uncaging" the fluorophore, or the nonfluorescent quencher, with somewhat similar results (under some conditions, however, the presence of the metallic center can quench the fluorophore).
- V-VIII wherein R 1 and R 2 and/or R 3 and R 4 combine to form a carbocyclic ring substituted by one or more oxo groups, can attach to surfaces and are useful for the delivery of compounds to surfaces.
- such compounds can bind to nanoparticles or nanopowders and be used to deliver biologically active organic molecules or labeling molecules.
- Nanoscale delivery systems have substantial applications in the controlled and targeted transport of drugs. Drugs can be carried selectively to targeted cells by means of nanoparticles with specific surface fictionalization. Nanoparticles can penetrate cell membranes and overcome physiological barriers in the organism, and nanoparticles can also improve the solubility and bio-availability of drugs.
- the invention provides a method for enhancing the solubility of an organic molecule, comprising complexing an organic molecule to a photolabile caging group to form a Photolabile Compound, such that exposing the compound to light under sufficient conditions releases the organic molecule from the compound.
- the organic molecule has:
- the present invention encompasses a composition comprising an effective amount of a Photolabile Compound and a physiologically acceptable carrier, vehicle, diluent, or excipient.
- a physiologically acceptable carrier vehicle, diluent, or excipient.
- suitable carriers, vehicles, diluents, or excipients are known to those skilled in the art and include, without limitation, physiologically sterile saline and others as described herein.
- the present invention provides a vessel containing a Photolabile Compound.
- the vessel can further contain a biological sample, wherein the sample is, for example, hair, an organ specimen; a tissue or cell, for example, a neuronal tissue or cell; a tumor or cancer or neoplastic tissue or cell; or a tissue or cell removed from a patient or subject of interest.
- Tissue specimens sliced from microtomes are examples of suitable biological samples.
- any type of vessel that is capable of transmitting the wavelengths of light used for releasing the organic molecules or labeling molecules comprising the Photolabile Compounds, and that is inert to solvent in which a Photolabile Compound is suspended, is suitable for use.
- the vessel can be made of glass, plastic, acrylic, quartz, a noble metal, etc.
- the vessel is composed of, or encased in, metal, e.g., aluminum, titanium, or stainless steel, exposure to light is performed through the top of the vessel, or through a "window" or other light-penetrable opening in the vessel.
- acrylic plastic or acrylamide-bisacrylamide gel, etc. can be used as media in which the Photolabile Compounds are contained.
- an acrylic plastic coating formulated using a CHCb solution of acrylic and a Ru(bpy) complex changed its spectrum following irradiation, thus allowing photorelease in a solid state.
- the temperature may be kept at 4K.
- Solvents suitable in which a Photolabile Compounds can be exposed to light include aqueous solvents; water; acetonitrile; alcohol, e.g., methanol, ethanol; acetone; chlorinated solvents such as CH 2 Cl 2 and CHCb; or dimethylsulfoxide.
- Suitable temperatures at which a Photolabile Compound is exposed to light range, in general, from about 0°C to about 100-150 0 C.
- this invention encompasses a method for releasing an organic molecule or a labeling molecule from a Photolabile Compound.
- the method comprises exposing a Photolabile Compound to light under conditions sufficient to release the organic molecule or labeling molecule from the compound.
- the light comprises a wavelength of about 300 to about 500 nm, or about 300 to about 360 nm, or about 450 to about 500 nm.
- the exposing can occur at a temperature from about O 0 C to about 150°C.
- the methods of the invention comprise a Photolabile Compound, e.g., a compound of Formula I-VIII, light of a wavelength of about 300 nm to about 500 nm; L 1 being L 2 , and a temperature of about 0°C to about 15O 0 C.
- the methods comprise a Photolabile Compound, light of a wavelength of about 300 nm to about 360 nm; L 1 being L 2 , and a temperature of about 0 0 C to about 150 0 C.
- the methods comprise a Photolabile Compound, light of a wavelength of about 450 nm to about 500 nm; L 1 being L 2 , and a temperature of about O 0 C to about 150 0 C.
- the methods comprise a Photolabile Compound, visible or infrared light; L 1 being L 2 , and a temperature of about O 0 C to about 150 0 C.
- the invention encompasses a method for assaying an organic molecule, comprising exposing a Photolabile Compound and a biological sample to light under conditions sufficient to release the organic molecule from the Photolabile Compound, and (b) determining an effect of the organic molecule on the biological sample.
- the sample can be a biological sample, such as a sample excised, removed, or otherwise taken from a subject's body.
- the subject's biological sample can be, for example, a hair sample, an organ or tissue sample, e.g., from a biopsy or an autopsy, or a cell sample.
- the biological sample can be a body fluid sample.
- Body fluid samples include, without limitation, blood, serum, plasma, lymph, saliva, sputum, tears, semen, or urine.
- Biological samples can further include, without limitation, brain tissue, brain cells, muscle tissue, muscle cells, muscle fibers, fibroblasts, tissue slices, or fine tissue specimens, from any organ of the body, sarcoplasmic reticulum, skin tissue, membrane preparations or fragments, etc.
- the light for exposing the compounds according to the methods of this invention can be sunlight, photo-optic light, or laser light.
- the light for exposing the compound is other than UV radiation.
- the light can be visible light or infrared light, including one-photon and two-photon light.
- the light can be emitted from a variety of sources, including without limitation, a laser light source, a tungsten light source, a photooptic light source, etc.
- Another advantage of visible light to expose or irradiate the compounds of the invention relates to the convenience and ability to use a visible light microscope, for example, to view a sample into which a compound is introduced and to microscopically visualize or monitor a photoreleased ligand from the compound after exposure to visible light. Because many microscopes do not transmit UV light, it is advantageous to be able to use a non-quartz microscope in accordance with this invention. Yet another advantage to the use of visible light is that it is not detrimental to living cells and tissues, making it beneficial for in vivo patient use. In addition, for patient use, the light can be specifically directed to an area where a Photolabile Compound is introduced or administered by the use of laser technology, fibers, probes, tubes, and the like. Such probes, fibers, or tubes can be directly inserted, for example, into a body cavity or opening, or under or through the skin, to expose the Photolabile Compound to light.
- the present invention includes a method of making an organic molecule bioavailable to a subject.
- the organic molecule can be made bioavailable to a localized body region or area of the subject, or systemically to the whole body. Local bioavailability of the Photolabile Compounds is achieved, for example, via delivery devices and methods that allow the compounds to be directly administered, for example, inserted into a body cavity, or opening, or through or into the skin.
- the method of this embodiment involves administering a Photolabile Compound to the subject, and exposing the compound to light under conditions sufficient to release the organic molecule from the compound, thereby making the organic molecule bioavailable to the subject, and/or to a body site or region of the subject.
- the exposure to light can comprise the use of probes, fibers, tubes, and the like, which allow the light to be specifically directed to the area of interest on or within the body.
- the Photolabile Compounds can be administered to the patient kept in the dark; for photorelease of the organic molecule, the patient can be moved to the light where exposure to light and photorelease occur.
- the organic molecule has: (a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
- the organic molecule has:
- the Photolabile Compounds are useful for releasing an organic molecule, such as a drug, pharmaceutical, small biologically active molecule, and the like as described above. Release of the organic molecule from the Photolabile Compound allows the organic molecule to become bioavailable to a subject, or patient, afflicted with a disease, disorder, pathology, or condition.
- the Photolabile Compounds and organic molecules are useful in veterinary and human medicine.
- Diseases, disorders, pathologies, or conditions for which making an organic molecule bioavailable would serve to treat, ameliorate, reduce, eliminate, abate, or prevent the disease, disorder, pathology, or condition are further described below and include, as nonlimiting examples, peripheral and central nervous system disorders, neurological disorders and disorders related thereto, neurodegenerative disorders and disorders related thereto, epilepsy, seizures, migraines, headaches, stroke, anxiety, depression, restricted brain function, addictive disorders, neuroses, psychoses, pruritic conditions, Parkinson's disease, Huntington's chorea, cognitive disorders, memory lapses, Alzheimer's disease, dementia, dyskinesia, muscle spasms, retinopathy, vomiting, cancers, neoplasms, tumors, vascular diseases, and cardiovascular diseases.
- the organic molecule is a neurochemical that blocks potassium channels for use, for example, in treating neurodegenerative, or neurological diseases or disorders.
- the organic molecule is 4-AP, which is a calcium channel blocker.
- the organic molecule is TzGIy, which is an NMDA-receptor agonist that is more potent than NMDA.
- the exposure of the Photolabile Compound to light can occur at the site of the disease, disorder, pathology, or condition, such as a site of a tumor, neoplasm, or cancer lesion or growth, thereby releasing the organic molecule locally and more precisely at the needed location.
- the exposure of the Photolabile Compound to light can occur at the sight of a blood dyscrasia.
- the present invention provides methods for treatment, therapy, and prophylaxis by administering an effective amount of a Photolabile Compound, or a physiologically acceptable composition comprising a Photolabile Compound to a subject, so as to make an organic molecule bioavailable to the subject.
- the Photolabile Compound can be substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side- effects).
- the light e.g., infrared, laser, or visible light
- the light for photore I easing the organic molecule to make it bioavailable to the subject
- photooptic devices, probes and fibers such as are known in the art and described supra.
- Those having skill in the art can employ, manipulate, and internally direct the devices for exposing a Photolabile Compound to light after the Photolabile Compound is administered to a subject.
- the subject is preferably an animal, including but not limited to, mammals such as human and non-human primates, cows, pigs, horses, goats, sheep, rabbits, chickens, cats, dogs, guinea pigs, rats, mice, etc.
- mammals such as human and non-human primates, cows, pigs, horses, goats, sheep, rabbits, chickens, cats, dogs, guinea pigs, rats, mice, etc.
- the methods of the invention especially encompass human treatments.
- Photolabile Compound e.g., in sterile solution, encapsulation in liposomes, microparticles, microcapsules, or receptor-mediated endocytosis (See, e.g., Wu and Wu, 1987, J. Biol. Chem., 262:4429-4432).
- Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, topical, transdermal, parenteral, intrathecal, vaginal, rectal, colorectal, oral, intracranial, retroorbital, intrasternal routes, or a combination thereof.
- the Photolabile Compounds or compositions may be administered by any convenient route or mode, for example, by continuous infusion, non-continuous infusion, or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, epidermis, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active and/or therapeutic agents. Administration can be systemic or local.
- Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
- Photolabile Compounds or compositions locally to the area in need of treatment. This may be achieved, for example, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, where the implant is a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
- a transdermal patch can be used.
- the Photolabile Compound remains unexposed to light until the patch is manipulated by a patient or medical provider so that all or a portion of the patch containing a Photolabile Compound is exposed to light.
- the patch can be opened and the bioactive molecule released, or "activated" from the compound after exposure to light, for example, by the patient's moving from a dark room to a lighted room, or from a dark area to a light area; by the patient's directly exposing the patch, or a portion thereof, to a suitable light source, or by the patient's exposing all or a portion of the patch to daylight.
- a Photolabile Compound can be formulated into a light-sensitive composition, which is contained in a dark, light- protected container, and applied topically to the area of interest, e.g., applied to or rubbed onto the skin of a subject, in the dark. Following topical application in the dark, the area of interest is exposed to light, or to an appropriate light source, or the subject moves into the light, thereby causing the organic molecule of the Photolabile Compound to be released.
- the Photolabile Compounds or compositions can be delivered in a vesicle, in particular a liposome ⁇ See, e.g., Langer, 1990, Science, 249: 1527-1533; Treat et al., In: Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.)
- the Photolabile Compounds or compositions can be delivered in a controlled-release system.
- a pump may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201 ; Buchwald et al., 1980, Surgery, 88:507; Saudek et al., 1989, NEJM, Med. 321 :574 (1989)), or polymeric materials can be used (See, e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Press, Boca Raton, FIa. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev.
- a controlled-release system can be placed proximal to the therapeutic target, e.g., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, In: Medical Applications of Controlled Release, Vol. 2, pp. 1 15-138).
- other controlled release systems are found in Langer, 1990, .S 1 CIeTiCe, 249: 1527-1533.
- the Photolabile Compounds are also provided in effective amounts in pharmaceutical compositions comprising a pharmaceutically acceptable carrier, diluent, excipient, or vehicle, for example, for use as therapeutics.
- a pharmaceutically acceptable carrier for example, for use as therapeutics.
- pharmaceutically acceptable refers to approval by a regulatory agency of the Federal or a state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly, in humans.
- vehicle, carrier, or excipient refer to a diluent or adjuvant in or with which the therapeutic is administered.
- Such pharmaceutical carriers, vehicles, or excipients can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when a pharmaceutical composition is administered intravenously and is water soluble. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. If needed or desired, the composition of the invention can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the Photolabile Compounds and compositions of the present invention can be formulated as solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like.
- the compositions can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
- Oral formulations can include standard carriers, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers and the like are described in the current edition of "Remington's Pharmaceutical Sciences" by E. W. Martin.
- Such compositions routinely contain a therapeutically effective amount of the Photolabile Compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to a subject.
- the formulation should suit the mode of administration.
- a Photolabile Compound of the invention is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
- compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
- the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection.
- the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container, such as an ampoule or sachette indicating the quantity of active agent.
- composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- Sterility for of a composition for therapeutic administration is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
- Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- Therapeutics are typically stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. Where necessary, the ampoule or vial is essentially impenetrable by light.
- a lyophilized therapeutic formulation 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous therapeutic solution, and the resulting mixture is lyophilized.
- the infusion solution is prepared by reconstituting the lyophilized therapeutic using bacteriostatic Water-for-Injection.
- the amount of a Photolabile Compound which will be effective in the treatment, amelioration, reduction, elimination, inhibition, or prevention of a particular disease, condition, pathology, or disorder associated with the use and bioactivity of an organic molecule can be determined by standard clinical techniques.
- An "effective amount” or a “pharmaceutically effective amount” of a Photolabile Compound of this invention refers to an amount effective for treating, ameliorating, reducing, abating, eliminating, preventing, a disease, condition, pathology, or disorder for which the compound is being used.
- an effective amount is an amount effective for making an organic molecule of the invention bioavailable to a subject.
- the effective amount of the therapeutic agent refers to an amount effective for providing the therapeutic effect of the therapeutic agent.
- the precise dose to be employed in the formulation will also depend on the route of administration, as well as an individual patient's circumstances, such as age, health and vital statistics of the patient, and the severity of the disease, condition, or disorder. Dosing should be decided according to the judgment of the medical practitioner based on an evaluation of the patient and considerations of a patient's physiologic situation and medical history. In addition, in vitro assays may optionally be used to assist in determining optimal dosage ranges. Effective doses can be extrapolated from dose-response curves derived from in vitro or in vivo animal model test systems.
- Compound administered parenterally per dose will be in the range of about 1 ⁇ g/kg/day to 10 mg/kg/day of a subject's body weight, although, as noted above, this will be subject to discretion based on the subject's condition and the above-mentioned variables.
- a therapeutic dose can also be at least 0.01 mg/kg/day, or between about 0.01 and 1 mg/kg/day, with particular regard for human administration. If given continuously, a therapeutic is typically administered at a dose rate of about 1 ⁇ g/kg/hour to about 50 ⁇ g/kg/hour, either by 1 to 4 injections per day or by continuous subcutaneous infusions, e.g., using a mini-pump.
- An intravenous bag solution may also be employed.
- suitable effective dosage amounts range from about 10 ⁇ g to about 2500 mg about every 4 hours, although the amounts are typically about 100 mg or less.
- the effective dosage of a Photolabile Compound ranges from about 0.01 mg to about 100 mg about every 4 hours.
- the effective dosage of a compound of the invention ranges from about 0.020 mg to about 50 mg every 4 hours, and in another embodiment, about 0.025 mg to about 20 mg about every 4 hours.
- the effective dosage amounts refer to total amounts administered. Thus, if more than one of the Photolabile Compounds is administered, the effective dosage amounts correspond to the total amount administered.
- an effective amount will typically range from about 0.01 ⁇ g/L to about 5 mg/L; in another embodiment from about 0.01 ⁇ g/L to about 2.5 mg/L; in another embodiment, from about 0.01 ⁇ g/L to about 0.5 mg/L; and in yet another embodiment, from about 0.01 ⁇ g/L to about 0.25 mg/L of a solution or suspension of a pharmaceutically acceptable carrier, diluent, or excipient.
- the volume of solution or suspension is from about 1 ⁇ L to about 1 mL; in another embodiment, the volume of solution or suspension is about 200 ⁇ L.
- neoplastic or hyperproliferative diseases, disorders, pathologies, or conditions that can be treated, ameliorated, reduced, abated, eliminated, inhibited, prevented, and/or diagnosed using the Photolabile Compounds and photoreleased organic molecules include, but are not limited to, neoplasms (cancers or tumors) located in the colon, abdomen, bone, breast, digestive system, esophagus, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovaries, cervix, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thoracic areas, bladder, and urogenital system.
- neoplasms cancers or tumors located in the colon, abdomen, bone, breast, digestive system, esophagus, liver, pancreas, peritoneum, endocrine glands (
- Cancers that may be treatable using the Photolabile Compounds include follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer, or metastases thereof.
- Autoimmune diseases, disorders, or conditions may be treatable with the Photolabile Compounds and include multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Bechet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis, rheumatoid arthritis, ischemic injury (e.g., caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (e.g., caused by alcohol), septic shock, cachexia and anorexia.
- Viral infections such as herpes viruses, pox viruses and adenoviruses
- inflammation graft versus host (GVH) disease, acute graft rejection
- Additional diseases or conditions associated with abnormal and increased cell survival that may be treated, ameliorated, reduced, abated, eliminated, inhibited, prevented, and/or diagnosed using the Photolabile Compounds include, but are not limited to, progression and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia, including myeloblasts, promyelocytic, myelomonocytic, monocytic, and erythroleukemia) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to,
- the Photolabile Compounds may be needed as therapeutics to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and the healing of dermal wounds.
- the Photolabile Compounds of the invention may be clinically useful in stimulating wound healing, including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment using steroids, radiation therapy, anti-neoplastic drugs and anti-metabolites.
- Photolabile Compounds include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Retinitis pigmentosa (RP), cerebellar degeneration and brain tumor or prior associated disease).
- AIDS neurodegenerative diseases, disorders, and/or conditions
- ALS amyotrophic lateral sclerosis
- RP Retinitis pigmentosa
- cerebellar degeneration and brain tumor or prior associated disease.
- diseases and conditions that are treatable using calcium channel blockers include without limitation, heart disease, hypertension, angina, chest pain, cardiovascular diseases, such as coronary artery disease, cardiomyopathies, valvular heart disease, renal disease, Peyronie's disease and neurological, neurophysiological, or neuromuscular diseases and conditions, e.g., amyotrophic lateral sclerosis (ALS), multiple sclerosis, and epilepsy.
- cardiovascular diseases such as coronary artery disease, cardiomyopathies, valvular heart disease, renal disease, Peyronie's disease and neurological, neurophysiological, or neuromuscular diseases and conditions, e.g., amyotrophic lateral sclerosis (ALS), multiple sclerosis, and epilepsy.
- ALS amyotrophic lateral sclerosis
- multiple sclerosis multiple sclerosis
- diseases that are treatable using NMDA receptor agonists or antagonists include without limitation, neurological, neurodegenerative, or neurophysiological diseases, disorders, and conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and dyskinesias.
- neurological, neurodegenerative, and neurophysiological diseases e.g., Parkinson's disease, Alzheimer's disease, etc.
- kits comprising a Photolabile Compound and instructions for use.
- a kit may be used in a diagnostic, screening, or testing assay.
- [Ru(bpy) 2 (5HT)(PPh 3 )]Cl 2 is made according to the procedure used to make [Ru(bpy) 2 (4AP)(PPh 3 )]Cl 2 set forth in Example 4, except that serotonin is used in place of 4AP.
- [Ru(bpy) 2 (4 AP) 2 ]Cl 2 is very soluble in water and stable in the dark, while undergoing decomposition under irradiation with visible light in its metal-to- ligand charge transfer (MLCT) band, centered at 489 nm.
- MLCT metal-to- ligand charge transfer
- the absorption band is red-shifted to 492 nm, consistent with the lower polarity of the solvent, despite a previous characterization that reported 450 nm.
- light exposure of a CH3CN solution of [Ru(bpy) 2 (4AP)2]Cl2 produced a yellow compound with abso ⁇ tion maximum at 450 nm. This may correspond to the previously misinterpreted assignments for this compound (D.
- FIG. 1 shows the signal assigned to the meta hydrogens [Ru(bpy) 2 (4AP) 2 ]Cl 2 (ml). After irradiation, this signal decreased, and two new signals appeared at lower fields: one corresponding to the free ligand (m3), and the other corresponding to the aquo-4AP complex (m2), indicating photorelease of the 4AP. These two latter signals integrated for 0.30 and 0.27 of the initial signal, which corresponds to a photoreaction of 60%.
- FIG. 16 The inset in Figure 16 (top) shows the yield of free glutamate generated by the photolysis obtained from the analysis of the spectra.
- the irradiance of the light source was calibrated using the known efficiency of the photolysis of [Ru(bpy)(Py) 2 ] 2+ .
- This example describes a caged fluorescent probe based on a ruthenium-bipyridine core, bearing a modified rhodamine as an active derivative of a labeling molecule.
- This complex behaves as a caged fluorescent probe, increasing its fluorescence around 6-fold upon visible light excitation.
- Photolabile Compounds comprising a labeling molecule or an active derivative thereof in increasing fluorescence of fluorescent molecule or an active derivative thereof, such as, rhodamine B, rhodamine 6G, RhodB- MAPN, Rhod-6G-MAPN, RhodB-MAMePy and Rhod-6G-MAMePy.
- All reagents were purchased from Sigma-Aldrich and used as received.
- the photouncaging quantum yield measurements were performed with a Nd:YAG diode pumped solid state laser doubled to 473 nm with a constant power of 6.3 mW.
- the light was collimated and sent through an optical path of 1 cm into a fluorescence glass cuvette, with stirring.
- Total irradiation energy was measured using a Coherent Fieldmaster FM light meter with a visible light photodiode model SR45.
- Intracellular recordings were obtained with ⁇ 20 M ⁇ sharp capillary microelectrodes, a Neuroprobe 1600 (A-M Systems) amplifier and a A/D signal acquisition board at 1 kHz sampling rate and custom-made software.
- the microelectrode was filled with recording solution to which 1 mM caged fluorescent dye (chloride form) was added. Square, biphasic pulses of 1 nA, 2 Hz were applied for less that 5 min.
- Rhodamine B-Methylaminopropionitrileamide (RhodB-)
- RhodB-MAPN chloride salt is somewhat hygroscopic and must be stored in a moisture free environment.
- Rhodamines are useful fluorophores, due to their emission quantum yield approaching unity and their high resistance to photobleaching. They are comprised of a xanthene moiety that provides the fluorescence and a benzoic acid which modulates their spectral properties.
- Scheme I A shows the structure of rhodamine B which was chosen as the starting point for this example.
- Ruthenium-bipyridyl complexes can easily be coordinated to donor nitrogens such as those of the aliphatic amines, pyridines, imines, and even nitriles, but not to those of anilines, not even primary ones. Diethylanilines of the rhodamine B do not form stable complexes with Ru centers and although carboxylates can be coordinated to Ru-bpy cores, such complexes are easily hydrolyzed in aqueous solutions at room temperature.
- rhodamine B was modified by adding a "sticky tail" in order to coordinate the fluorescent molecule to the metal center.
- carboxilate was amidated with aminopropionitrile, using the Adamczyk procedure (Adamczyk, M. J. Bioorg. Med Chem Lett. 2000, 10: 1539— 1541).
- the obtained compound is RhodB-APN, indicated in scheme IB.
- Figure 20 depicts the emission spectra of the complex during irradiation.
- the inset shows the maxima of the spectra as a function of the irradiation time.
- This example provides an activatable fluorescent probe with surprising sensitivity in the visible light region. It increases its intrinsic fluorescence up to 6-fold after blue light irradiation.
- This probe is physiologically friendly and can be injected into living cells - even excitable ones like neurons - with no sign of acute toxicity in short-term (- 2 h) experiments.
- the probe was used to image the laminar flow inside a thin spectrophotometric flow cell and to visualize the parabolic-shaped flow in a FIA capillary. This probe reveals not only the broadening of the plume, but also the memory effect due to accumulation of analyte near the walls, where the flow velocity approaches zero.
- the complex [Ru(bpy)2(RhodB-MAPN)Cl]Cl is a surprisingly effective tool to image any kind of systems where manipulation of fluorescence is required.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.
Description
PHOTOLABILE COMPOUNDS
[0001 ] This invention was made with U.S. government support. The U.S. government has certain rights in the invention.
[0002] This patent disclosure contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Provisional Patent Application Ser. No. 61/220,922, filed June 26, 2009, the entire disclosure of which is incorporated by reference herein. U.S. Pat. Pub. No. 2008-0176940 is also incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0004] The present invention relates generally to novel Photolabile Compounds and methods for uncaging an organic molecule, such as a bioactive molecule, which can have a variety of uses both in vitro and in vivo.
BACKGROUND OF THE INVENTION
[0005] Photolabile protecting groups, which are also called caging groups, are classes of protecting groups that are particularly useful in the biological sciences. Because light can be controlled with precision both spatially and temporally, cleaving a protecting group from a bioactive molecule allows release, or uncaging, of the molecule. Protecting groups typically mask or conceal charged (for example, carboxylate or phosphate) or polar (for example, amine, hydroxyl, or sulfhydryl) groups on the compounds. Frequently such functionalities increase the hydrophobicity and membrane permeability of the protected molecules. Prior to photolysis, the Photolabile Compounds are typically chemically or biologically inactive because at
least one of the compounds' main functionalities is blocked. The activity of the molecule can be triggered by a pulse of light, thereby releasing the molecule from the photoreleasable compound. Thus, photolabile protecting groups can be removed from a protected compound by irradiation, for example, to control the release of the compound when and where desired, either in vivo or in vitro.
[0006] Commercially available Photolabile Compounds typically require ultraviolet (UV) light to remove the compounds from the cage. However, UV light can cause damage to organs, tissues and cells, thus making UV light detrimental for in vivo use. Thus, there is a need in the art to utilize new Photolabile Compounds having ligands that can be released using light other than UV light, particularly for in vivo applications. The present invention provides novel Photolabile Compounds and methods for using the compounds, which provide advantages over currently available compounds that are photolabile using only UV light.
SUMMARY OF THE INVENTION
[0007] It is an aspect of the present invention to provide novel Photolabile Compounds that protect an organic molecule, such as a bioactive molecule. Upon exposure to light, the organic molecule is released, and is useful in the methods described herein.
[0008] In one aspect, the present invention provides compounds of Formula I:
wherein M is Ru;
each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with M;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with M;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with M;
(d) an -NH2 group whose nitrogen atom forms a bond with M; or
(e) a -COOH group, one of whose oxygen atoms forms a bond with M; L2 is (R9)3P, (R9O)3P, or L'and m is 2; or L2 is -CN and m is 1 ; or L2 is a labeling molecule or an active derivative thereof connected to M through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to M through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -Ci-Ci8 alkyl, -C3-C8 cycloalkyl, or phenyl;
R'-R8 are independently -H, -Ci-C18 alkyl, -NH2, -COOH, -(Ci-Ci8 alkyl)-O-(Ci-Ci8 alkyl), or -OC(OXC-C8 alkyl); and
X is CI', F, Br \ I", PF6 ", CF3SO3 ", (Ci-Ci8 alkyl)-CO2 ", or (Ci-Ci8 alkyl)-SO3 ".
[0009] In one embodiment of the compounds of Formula I,
M is Ru; each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with M;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with M;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with M;
(d) an -NH2 group whose nitrogen atom forms a bond with M; or
(e) a -COOH group, one of whose oxygen atoms forms a bond with M; L2 is (R9)3P, (R9O)3P, or L1 and m is 2; or L2 is -CN and m is 1 ;
R'-R8 are independently -H, -Ci-Ci8 alkyl, -NH2, -COOH, -(Ci-Ci8 alkyl)-O-(Ci-Ci8 alkyl), or -OC(O)(C, -C ) 8 alkyl); and
X is Cl", F, Br ", I", PF6 ", CF3SO3 ", (Ci-C18 alkyl)-CO2 ', or (Ci-C18 alkyl)-SO3 ".
[0010] In some embodiments of the compounds of Formula I, when L2 is (R9)3P, each R9 is different from each other.
[001 1 ] In some embodiments of the compounds of Formula 1, when L2 is (R9)3P, two R9 are the same and different from the remaining R9.
[0012] In some embodiments of the compounds of Formula I, when L2 is (Ph)3P, each phenyl is not substituted with methyl.
[ 0013] In another aspect, the present invention provides compounds of Formula II:
II
wherein: each L1 is independently an organic molecule having:
(a) a tetrazolyl group, one of its nitrogen atoms forming a bond with Ru;
(b) nicotine or caffeine, whose pyridyl nitrogen atom forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru; or
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru; L2 is (R9)3P, (R9O)3P, or L'and m is 2; or L2 is -CN and m is 1 ; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the phosphorous
atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -Ci-Cis alkyl, -C3-C8 cycloalkyl, or phenyl;
R'-R8 are independently -H, -C1-Ci8 alkyl, -NH2, -COOH, -(Ci-Ci8 alkyl)-O-(Ci-C,8 alkyl), or -OC(O)(C-C8 alkyl); and
X is Cl", F, Br ", I\ PF6 ", CF3SO3 ', (Ci-C8 alkyl)-CO2 ", Or (C-C8 alkyl)-SO3 ".
[0014] In one embodiment of the compounds of Formula II,
each L1 is independently an organic molecule having:
(a) a tetrazolyl group, one of its nitrogen atoms forming a bond with Ru;
(b) nicotine or caffeine, whose pyridyl nitrogen atom forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru; or
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru; L2 is (R9)3P, (R9O)3P, or L1 and m is 2; or L2 is -CN and m is 1 ;
R'-R8 are independently -H, -C-C8 alkyl, -NH2, -COOH, -(Ci-C18 alkyl)-O-(C,-C8 alkyl), Or -OC(O)(C-C8 alkyl); and X is Cl", F, Br ", T, PF6 ", CF3SO3 -, (C-C8 alkyl)-CO2 ", or (C,-C,8 alkyl)-SO3 ".
[0015] In some embodiments of the compounds of Formula II, when L2 is (R )3P, each R9 is different from each other.
[0016] In some embodiments of the compounds of Formula II, when L2 is (R9)3P, two R9 are the same and different from the remaining R9.
In some embodiments of the compounds of Formula II, when L2 is (Ph)3P, each phenyl is not substituted with methyl.
III
wherein:
L1 is 4-aminopyridine (4-AP), whose pyridyl nitrogen atom forms a bond with Ru;
L2 is (R9)3P, (R9O)3P, or L'and m is 2; or L2 is -CN and m is 1 ; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R )=NH, C(R )=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -C1-C18 alkyl, -C3-C8 cycloalkyl, or phenyl;
R'-R8 are independently -H, -Ci-Ci8 alkyl, -NH2, -COOH, -(Ci-C18 alkyl)-O-(C,-C,8 alkyl), or -OC(O)(Ci-Ci8 alkyl); and
X is Cl\ F, Br \ T, PF6 ', CF3SO3 -, (Ci-C8 alkyl)-CO2 \ or (C1-Ci8 alkyl)-SO3 \
[0018] In one embodiment of the compounds of Formula III,
L1 is 4-aminopyridine (4-AP), whose pyridyl nitrogen atom forms a bond with Ru; L2 is (R9)3P, (R9O)3P, or L1 and m is 2; or L2 is -CN and m is 1 ;
R'-R8 are independently -H, -Ci-Ci8 alkyl, -NH2, -COOH, -(C1-Ci8 alkyl)-O-(Ci-C) 8 alkyl), or -OC(O)(C-C18 alkyl); and X is Cl\ F, Br ", I\ PF6 ", CF3SO3 ", (C1-C8 alkyl)-CO2 -, or (C-C18 alkyl)-SO3 \
[0019] In some embodiments of the compounds of Formula III, when L2 is (R9)3P, each R9 is different from each other.
[0020) In some embodiments of the compounds of Formula III, when L2 is (R9)3P, two R9 are the same and different from the remaining R .
[0021 ] In some embodiments of the compounds of Formula III, when L2 is (PIO3P, each phenyl is not substituted with methyl.
[0022] In another aspect, the present invention provides compounds of Formula FV:
IV
wherein:
M1 is Li+, Na+, or K+;
M2 is Ru; and L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with M2;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with M2;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with M2;
(d) an -NH2 group whose nitrogen atom forms a bond with M2; or
(e) a -COOH group, one of whose oxygen atoms forms a bond with M2.
[0023] In another aspect, the present invention provides compounds of Formula V:
wherein: each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl;
L2 is (R9)3P, (R9O)3P, or Ll and m is 2; or L2 is -CN and m is 1 ; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -Ci-C]8 alkyl, -C3-C8 cycloalkyl, or phenyl;
wherein when L2 is P(phenyl)3 or a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of P(phenyl)2, each phenyl is independently substituted with -Ci-Ci8 alkyl, -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-C)8 alkyl)- oxy, -(C1-C8 alkyO-amino, -(C1-C8 alkyl)-thio, -CO2Y, -C(=O)Y, -CX=O)NY2, -NH2, -NO2, -OH, or -SH, and
R1 to R4 are independently -H, -C-C18 alkyl; -NH21-(C1-C18 alkyl)-O-(C-C18 alkyl), -OC(O)(Ci-Ci8 alkyl), -(C1-C18 alkyl)-OH, aryl, -(C-C18 alkyl)-oxy, -(C1-C18 alkyO-amino, -(C-C8 alkyl)-thio, -CO2Y, -C(=O)Y, -C(=0)NY2, -NO2, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups; wherein when L2 is not P(phenyl)3, R1 to R4 are independently -H, -(Ci-C18 alky I)- OH, aryl, -(Ci-C8 alkyl)-oxy, -(C-C18 alkyl)-amino, -(C1-C8 alkyl)-thio, -CO2Y, - C(=O)Y, -C(=0)NY2, -NO2, -OH, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups, wherein at least one of R1 to R4 is not H;
X is Cl", F, Br ", I", PF6 ", CF3SO3 ", (Ci-C18 alkyl)-CO2 ", or (Ci-C18 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-C]8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
[0024] In one embodiment of the compounds of Formula V,
each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -C]-Ci8 alkyl, or aryl; wherein when L2 is P(phenyl)3, each phenyl is independently substituted with -C]-Ci8 alky], -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-C8 alkyl)-oxy, -(Ci-Ci8 a!kyl)-amino, -(Ci-Ci8 alkyl)-thio, -CO2Y, -C(O)Y, -C(=0)NY2, -NH2, -NO2, -OH, or -SH, and
R1 to R4 are independently -H, -Ci-Ci8 alkyl; -NH2,-(Ci-Ci8 alkyl)-O-(CrCi8 alkyl), -OC(O)(Ci-C18 alkyl), -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-C18 alkyl)-oxy, -(C]-C18 alkyO-amino, -(Ci-Ci8 alkyl)-thio, -CO2Y, -C(O)Y, -C(=O)NY2, -NO2, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups; wherein when L2 is not P(phenyl)3, R1 to R4 are independently -H, -(Ci-C)8 alkyl)- OH, aryl, -(C1-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyl)-amino, -(C1-C18 alkyl)-thio, -CO2Y, - C(=O)Y, -C(=O)NY2, -NO2, -OH, or -SH, or R! and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups, wherein at least one of R1 to R4 is not H;
X is Cl", F, Br ", I\ PF6 ", CF3SO3 ", (Ci-Ci8 alkyl)-CO2 ", or (C-Ci8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -C-Ci8 alkyl, aryl, -(Ci-C8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
[0025] In some embodiments of the compounds of Formula V, when L2 is (R9)3P, each R9 is different from each other.
[0026] In some embodiments of the compounds of Formula V, when L2 is (R9)3P, two R9 are the same and different from the remaining R9.
[0027] In some embodiments of the compounds of Formula V, when L2 is (Ph)3P, each phenyl is not substituted with methyl.
VI wherein: each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-Cig alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl;
L2 is P(phenyl)3, wherein each phenyl is independently substituted with -Ci-Ci8 alkyl, -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-C]8 alkyl)-oxy, -(Ci-C]8 alkyl)-amino, -(Ci-Ci8 alkyl)- thio, -CO2Y, -C(=O)Y, -C(=O)NY2, -NH2, -NO2, -OH, OΓ -SHLOΓ L2 is a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2;
wherein each R9 is independently -Ci-Cis alkyl, -C3-C8 cycloalkyl, or phenyl;
R1 to R4 are independently -H, -Ci-Ci8 alkyl; -NH2, -(Ci-Ci8 alkyl)-O-(Ci-Ci8 alkyl), -OC(O)(C-C18 alkyl), -(C-C18 alkyl)-OH; aryl, -(C1-C8 alkyl)-oxy, -(C1-C18 alkyl)- amino, -(Ci-C8 alkyl)-thio, -CO2Y, -C(=O)Y, -C(=O)NY2, -NO2, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups;
X is Cl", F, Br ", I", PF6 ", CF3SO3 ", (C-C8 alkyl)-CO2 \ or (C-C8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -C-C)8 alkyl, aryl, -(C-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
[0029] In one embodiment of the compounds of Formula VI,
each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-C]8 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl;
L2 is P(phenyl)3, wherein each phenyl is independently substituted with -C-Ci8 alkyl, -(C-C8 alkyl)-OH, aryl, -(Ci-C8 alkyl)-oxy, -(Ci-C8 alkyl)-amino, -(C-C8 alkyl)- thio, -CO2Y, -C(=O)Y, -C(=O)NY2, -NH2, -NO2, -OH, or -SH;
R1 to R4 are independently -H, -C-C8 alkyl; -NH2, -(Ci-C18 alkyl)-O-(C-C8 alkyl), -OC(O)(C-C8 alkyl), -(C1-C8 alkyl)-OH, aryl, -(C-C8 alkyl)-oxy, -(C-C8 alkyl)- amino, -(C-C8 alkyl)-thio, -CO2Y, -C(=O)Y, -C(=O)NY2, -NO2, or -SH, or R1 and R2
and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups;
X is Cl", F, Br ", I\ PF6 ", CF3SO3 ", (C,-C,8 alkyl)-CO2 ", or (C1-Ci8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-Ci8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
[0030] In some embodiments of the compounds of Formula VI, when L2 is (R9)3P, each R9 is different from each other.
|0031 ] In some embodiments of the compounds of Formula VI, when L2 is (R9)3P, two R9 are the same and different from the remaining R9.
[0032] In some embodiments of the compounds of Formula VI, when L is (Ph)3P, each phenyl is not substituted with methyl.
[0033] In another aspect, the present invention provides compounds of Formula VII:
VII
wherein: each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl;
L2 is (R9)3P, (R9O)3P, or L1, wherein each R5 is independently -Ci-C]8 alkyl, -C3-C8 cycloalkyl, or phenyl, m is 2, and L2 is not P(phenyl)3; or L2 is -CN and m is 1 ;.or L2 is a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -C1-C18 alkyl, -C3-C8 cycloalkyl, or phenyl;
R1 to R4 are independently -H, -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-Ci8 alkyl)-oxy, -(Ci-C)8 alkyO-amino, -(C,-C,8 alkyl)-thio, -CO2Y, -C(=0)Y, -C(=O)NY2, -NO2, -OH, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups, wherein at least one of R1 to R4 is not H;
X is Cl", F, Br \ I", PF6 ', CF3SO3 ', (Ci-C)8 alkyl)-CO2 ~, or (C1-C18 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-Ci8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
[0034] In one embodiment of the compounds of Formula VII,
each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl;
L2 is (R9)3P, (R9O)3P, or L1, wherein each R5 is independently -Ci-Ci8 alkyl, -C3-C8 cycloalkyl, or phenyl, m is 2, and L2 is not P(phenyl)3; or L2 is -CN and m is 1 ;
R1 to R4 are independently -H, -(Ci-Ci8 alkyl)-OH, aryl, -(C)-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyO-amino, -(C1-Ci8 alkyl)-thio, -CO2Y, -C(O)Y, -C(=O)NY2, -NO2, -OH, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups, wherein at least one of R1 to R4 is not H;
X is Cl", F, Br \ I", PF6\ CF3SO3 ", (CI-CI 8 alkyl)-CO2 \ or (C1-C, 8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-Ci8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
[0035] In some embodiments of the compounds of Formula VII, when L2 is (R9)3P, each R9 is different from each other.
[0036] In some embodiments of the compounds of Formula VII, when L2 is (R9)3P, two R9 are the same and different from the remaining R9.
[0037] In some embodiments of the compounds of Formula VII, when L2 is (Ph)3P, each phenyl is not substituted with methyl.
VIII
wherein: each L1 is independently a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L1 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -Ci-Ci8 alkyl, -C3-C8 cycloalkyl, or phenyl;
L2 is Cl-, phosphine, OH2, or pyridine and m is 2; or L2 is -CN and m is 1 ;
R1 to R4 are independently -H, -Ci-Ci8 alkyl; -NH2, -(Ci-Ci8 alkyl)-O-(Ci-C) 8 alkyl), -OC(OXC-C8 alkyl), -(C-C8 alkyl)-OH, aryl, -(C1-C8 alkyl)-oxy, -(C1-C8 alkyl)- amino, -(C1-C8 alkyl)-thio, -CO2Y, -C(=0)Y, -C(=O)NY2) -NO2, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups;
X is Cl", F, Br \ I\ PF6 ', CF3SO3 ', (C1-C18 alkyl)-CO2 ", or (C1-C18 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-C]8 alkyl, aryl, -(C1-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
[0039] In one embodiment of the compounds of formula VIII,
each L is independently a labeling molecule;
L is CI-, phosphine, OH2, or pyridine and m is 2; or L2 is -CN and m is 1 ;
R1 to R4 are independently -H, -Ci-Ci8 alkyl; -NH2, -(Ci-Ci8 alkyl)-O-(Cι-Ci8 alkyl), -OC(O)(C1-C18 alkyl), -(C1-C18 alkyl)-0H, aryl, -(C1-C18 alkyl)-oxy, -(C1-C18 alkyl)- amino, -(Ci-C8 alkyl)-thio, -CO2Y, -C(=O)Y, -C(=0)NY2, -NO2, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups;
X is Cl", F, Br ", I", PF6 ", CF3SO3 ", (Ci-C18 alkyl)-CO2 ", or (C1-Ci8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-Ci8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
[ 0040] In some embodiments of the compounds of Formula VlII, when L2 is (R9)3P, each R9 is different from each other.
[0041 ] In some embodiments of the compounds of Formula VIII, when L2 is (R9)3P, two R9 are the same and different from the remaining R9.
[0042] In some embodiments of the compounds of Formula VIII, when L2 is (Ph)3P, each phenyl is not substituted with methyl.
[0043] In some embodiments of the compounds of Formula I-III and V-VIII, L2 is Rhodamine B-Methylaminopropionitrileamide (RhodB-MAPN). In some embodiments of the compounds of Formula I-III and V-VIII, L is Rhodamine G- Methylaminopropionitrileamide (RhodG-MAPN).
[0044] In some embodiments of the compounds of Formula I-III and V-VIII, L2 is:
10045] In some embodiments of the compounds of Formula I-III and V-VIII, L2 is:
RhodβG-MAMePy
(RhodόG-MAMePy) or a chloride salt thereof (Rhod6G-MAMePy-Cl).
[0046] In some embodiments of the compounds of Formula I-III and V-VIII, the labeling molecule is rhodamine B. In some embodiments of the compounds of Formula I-III and V-VIII, the labeling molecule is rhodamine 6G.
[0047] In some embodiments of the compounds of Formula I-III and V-VIII, the labeling molecule is selected from the group consisting of bodipy, dansyl, -fluorescein, Texas red, cyanine dyes, pyrene, coumarins, Cascade BlueTM, Pacific Blue, Marina Blue, Oregon Green, 4',6-Diamidino-2-phenylindole (DAPI), indopyra dyes, lucifer yellow, propidium iodide, porphyrins, and arginine.A compound of Formula I-VIII ("a Photolabile Compound") releases L1 upon exposure to light.
[0048] In another aspect, the present invention provides a composition comprising an effective amount of a Photolabile Compound and a physiologically acceptable carrier, vehicle, diluent, or excipient.
[0049] In another aspect, the present invention provides a vessel containing a Photolabile Compound.
[0050] In yet another of its aspects, the present invention provides a kit comprising a Photolabile Compound and instructions for use.
[0051 ] Another aspect of the present invention provides methods for releasing an organic molecule or a labeling molecule from a Photolabile Compound, comprising exposing a Photolabile Compound to light under conditions sufficient to release the organic molecule or labeling molecule.
[0052 ] In yet another aspect, the present invention provides a method for making an organic molecule bioavailable to a subject in need of the organic molecule, comprising administering a Photolabile Compound to the subject; and exposing the compound to light under conditions sufficient to release the organic molecule from the compound.
[0053] In another aspect, the present invention provides methods for treating diseases and disorders in a subject, comprising: (a) administering a Photolabile Compound to the subject; and (b) exposing the Photolabile Compound to light under conditions sufficient to release the organic molecule from the Photolabile Compound. In some embodiments, the diseases and disorders treated by the methods of the invention include neurological, neurophysiological, or neuromuscular diseases and conditions, such as epilepsy and multiple sclerosis; cancers; diaphoresis; and blood dyscrasias.
[0054] In another aspect, the present invention provides methods for assaying an organic molecule, comprising: (a) exposing a Photolabile Compound and a biological sample to light under conditions sufficient to release the organic molecule from the Photolabile Compound, and (b) determining an effect of the organic molecule on the biological sample.
[0055] In one aspect, the invention provides a compound selected from the group consisting of: [Ru(bpy)2(RhodB-MAPN)Cl]Cl, [Ru(bpy)2(Rhod6G-MAPN)Cl]Cl, [Ru(bpy)2(RhodB-MAMePy)Cl]Cl.
[0056] In another aspect, the invention provides a compound selected from the group consisting of: [Ru(bpy)2(RhodB-MAPN)Cl]Z, [Ru(bpy)2(Rhod6G-MAPN)Cl]Z, [Ru(bpy)2(RhodB-MAMePy)Cl]Z, wherein Z is an anion. In some embodiments, Z CI', F, Br" or I\
[0057] Additional aspects, features and advantages afforded by the present invention will be apparent from the detailed description, figures, and exemplification hereinbelow.
BRIEF DESCRIPTION OF THE FIGURES
[0058] Fig. 1 depicts a partial 1H NMR spectra of [Ru(bpy)2(4 AP)2]Cl2, as described herein (Example 1), showing the signals corresponding to the 4-AP meta hydrogens. ml: in [Ru(bpy)2(4AP)2]2+; m2: in [Ru(bpy)2(H2O)(4AP)2]2+; m3: in free ligand 4- AP.
[0059] Fig. 2 (Top) shows action potentials (spikes) recorded in a medicinal leech {Hirudo medicinalis) neuron for saline and solutions of [Ru(bpy)3]Cl2 and [Ru(bpy)2(4 AP)2]Cl2 (Bottom): Frequency of the spikes. Arrows indicate irradiation with Xe flashlamp. (Middle): Composition of the extracellular medium.
[0060] Fig. 3 shows cyclic voltammetry (CV) profile of [Ru(bpy)2(4AP)2]Cl2 in water. The supporting electrolyte was KNO3 (1 M). dE/dt = 100 mV/s in glassy carbon electrode.
[0061 ] Figs. 4A and 4B show NMR spectra of [Ru(bpy)2(4AP)2]Cl2 in D2O before (Fig. 4A) and after (Fig. 4B)irradiation. Bruker 500 MHz.
[0062] Fig. 5 shows the UV-visible (UV-vis) spectra of Ru(bpy)2(4AP)2 before and after complete photolysis. The photoproducts after exposure to light were Ru(bpy)2(4AP)(H2O) and free 4AP. The complex did not undergo dark decomposition for more than 20 hours. After 7 hours in the dark, the irradiated solution showed less than 4% of 4AP recombination.
[0063] Fig. 6 shows a UV-vis spectrum of the filter used for the ganglion irradiation experiments as described in Example 3.
[0064] Figs. 7 A and 7B show action potentials and frequency of the spikes obtained in studies of medicinal leech {Hirudo medicinalis) ganglia. Fig. 7A shows a recording of Retzius neuron voltage activity during perfusion of free 4AP on the leech ganglia. [4AP] = 0, 10, 20 and 50 mM. Flow rate = lml/min. Carrier: saline solution, as described in Example 3. Fig. 7B shows the recording of Retzius neuron activity during exposure to a 0.1 msec flash of green light through the filter of FIG. 6. Flow rate = l ml/min. Carrier: saline solution, as described in Example 3. Pulse energy: 0.5 J.
[0065] Figs. 8A and 8B relate to spectra changes of [Ru(bpy)2(4AP)2]Cl2 during exposure to light. Fig. 8A: spectrum changes of [Ru(bpy)2(4AP)2]CI2 during . irradiation with 473 nm laser light. Power: 6.39 mW continuous. Initial concentration of [Ru(bpy)2(4AP)2]Cl2: 27.9 μM. A(473nm)=0.18. Fig. 8B: Fraction of [Ru(bpy)2(4AP)(H2θ)]2+ as a function of irradiation time obtained from the spectra depicted in FIG. 8A.
[0066] Fig. 9 shows a graph of photoreleased 4AP versus pulse energy. The light source was pulsed Xe lamp with a bandpass filter. [Ru(bpy)2(4AP)2]Cl2 = 44 μM; Vol. = 3 mL. The data were obtained from UV-vis spectra analysis.
[0067] Fig. 10 shows several two-photon fluorescence images of [Ru(bpy)2(TzGly)(py)]Cl2 at different excitation wavelengths. (Magnification: ~20x).
[0068] Fig. 11 depicts a graph of total two-photon fluorescence versus excitation wavelength of [Ru(bpy)2(4AP)2]Cl2.
[0069] Fig. 12 presents a UV-vis spectrum of TzGIy before and after irradiation with 400-600 nm light.
[0070] Figs. 13A and 13B: Fig. 13A depicts the structure of TzGIy. Fig. 13B demonstrates the spiking of a mouse cortical neuron caused by the addition of TzGIy (1 μM) to neuron via perfusion. The measurement results were obtained by the whole- cell patch-clamp method, as known and used in the art.
[0071 ] Figs. 14A-G relate to experiments performed on neurons contacted with [Ru(bpy)2(TzGly)(py )]C12. Figs. 14A, B and C show fluorescent-image micrographs of a neuron, including magnified views of dendritic spines. Fig. 14D shows the effect of laser irradiation (~40 mW) on the spiking of a single neuron in the presence of [Ru(bpy)2(TzGly)2]Cl2. Concentration of [Ru(bpy)2(TzGly)2]Cl2 = 100 μM; Pulse length: 10 ms; Power: 40 mW; Wavelength: 720 nm. Figs. 14E-G relate to experiments carried out as controls to the experiments of Figs. 14A-D. Figs. 14E and F show magnified views of the dendritic spines of a neuron. Fig. 14G'presents a plot showing the effect of laser irradiation on a control neuron in the absence of
[Ru(bpy)2(TzGIy)2]Cl2. No increased activity is observed. Pulse length: 10 ms; Power: 40 mW; Wavelength: 720 nm.
[0072 J Fig. 15 depicts a cyclic voltammetry (CV) profile of native [Ru(bpy)2(PMe3)Glu] at 100 mV/s on Pt wire electrode in CH3CN containing 100 mM TBAPF6.
[0073] Fig. 16 shows (top) UV-Vis spectra of [Ru(bpy)2(PMe3)Glu] 0.1 mM at pH=7 during 360 seconds irradiation using 450nm light; (inset) amount of photoreleased glutamate derived from the experimental data (circles); fitting to the theoretical equation (line); (bottom) absorbance changes at 532 nm after flash photolysis of [Ru(bpy)2(PMe3)Glu] 1 mM (10 ns/pulse, 256 pulses averaged).
[0074) Fig. 17 shows the aromatic section of the 1H-NMR spectra of [Ru(bpy)2(PMe3)Glu] in D2O before (upper trace) and after (lower trace) photolysis, showing the aromatics signals of [Ru(bpy)2(PMe3)H2O]2+.
[0075] Fig. 18 shows the aliphatic section of the 1H-NMR spectrum of [Ru(bpy)2(PMe3)Glu] in D2O before (upper trace) and after (lower trace) photolysis. In the last case, the signals at 3.50, 2.30, 2.04 and 1.94 ppm correspond to free glutamate.
[0076] Fig. 19 shows 1H NMR aliphatic region spectra of the complex [Ru(bpy)2(RhodB-MAPN)Cl]+ (A) before irradiation. (B) after 5 min irradiation. (C) free RhodB-MAPN spectrum. Note in B that the signals of the free ligand a, b, and c are apparent, indicating its photorelease. The signals d and e, corresponding to the ethyl groups in RhodB-MAPN, are far from the coordination center and therefore do not suffer big changes. A photolysis reaction schematic is added for clarity.
[0077] Fig. 20 shows emission spectra of a 10 μM aqueous solution of the complex [Ru(bpy)2(RhodB-M APN)Cl]+ during irradiation of the cuvette with a 473 nm laser diode. A spectrum was measured every 10 s. Inset shows emission maxima during irradiation.
DETAILED DESCRIPTION OF THE INVENTION
(0078] The present invention relates generally to Photolabile Compounds comprising organic molecules or labeling molecules and methods for using the Photolabile Compounds. The organic molecules can be biologically active. In one embodiment of this invention, an organic molecule, e.g., a biologically active molecule, is protected and subsequently released upon exposure to light, advantageously, visible light.
[0079] In contrast to known methods, visible light, e.g., a visible light pulse, can be used to release an organic molecule or a labeling molecule from a Photolabile Compound. Thus, in the present methods, samples, e.g., organs, tissues or cells, or subjects to which a Photolabile Compound is administered, undergo only minimal, if ' any, exposure to UV radiation, which has detrimental effects on cellular components and, ultimately, on cell growth and viability.
[0080] In accordance with the present invention, and without wishing to be bound by theory, the Ru-organic molecule bond or Ru-labeling molecule bond is normally weaker than a covalent σ bond, and therefore can be broken using a lower energy irradiation. Further in accordance with this invention, and without wishing to be bound by theory, the energy required for the release of an organic molecule or a labeling molecule by exposure to light is relatively low. In the Photolabile Compounds of this invention, the organic molecule or labeling molecule is photoreleased by irradiation of the Photolabile Compound using light as described herein.
[0081 ] Also, according to this invention, photorelease can occur in vivo or in a biological sample, e.g., a body fluid, a body sample, such as an organ or tissue sample, in living cells and in the body. Thus, the Photolabile Compounds are especially valuable for in vivo biological applications, such as treatments for various diseases, conditions and disorders of the body. The use of Photolabile Compounds as described herein allows precise control of the onset of a bioactive function or a bioactivity in the body, for example, in living organs, tissues, and cells, i.e., within nanoseconds to milliseconds, with minimal harm to a biological sample, or to the body or its organ, tissue and cellular components. In addition, exposure of a biological sample to light can be localized to the site where an organic molecule is needed or desired. This is particularly beneficial for administration to a subject, particularly a human patient.
[0082] The Photolabile Compounds are also suitable for use in non-biological systems, such as in solar cells, photocells, or an optical memory, e.g., a three dimensional optical memory.
[0083] In one embodiment, the invention encompasses a compound of Formula I:
wherein:
R'-R8, L'_ L2 , X, M and m are as defined above for the compounds of Formula I.
[0084] In another embodiment, the invention encompasses a compound of Formula II:
II
wherein:
R'-R8, L1 , L2 , X and m are as defined above for the compounds of Formula II.
[0085] In another embodiment, the invention encompasses a compound of Formula III:
III
wherein:
R -R , L L , X and m are as defined above for the compounds of Formula III. [0086] In another embodiment, the invention encompasses a compound of Formula IV:
IV
wherein M | 1 , » MΛ2 , and L are as defined above for the compounds of Formula IV.
V
wherein:
[0088] In another embodiment, the invention encompasses a compound of Formula VI:
VI
wherein:
R'-R4, L1 L2 , X and m are as defined above for the compounds of Formula VI.
10089] In an embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and each phenyl is independently substituted at the 3 or 4 position.
[0090] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -(C|-Ci8 alkyl)- OH.
[0091 ] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and each phenyl is substituted with -(Ci-Ci8 alkyl)-OH.
[0092] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -COOH.
[0093] In another embodiment, the invention encompasses a compound of Formula II, wherein L2 is P(phenyl)3 and each phenyl is substituted with -COOH.
[0094] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -OH.
[0095] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and each phenyl is substituted with -OH.
[0096] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -NH2.
[0097] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and each phenyl is substituted with -NH2.
[0098] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -NO2.
[0099] In another embodiment, the invention encompasses a compound of Formula VI, wherein L2 is P(phenyl)3 and each phenyl is substituted with -NO2.
[00100] In another embodiment, the invention encompasses a compound of
Formula VI, wherein L1 is an organic molecule comprising PMe2 whose phosphorus atom forms a bond with Ru.
[00101 ] In another embodiment, the invention encompasses a compound of
Formula VI, wherein L1 is an organic molecule comprising P(phenyl)2 whose phosphorus atom forms a bond with Ru.
[00102] In another embodiment, the invention encompasses a compound of
Formula VII:
VII
wherein:
R'-R4, L1, L2 , X and m are as defined above for the compounds of Formula VII.
[00103 ] In another embodiment, the invention encompasses a compound of
Formula VII, wherein L is P(methyl)(phenyl)2.
[00104] In another embodiment, the invention encompasses a compound of
Formula VII, wherein L is P(methyl)2(phenyl).
[00105] In another embodiment, the invention encompasses a compound of
Formula VII, wherein L1 is an organic molecule comprising PMe2 whose phosphorus atom forms a bond with Ru.
[ 00106] In another embodiment, the invention encompasses a compound of
Formula VII, wherein L1 is an organic molecule comprising P(phenyl)2 whose phosphorus atom forms a bond with Ru.
[00107] In another embodiment, the invention encompasses a compound of
VIII
wherein:
R'-R4, L1 , L2 , X and m are as defined above for the compounds of Formula VIII.
[00108] The Photolabile Compounds of Formulas I-VIII can exist in a cis or trans configuration. Accordingly, Formulas I-VIII encompass both cis and trans forms of the Photolabile Compounds.
[00109] In the compounds of the present invention, the term "-(Ci-Ci8) alkyl" refers to a saturated straight or branched non-cyclic hydrocarbon having 1 to 18 carbon atoms. Representative saturated straight chain -(Ci-Ci8) alkyls include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonyl, -n-decyl, -n- undecyl, -n-dodecyl, -n-tridecyl, -n-tetradecyl, -n-pentadecyl, -n-hexadecyl, -n- heptadecyl and -n-octadecyl. Representative saturated branched -(Ci-Ci8) alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, -2-methylbutyl, -3- methylbutyl, -2,2-dimethylbutyl, -2,3-dimethylbutyl, -2-methylpentyl, -3-methylpentyl, -4-methylpentyl, -2-methylhexyl, -3-methylhexyl, -4-methylhexyl, -5-methylhexyl, - 2,3-dimethylbutyl, -2,3-dimethylpentyl, -2,4-dimethylpentyl, -2,2-dimethylhexyl, -2,3- dimethylhexyl, -2,4-dimethylhexyl, -2,5-dimethylhexyl, -2,2-dimethylpentyl, -3,3- dimethylpentyl, -3,3-dimethylhexyl, -4,4-dimethylhexyl, -2-ethylpentyl, -3-ethylpentyl, -2-ethylhexyl, -3-ethylhexyl, -4-ethylhexyl, -2-methyl-2-ethylpentyl, -2-methyl-3- ethylpentyl, -2-methyI-4-ethylpentyl, -2-methyI-2-ethylhexyl, -2-methyl-3-ethylhexyl, -2-methyl-4-ethylhexyl, -2,2-diethylpentyl, -3,3-diethylhexyl, -2,2-diethylhexyl, -3,3- diethylhexyl and the like.
[001 10] In the compounds of the present invention, the term "-(C3-C8) cycloalkyl" refers to a saturated cyclic hydrocarbon having from 3 to 8 carbon atoms. Representative -(C3-C8) cycloalkyls include -cyclopropyl, -cyclobutyl, -cyclopentyl, - cyclohexyl, -cycloheptyl and -cyclooctyl hydrocarbons.
[001 1 1 ] In the compounds of the present invention, the term "aryl" refers to an aromatic group containing 1 to 3 aromatic rings, either fused or linked.
[001 12 ] In the compounds of the present invention, the term "heterocyclic group" or "heterocyclic" or "heterocyclyl" or "heterocyclo" as used herein refers to fully saturated, or partially or fully unsaturated, including aromatic (i.e., "heteroaryl") cyclic groups (for example, 4 to 7 membered monocyclic, 7 to 1 1 membered bicyclic, or 10 to 16 membered tricyclic ring systems) which have at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1 , 2, 3, or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized. The heterocyclic group may be attached to the remainder of the molecule at any heteroatom or carbon atom of the ring or ring system. Exemplary heterocyclic groups include, but are not limited to, azepanyl, azetidinyl, aziridinyl, dioxolanyl, furanyl, furazanyl, homo piperazinyl, imidazolidinyl, imidazolinyl, isothiazolyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiomorpholinyl, thiophenyl, triazinyl, and triazolyl. Exemplary bicyclic heterocyclic groups include indolyl, isoindolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzothienyl, quinuclidinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, benzofurazanyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl] or furo[2,3- b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo- quinazolinyl), triazinylazepinyl, tetrahydroquinolinyl and the like. Exemplary tricyclic
heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl and the like.
[001 13] The term "cyclic aliphatic amine" or "cyclic aliphatic amine group" as used herein refers to a non-aromatic secondary amine or tertiary cyclic amine group. Examples of cyclic aliphatic amines include, but are not limited to, aziridine and piperidine.
[001 14] The term "active derivative" or "active derivative of a labeling molecule" as used herein refers to a chemical derivative of a labeling molecule, which retains the labeling function of the labeling molecule (e.g., its fluorescence properties). In some embodiments, such active derivative offers superior properties for attachment to Ru atom through a phosphine group, an aliphatic amine group, an imine group, a pyridyl group, or a nitrile group. A specific example of an active derivative of rhodamine (a labeling molecule) is B-Methylaminopropionitrileamide (RhodB- MAPN). A person of skill in the art can modify the labeling molecule to create a derivative thereof and then test the resultant derivative for activity in the same way that the activity of a labeling molecule is tested to determine whether the derivative is active.
[001 15] An amino acid group, such as an α-amino acid, is an organic molecule having an amino group (-NH2) and a carboxylic acid group. An amino acid can be one of the 20 common α-amino acids (GIy, Ala, VaI, Leu, He, Ser, Thr, Asp, Asn, Lys, GIu, GIn, Arg, His, Phe, Cys, Trp, Tyr, Met and Pro), or another naturally occurring amino acid, such as norleucine, ethylglycine, ornithine, gamma-amino butyric acid, and phenylglycine.
[001 16] Examples of a 6-membered monocyclic aromatic ring, wherein one of the ring's members is a nitrogen atom, include a pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl ring.
[001 17] Examples of a 5-membered monocyclic aromatic ring, wherein one of the ring's members is a nitrogen atom, include a pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, thiazolyl and thiadiazolyl ring.
[001 18] Examples of an 8-10-membered bicyclic aromatic ring, wherein one of the rings is aromatic and has a nitrogen atom member, include an indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, quinolyl, isoquinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, l ,3,7-trimethyl-2,6-dioxopurinyl, quinazolinyl, cinnolinyl, pteridinyl, 6-amino-l H-purinyl and 2-aminohypoxanthinyl bicyclic aromatic ring.
[001 19] In general terms, illustrative examples of organic molecules useful in the present Photolabile Compounds embrace a variety of agents, such as pharmaceutical agents, small molecules, drugs, neurochemicals, peptides, proteins, and chemotherapeutic agents, as nonlimiting examples.
[00120] Illustrative organic molecules can further include luciferin, enzyme inhibitors, fatty acids (e.g., arachidonic acid), protein kinase C activators (e.g., dioctanoylglycerol), tubulin assembly promoters (e.g., paclitaxel), antibiotics (e.g., penicillins or A23187), neurotransmitters (e.g., L-glutamic acid, aspartic acid, carbamylcholine, dopamine, epinephrine, GABA, glutamic acid, glycine, haloperidol, isoproterenol, kainic acid, NMDA, NMDA receptor antagonist MK-801, norepinephrine, phenylephrine, propranolol), 4-aminopyridine (4AP), serotonin (5 hydroxy triptamine, 5HT), (RS)-(tetrazol-5-yl) glycine (TzGIy), tetrazolyl-α-amino-3- hydroxy-5-methyl-4-isoxazoleproprionic acid ((tetrazol-5-yl) AMPA), nicotine, nicotinic acid, isoxazole, and fluorescent dyes (e.g., fluorescein, HPTS, rhodamines, succinimidyl esters and sulfosuccinimidyl esters of carboxy-Q-rhodamine, or Rhodamine Green), nucleotides (e.g., ATP, ADP, cAMP, GDP, GTP, cGMP, GTP-γ-S, GDP-β, 8-substituted derivatives of cAMP or cGMP, e.g., 8-bromo-cAMP, 8-bromo- cGMP, 8-chloro-cAMP, 8-chloro-cGMP, 8-parachlorophenylthio (cCPT) cAMP or cGMP, phosphates (e.g., phosphates, phosphate esters), phenylphosphate (PPb.3), Py, nucleosides, nucleoside derivatives, nucleotide derivatives (e.g., cADP-ribose, 8- amino-cADP ribose, or 8-bromo-cADP-ribose), cyclitols (e.g., inositol), cyclitol phosphates (e.g., myo-inositol phosphate, myo-inositol-l ,4,5-triphosphate, myoinositol- 1 ,3,4,5-tetrakisphosphate, or myo-inositol-3,4,5,6-tetrykisphosphate), NO (e.g., from the decomposable compound HON=N(O) (Net2)), chelants (e.g., EDTA, EGTA), and ionophores (e.g., nigericin). The organic molecule can be cell permeant,
as described, for example, in Furuta et al., Biochem. Biophys. Res. Commun., 228: 193- 198 (1996).
|00121 ] Other useful examples of organic molecules include adenosine 5'- diphosphate ADP; adenosine 5'-triphosphate ATP; adenosine 5'-monophosphate AMP; aminobutyric acid; L-glutamic acid; cyclic adenosine 5'-diphosphate ribose; adenosine 3', S'-cyclicmonophosphate; fluorescein; methyl-D-aspartic acid; tyramine; tryptophan; 4-aminopyridine (4AP); epinephrine; norepinephrine; dopamine; serotonin (5 hydroxy triptamine, 5HT); (RS)-(tetrazol-5-yl) glycine (TzGIy), which is a potent N- methyl-D-aspartate receptor (NMDA) agonist; tetrazolyl-α-amino-3-hydroxy-5- methyl-4-isoxazoleproprionic acid ((tetrazol-5-yl) AMPA); caffeine and nicotine.
[00122 ] In accordance with this invention, the organic molecule ligands glutamate, gamma aminobutyric acid (GABA), alaninate, glycinate and the like have been demonstrated to photorelease from a Photolabile Compound after exposure to visible light; such Photolabile Compounds are stable in solutions in addition to water. Organic molecules having an -NH2 group or an -COOH group may be released in solvents other than water, for example, alcohol (e.g., methanol, ethanol), acetone, etc.
[00123] The organic molecule of the invention include phosphorus derivatives with a -PR.2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-Ciβ alkyl, or aryl. Exemplary phosphorus derivatives include dimethylphosphinyl, diethylphosphinyl, and diphenylphosphinyl.
[00124] The organic molecule of the invention include sulfur derivatives with an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently - H, -Ci-C]8 alkyl, or aryl. Exemplary sulfur derivatives include isopropyl beta-D-1- thiogalactopyranoside (IPTG), thioethers, thiolates, methylthio, ethylthio, and phenylthio.
[00125] In general terms, illustrative examples of labeling molecules useful in the present Photolabile Compounds embrace a variety of agents, such as molecules with a fluorescent, a bioluminescent, a chemiluminescent, a colorimetric or a radioactive group, as nonlimiting examples.
[00126] A fluorescent molecule can be selected from bodipy, dansyl, fluorescein, rhodamine, Texas red, cyanine dyes, pyrene, coumarins, Cascade Blue™, Pacific Blue, Marina Blue, Oregon Green, 4',6-Diamidino-2-phenylindole (DAPI), indopyra dyes, lucifer yellow, propidium iodide, porphyrins, arginine, and variants and derivatives thereof. For further information on fluorescent label moieties and fluorescence techniques, see, e.g., Handbook of Fluorescent Probes and Research Chemicals, by Richard P. Haughland, Sixth Edition, Molecular Probes, (1996), which is hereby incorporated by reference in its entirety.
[00127] The Photolabile Compounds of Formulas I-I1I and V-VIII where L2 is other than Li can be made by allowing about a molar equivalent of Ru(bdt)2Cl2, where bdt is bipyridine or phenanthroline substituted with an Ri-Rs group as defined in Formulas I- III or R1-R4 group as defined in Formulas V- VIII, to react with about a molar equivalent of an organic or labeling molecule in water, ethanol, methanol, isopropyl alcohol, ethylene glycol, acetone, methylene chloride or a mixture thereof at reflux under nitrogen. After about 4 to about 8 hours, the resultant solution is cooled and to it is added at least about an equivalent of L2. The resultant mixture is heated at reflux for about 4 to about 20 h. After cooling to room temperature, the resultant solution is diluted with water, and to it is added excess NH4PFO. The resultant precipitate is filtered, purified via silica-gel chromatography, dried and dissolved in acetone. (H-Bu)4NH4 + X, wherein X is defined in Formula I-III and V-VIII, is added to the acetone solution, and the resultant Photolabile Compound of Formula I-III and V- VIII where L2 is other than L] is filtered.
[00128] The Photolabile Compounds of Formulas I-III and V-VIII where L2 is
Li can be made by allowing about a molar equivalent of Ru(bdt)2Cl2, where bdt is bipyridine or phenanthroline substituted with an Ri-R8 group as defined in Formulas I- IUI or Ri-R4 group as defined in Formulas V- VIII, to react with an excess amount of an organic or labeling molecule in water, ethanol, methanol, isopropyl alcohol, ethylene glycol, acetone, methylene chloride or a mixture thereof at reflux under nitrogen. After about 4 to about 8 hours, the resultant solution is cooled to room temperature. The resultant mixture is diluted with water, and to it is added excess NH4PFO. The resultant precipitate is filtered, purified via silica-gel chromatography, dried and dissolved in acetone. (n-Bu)4NH)+ X, wherein X is defined in I-III and V-
VIII, is added to the acetone solution, and the resultant Photolabile Compound of Formula I-III and V-VIII where L2 is Li is filtered.
[00129] The Photolabile Compounds of Formula IV where M2 is Ru can be obtained by dissolving about 1 molar equivalent of (M')3[M2(CN)sNH3] 2H2O, where M1 is defined in Formula IV, in about 15 mL of argon-deoxygenated 1 :1 ethanol:water containing about 10 molar equivalents of the organic molecule. The resultant mixture is maintained at about room temperature under argon for about 1 hour and concentrated in vacuo at about room temperature to a volume of about 1 mL. To the resultant concentrate is added a cold, saturated ethanol solution of M1I, resulting in a precipitation of the Photolabile Compounds of Formula IV where M2 is Ru, which are washed with ethanol and diethyl ether.
[00130] For the present invention, photorelease can generally occur rapidly, e.g., after about a few nanoseconds to about 500 milliseconds ( See Salierno et al., J Inorg Biochem. 2010 104(4):418-22) following exposure to visible light of the appropriate wavelength. Suitable wavelengths of light for effective photorelease of an organic molecule or a labeling molecule from a Photolabile Compound range from about 300 to about 500 nm, or from about 300 to about 360 nm, or from about 450 to about 500 nm, e.g., 473 nm and may be extended up to 700nm. Suitable light sources include those which are capable of irradiating light of the appropriate wavelengths, for example and without limitation, commercially available tungsten lamps (Cole-Parmer), arc lamps, xenon continuous lamps, lasers, e.g., blue or green lasers or photooptic light sources. Such light sources are commercially available (CrystaLaser, Reno, Nevada; Lasever, Jiangdong, Ningbo, China). Other forms of light, such as sunlight, infrared light, pulsed infrared light, or UV radiation can also be used for the invention, as necessary or desired.
[00131 ] Devices and systems suitable for exposing the Photolabile Compounds to light, particularly visible or infrared light, further include imaging probes, imaging catheters and fiber optic probes, particularly those containing gradient index, or graded-index, (GRTN) lenses, which are described in U. Utzinger et al., 2003, J. Biomed. Optics, 8(1): 121-147; and Fujimoto et al., Photonic Materials, Devices and Systems - Laser Medicine and Medical Imaging Group, RLE Progress Report 144, pp
27-1 to 27-35, and which are commercially available. (Sp3 plus, UK). The light suitable for exposing the Photolabile Compounds to photorelease an organic molecule or a labeling molecule comprises a wavelength of about 300 to about 500 nm, or about 300 to about 360 nm, or about 450 to about 500 nm. Suitable light includes visible or infrared light.
[00132 ] Further in accordance with this invention, the organic molecules or labeling molecules can also be released from the Photolabile Compounds via one- photon or two-photon photolysis. Optical memories that utilize a two-photon excitation are described, for example, by Strickler and Webb, 1991 , Optics Letters, 16: 1780-1782. A feature of two-photon excitation is the elimination of out-of-focus background. {See, e.g., W. Denk et al., 1990, Science, 248:73-76). Thus, two-photon uncaging can release an organic molecule or a labeling molecule only in the plane of focus. (See, e.g., W. Denk et al., 1994, Proc Natl. Acad Sci. USA, 91 :6629-6633).
[00133] In an embodiment, the present invention encompasses a compound of
Formula I, wherein the organic molecule is 4-AP. In another embodiment, the invention encompasses a compound of Formula I, wherein the organic molecule is TzGIy. In another embodiment, the invention encompasses a compound of Formula I, wherein the organic molecule is (tetrazol-5-yl) AMPA. In another embodiment, the invention encompasses a compound of Formula I, wherein the organic molecule is nicotine or caffeine. In another embodiment, the invention encompasses a compound of Formula I, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine. In another embodiment, the present invention encompasses a compound of Formula I, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', 5'-cyclicmonophosphate. In another embodiment, the invention encompasses a compound of Formula I wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D-aspartic acid.
[00134] In an embodiment, the present invention encompasses a compound of
Formula II or III, wherein the organic molecule is 4-AP. In another embodiment, the invention encompasses a compound of Formula II, wherein the organic molecule is TzGIy. In another embodiment, the invention encompasses a compound of Formula II,
wherein the organic molecule is (tetrazol-5-yl) AMPA. In another embodiment, the invention encompasses a compound of Formula II, wherein the organic molecule is nicotine or caffeine. In another embodiment, the invention encompasses a compound of Formula II, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine. In another embodiment, the present invention encompasses a compound of Formula II, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5 '-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate. In another embodiment, the invention encompasses a compound of Formula II, wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D-aspartic acid.
[00135] In an embodiment, the present invention encompasses a compound of
Formula IV, wherein the organic molecule is 4-AP. In another embodiment, the invention encompasses a compound of Formula IV, wherein the organic molecule TzGIy. In another embodiment, the invention encompasses a compound of Formula IV, wherein the organic molecule is (tetrazol-5-yl) AMPA. In another embodiment, the invention encompasses a compound of Formula IV, wherein the organic molecule is nicotine or caffeine. In another embodiment, the invention encompasses a compound of Formula IV, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine. In another embodiment, the present invention encompasses a compound of Formula IV, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate. In another embodiment, the invention encompasses a compound of Formula IV, wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D- aspartic acid.
[00136] In an embodiment, the present invention encompasses a compound of
Formula V, wherein the organic molecule 4-AP. In another embodiment, the invention encompasses a compound of Formula V, wherein the organic molecule is TzGIy. In another embodiment, the invention encompasses a compound of Formula V, wherein the organic molecule is (tetrazol-5-yl) AMPA. In another embodiment, the invention encompasses a compound of Formula V, wherein the organic molecule is nicotine or caffeine. In another embodiment, the invention encompasses a compound of Formula
V, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine. In another embodiment, the present invention encompasses a compound of Formula V, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'- diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate. In another embodiment, the invention encompasses a compound of Formula V wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D-aspartic acid.
[00137] In an embodiment, the present invention encompasses a compound of
Formula VI, wherein the organic molecule is 4-AP. In another embodiment, the invention encompasses a compound of Formula VI, wherein the organic molecule is TzGIy. In another embodiment, the invention encompasses a compound of Formula
VI, wherein the organic molecule is (tetrazol-5-yl) AMPA. In another embodiment, the invention encompasses a compound of Formula VI, wherein the organic molecule is nicotine or caffeine. In another embodiment, the invention encompasses a compound of Formula VI, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine. In another embodiment, the present invention encompasses a compound of Formula VI, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate. In another embodiment, the invention encompasses a compound of Formula VI wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D- aspartic acid.
[00138] In an embodiment, the present invention encompasses a compound of
Formula VII, wherein the organic molecule is 4-AP. In another embodiment, the invention encompasses a compound of Formula VII, wherein the organic molecule is TzGIy. In another embodiment, the invention encompasses a compound of Formula
VII, wherein the organic molecule is (tetrazol-5-yl) AMPA. In another embodiment, the invention encompasses a compound of Formula VII, wherein the organic molecule is nicotine or caffeine. In another embodiment, the invention encompasses a compound of Formula VII, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine. In another embodiment, the present invention encompasses a compound of Formula VII, wherein the organic molecule is adenosine
5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', S'-cyclicmonophosphate. In another embodiment, the invention encompasses a compound of Formula VII wherein the organic molecule is aminobutyric acid or L-glutamic acid, or methyl-D- aspartic acid.
[00139] In an embodiment, the present invention encompasses a compound of
Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is fluorescein. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is iodeosin. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is a fluorescent molecule containing a -CN group whose nitrogen atom forms a bond with Ru. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is a fluorescent molecule containing a pyridyl group whose nitrogen atom forms a bond with Ru. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is a fluorescent molecule containing an amino group whose nitrogen atom forms a bond with Ru. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is a fluorescent molecule containing a phosphine group whose nitrogen atom forms a bond with Ru.
[00140] In another embodiment, the invention encompasses a compound of
Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine containing a -CN group whose nitrogen atom forms a bond with Ru. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine containing a pyridyl group whose nitrogen atom forms a bond with Ru. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine containing an amino group whose nitrogen atom forms a bond with Ru. In another embodiment, the invention encompasses a compound of Formulas I-III and V-VIII, wherein the labeling molecule is rhodamine containing a phosphine group whose nitrogen atom forms a bond with Ru.
[00141 ] In some embodiments, of the compounds of Formula I-III and V-VIII,
L2 Is:
RhOdB-MAMePy
(RhodB-MAMePy) or a chloride salt thereof (RhodB-MAMePy-Cl).
[00142] In some embodiments of the compounds of Formula I-III and V-VIII,
L2 is:
RhodθG-MAMePy
(Rhod6G-M AMePy) or a chloride salt thereof (Rhod6G-MAMePy-Cl). .
[00143] In some embodiments, the labeling molecule or an active derivative thereof is bonded to Ru to Ru through other coordinating groups: -NH2, pyridyl, or a phosphine group.
[00144] In some embodiments of Photolabile Compounds, L2 comprises a labeling molecule or an active derivative thereof, which can serve as a light antenna and can transfer energy to the portion of the compound that effects photorelease of
moiety L1. This way the light gathering becomes dissociated from the chemical release step, enabling orthogonal chemical strategies for both processes. Thus, in some embodiments, a Photolabile Compound has a dual functional ization, one being a light antenna and second being a photorelease entity.
[00145] In one aspect, a Photolabile Compound can be used in combinatorial chemistry strategies. For example, one could generate a systematic series of derivatives in the photorelease part of the molecule and perform large-scale screening with them. Alternatively or in addition, one could fix the photorelease part of the molecule while derivatizing the light antenna moiety.
[00146] In another aspect, the magnetic and/or radio-opaque properties of a
Photolabile Compound are used as a means of indentifying it or manipulating it in living cells. In one such embodiment, Photolabile Compounds are used as MRI (Magnetic Resonance Imaging) contrast agents.
[00147] When L2 comprises a labeling molecule such as a fluorophore or a derivative thereof, L2 can servean antenna, to extend the irradiation spectrum to lower energies with very high absorption and efficiency. In specific embodiments, the fluorescent dye is linked through a derivatization using a non-releasable ligand, i.e., a phosphine ( :P(R)2-fluorophore). In these embodiments, the light is collected by the fluorescent moiety acting as an antenna, and transferred to the Ru center, populating the MLCT or d-d excited states. Once the excited state is reached, the other ligand (i.e., L1, which can be a biomolecule or drug) is released.
[00148] The fact that in this case the active wavelength is not determined by the Ru center but by the high absorption of the fluorescent dye (-100,000 M 1Cm"') allows the tuning of different complexes having different photouncageable drugs at different wavelengths, from 400 to 600 nm, providing orthogonality.
[00149] Use of a suitable organic dye coordinated to the ruthenium next to the coordinated fluorescent dye (i.e., a labeling molecule) permits the selective quenching of the fluorescence due to its proximity. In this case, the absorption of light via the Ru- bpy MLCT band (without antenna effect, the fluorescent being quenched by the nearby nonfluorescent dye), can photorelease either the fluorescent dye, increasing
dramatically the fluorescence and "uncaging" the fluorophore, or the nonfluorescent quencher, with somewhat similar results (under some conditions, however, the presence of the metallic center can quench the fluorophore).
[00150] Further in accordance with the invention, the compounds of Formulas
V-VIII, wherein R1 and R2 and/or R3 and R4 combine to form a carbocyclic ring substituted by one or more oxo groups, can attach to surfaces and are useful for the delivery of compounds to surfaces. For example, such compounds can bind to nanoparticles or nanopowders and be used to deliver biologically active organic molecules or labeling molecules. Nanoscale delivery systems have substantial applications in the controlled and targeted transport of drugs. Drugs can be carried selectively to targeted cells by means of nanoparticles with specific surface fictionalization. Nanoparticles can penetrate cell membranes and overcome physiological barriers in the organism, and nanoparticles can also improve the solubility and bio-availability of drugs.
[00151 ] In another embodiment, the invention provides a method for enhancing the solubility of an organic molecule, comprising complexing an organic molecule to a photolabile caging group to form a Photolabile Compound, such that exposing the compound to light under sufficient conditions releases the organic molecule from the compound. In an embodiment, the organic molecule has:
(i) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(ii) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(iii) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(iv) an -NH2 group whose nitrogen atom forms a bond with Ru;
(v) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(vi) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl; or
(vii) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl.
[00152 ] In an embodiment, the present invention encompasses a composition comprising an effective amount of a Photolabile Compound and a physiologically acceptable carrier, vehicle, diluent, or excipient. Suitable carriers, vehicles, diluents, or excipients are known to those skilled in the art and include, without limitation, physiologically sterile saline and others as described herein.
[00153] In another embodiment, the present invention provides a vessel containing a Photolabile Compound. The vessel can further contain a biological sample, wherein the sample is, for example, hair, an organ specimen; a tissue or cell, for example, a neuronal tissue or cell; a tumor or cancer or neoplastic tissue or cell; or a tissue or cell removed from a patient or subject of interest. Tissue specimens sliced from microtomes, for example, are examples of suitable biological samples.
[00154] Any type of vessel that is capable of transmitting the wavelengths of light used for releasing the organic molecules or labeling molecules comprising the Photolabile Compounds, and that is inert to solvent in which a Photolabile Compound is suspended, is suitable for use. For example, the vessel can be made of glass, plastic, acrylic, quartz, a noble metal, etc. In addition, if the vessel is composed of, or encased in, metal, e.g., aluminum, titanium, or stainless steel, exposure to light is performed through the top of the vessel, or through a "window" or other light-penetrable opening in the vessel. For solid-like materials, acrylic plastic or acrylamide-bisacrylamide gel, etc., for example, can be used as media in which the Photolabile Compounds are contained. For example, an acrylic plastic coating formulated using a CHCb solution of acrylic and a Ru(bpy) complex changed its spectrum following irradiation, thus allowing photorelease in a solid state. For such solid state aspects of the invention, the temperature may be kept at 4K.
[00155] Solvents suitable in which a Photolabile Compounds can be exposed to light include aqueous solvents; water; acetonitrile; alcohol, e.g., methanol, ethanol; acetone; chlorinated solvents such as CH2Cl2 and CHCb; or dimethylsulfoxide.
[00156] Suitable temperatures at which a Photolabile Compound is exposed to light range, in general, from about 0°C to about 100-1500C.
[00157] In another embodiment, this invention encompasses a method for releasing an organic molecule or a labeling molecule from a Photolabile Compound. The method comprises exposing a Photolabile Compound to light under conditions sufficient to release the organic molecule or labeling molecule from the compound. In the method, the light comprises a wavelength of about 300 to about 500 nm, or about 300 to about 360 nm, or about 450 to about 500 nm. Further, the exposing can occur at a temperature from about O0C to about 150°C. In an embodiment, the methods of the invention comprise a Photolabile Compound, e.g., a compound of Formula I-VIII, light of a wavelength of about 300 nm to about 500 nm; L1 being L2, and a temperature of about 0°C to about 15O0C. In another embodiment, the methods comprise a Photolabile Compound, light of a wavelength of about 300 nm to about 360 nm; L1 being L2, and a temperature of about 00C to about 1500C. In another embodiment, the methods comprise a Photolabile Compound, light of a wavelength of about 450 nm to about 500 nm; L1 being L2, and a temperature of about O0C to about 1500C. In another embodiment, the methods comprise a Photolabile Compound, visible or infrared light; L1 being L2, and a temperature of about O0C to about 1500C.
[00158] In an embodiment, the invention encompasses a method for assaying an organic molecule, comprising exposing a Photolabile Compound and a biological sample to light under conditions sufficient to release the organic molecule from the Photolabile Compound, and (b) determining an effect of the organic molecule on the biological sample. The sample can be a biological sample, such as a sample excised, removed, or otherwise taken from a subject's body. The subject's biological sample can be, for example, a hair sample, an organ or tissue sample, e.g., from a biopsy or an autopsy, or a cell sample. In addition, the biological sample can be a body fluid sample. Body fluid samples include, without limitation, blood, serum, plasma, lymph, saliva, sputum, tears, semen, or urine. Biological samples can further include, without limitation, brain tissue, brain cells, muscle tissue, muscle cells, muscle fibers, fibroblasts, tissue slices, or fine tissue specimens, from any organ of the body, sarcoplasmic reticulum, skin tissue, membrane preparations or fragments, etc.
[00159] The light for exposing the compounds according to the methods of this invention can be sunlight, photo-optic light, or laser light. Advantageously, in the methods of this invention, the light for exposing the compound is other than UV
radiation. Thus, for example, the light can be visible light or infrared light, including one-photon and two-photon light. The light can be emitted from a variety of sources, including without limitation, a laser light source, a tungsten light source, a photooptic light source, etc. Another advantage of visible light to expose or irradiate the compounds of the invention relates to the convenience and ability to use a visible light microscope, for example, to view a sample into which a compound is introduced and to microscopically visualize or monitor a photoreleased ligand from the compound after exposure to visible light. Because many microscopes do not transmit UV light, it is advantageous to be able to use a non-quartz microscope in accordance with this invention. Yet another advantage to the use of visible light is that it is not detrimental to living cells and tissues, making it beneficial for in vivo patient use. In addition, for patient use, the light can be specifically directed to an area where a Photolabile Compound is introduced or administered by the use of laser technology, fibers, probes, tubes, and the like. Such probes, fibers, or tubes can be directly inserted, for example, into a body cavity or opening, or under or through the skin, to expose the Photolabile Compound to light.
[00160] In another of its embodiments, the present invention includes a method of making an organic molecule bioavailable to a subject. The organic molecule can be made bioavailable to a localized body region or area of the subject, or systemically to the whole body. Local bioavailability of the Photolabile Compounds is achieved, for example, via delivery devices and methods that allow the compounds to be directly administered, for example, inserted into a body cavity, or opening, or through or into the skin. The method of this embodiment involves administering a Photolabile Compound to the subject, and exposing the compound to light under conditions sufficient to release the organic molecule from the compound, thereby making the organic molecule bioavailable to the subject, and/or to a body site or region of the subject. The exposure to light can comprise the use of probes, fibers, tubes, and the like, which allow the light to be specifically directed to the area of interest on or within the body. Alternatively, the Photolabile Compounds can be administered to the patient kept in the dark; for photorelease of the organic molecule, the patient can be moved to the light where exposure to light and photorelease occur. In an embodiment according to this method, the organic molecule has:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl.
[00161 ] In another embodiment, the organic molecule has:
(a) a tetrazolyl group, one of its nitrogen atoms forming a bond with Ru;
(b) nicotine or caffeine, whose pyridyl nitrogen atom forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -Ci-Ci8 alkyl, or aryl.
[00162 ] In a related embodiment, the Photolabile Compounds are useful for releasing an organic molecule, such as a drug, pharmaceutical, small biologically active molecule, and the like as described above. Release of the organic molecule from the Photolabile Compound allows the organic molecule to become bioavailable to a subject, or patient, afflicted with a disease, disorder, pathology, or condition. The Photolabile Compounds and organic molecules are useful in veterinary and human medicine. Diseases, disorders, pathologies, or conditions for which making an organic molecule bioavailable would serve to treat, ameliorate, reduce, eliminate, abate, or prevent the disease, disorder, pathology, or condition are further described below and
include, as nonlimiting examples, peripheral and central nervous system disorders, neurological disorders and disorders related thereto, neurodegenerative disorders and disorders related thereto, epilepsy, seizures, migraines, headaches, stroke, anxiety, depression, restricted brain function, addictive disorders, neuroses, psychoses, pruritic conditions, Parkinson's disease, Huntington's chorea, cognitive disorders, memory lapses, Alzheimer's disease, dementia, dyskinesia, muscle spasms, retinopathy, vomiting, cancers, neoplasms, tumors, vascular diseases, and cardiovascular diseases.
[00163 | As further, yet non-limiting examples, the organic molecule is a neurochemical that blocks potassium channels for use, for example, in treating neurodegenerative, or neurological diseases or disorders. In a particular embodiment, the organic molecule is 4-AP, which is a calcium channel blocker. In another embodiment, the organic molecule is TzGIy, which is an NMDA-receptor agonist that is more potent than NMDA. In one embodiment, for making an organic molecule of the invention bioavailable to a subject in need thereof, the exposure of the Photolabile Compound to light can occur at the site of the disease, disorder, pathology, or condition, such as a site of a tumor, neoplasm, or cancer lesion or growth, thereby releasing the organic molecule locally and more precisely at the needed location. In another embodiment, for making an organic molecule of the invention bioavailable to a subject in need thereof, the exposure of the Photolabile Compound to light can occur at the sight of a blood dyscrasia.
[00164] In other related embodiments, the present invention provides methods for treatment, therapy, and prophylaxis by administering an effective amount of a Photolabile Compound, or a physiologically acceptable composition comprising a Photolabile Compound to a subject, so as to make an organic molecule bioavailable to the subject. The Photolabile Compound can be substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side- effects). Advantageously, for methods in which a Photolabile Compound is administered to a subject, the light, e.g., infrared, laser, or visible light, for photore I easing the organic molecule to make it bioavailable to the subject can be directed to an internal site or region of interest by using photooptic devices, probes and fibers, such as are known in the art and described supra. Those having skill in the art
can employ, manipulate, and internally direct the devices for exposing a Photolabile Compound to light after the Photolabile Compound is administered to a subject.
[00165] In the methods of the present invention involving subjects, and/or the treatment, therapy, or prophylaxis of a disease, disorder, pathology, or condition, the subject is preferably an animal, including but not limited to, mammals such as human and non-human primates, cows, pigs, horses, goats, sheep, rabbits, chickens, cats, dogs, guinea pigs, rats, mice, etc. The methods of the invention especially encompass human treatments.
[00166) Various delivery systems are known and can be used to administer a
Photolabile Compound, e.g., in sterile solution, encapsulation in liposomes, microparticles, microcapsules, or receptor-mediated endocytosis (See, e.g., Wu and Wu, 1987, J. Biol. Chem., 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, topical, transdermal, parenteral, intrathecal, vaginal, rectal, colorectal, oral, intracranial, retroorbital, intrasternal routes, or a combination thereof.
[00167] The Photolabile Compounds or compositions may be administered by any convenient route or mode, for example, by continuous infusion, non-continuous infusion, or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, epidermis, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active and/or therapeutic agents. Administration can be systemic or local. In addition, it may be desirable to introduce the Photolabile Compounds or compositions into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
[00168] In a particular embodiment, it may be desirable to administer the
Photolabile Compounds or compositions locally to the area in need of treatment. This may be achieved, for example, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a
catheter, by means of a suppository, or by means of an implant, where the implant is a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
[00169] In another embodiment involving topical administration, a transdermal patch can be used. In accordance with this embodiment, the Photolabile Compound remains unexposed to light until the patch is manipulated by a patient or medical provider so that all or a portion of the patch containing a Photolabile Compound is exposed to light. Accordingly, the patch can be opened and the bioactive molecule released, or "activated" from the compound after exposure to light, for example, by the patient's moving from a dark room to a lighted room, or from a dark area to a light area; by the patient's directly exposing the patch, or a portion thereof, to a suitable light source, or by the patient's exposing all or a portion of the patch to daylight. A variety of types of transdermal patches are known and used by the skilled practitioner in the art. Alternatively for topical administration, a Photolabile Compound can be formulated into a light-sensitive composition, which is contained in a dark, light- protected container, and applied topically to the area of interest, e.g., applied to or rubbed onto the skin of a subject, in the dark. Following topical application in the dark, the area of interest is exposed to light, or to an appropriate light source, or the subject moves into the light, thereby causing the organic molecule of the Photolabile Compound to be released.
[00170] In another embodiment, the Photolabile Compounds or compositions can be delivered in a vesicle, in particular a liposome {See, e.g., Langer, 1990, Science, 249: 1527-1533; Treat et al., In: Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.) In yet another embodiment, the Photolabile Compounds or compositions can be delivered in a controlled-release system. For example, a pump may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201 ; Buchwald et al., 1980, Surgery, 88:507; Saudek et al., 1989, NEJM, Med. 321 :574 (1989)), or polymeric materials can be used (See, e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Press, Boca Raton, FIa. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas,
1983, J. Macromol. Sci. Rev. Macromol. Chem., 23:61 ; Levy et al., 1985, Science, 228: 190; During et al., 1989, Neurol., 25:351 ; and Howard et al., 1989, J. Neurosurg., 71 : 105). Moreover, a controlled-release system can be placed proximal to the therapeutic target, e.g., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, In: Medical Applications of Controlled Release, Vol. 2, pp. 1 15-138). As further guidance, other controlled release systems are found in Langer, 1990, .S1CIeTiCe, 249: 1527-1533.
[00171 ] The Photolabile Compounds are also provided in effective amounts in pharmaceutical compositions comprising a pharmaceutically acceptable carrier, diluent, excipient, or vehicle, for example, for use as therapeutics. In one embodiment, the term "pharmaceutically acceptable" refers to approval by a regulatory agency of the Federal or a state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly, in humans. The terms vehicle, carrier, or excipient refer to a diluent or adjuvant in or with which the therapeutic is administered. Such pharmaceutical carriers, vehicles, or excipients can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when a pharmaceutical composition is administered intravenously and is water soluble. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. If needed or desired, the composition of the invention can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
[00172 ] The Photolabile Compounds and compositions of the present invention can be formulated as solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like. The compositions can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulations can include standard carriers, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers and the like
are described in the current edition of "Remington's Pharmaceutical Sciences" by E. W. Martin. Such compositions routinely contain a therapeutically effective amount of the Photolabile Compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to a subject. The formulation should suit the mode of administration.
[00173] In another embodiment, a Photolabile Compound of the invention is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container, such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration. Sterility for of a composition for therapeutic administration is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. Therapeutics are typically stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. Where necessary, the ampoule or vial is essentially impenetrable by light. As an example of a lyophilized therapeutic formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized therapeutic using bacteriostatic Water-for-Injection.
|00174) The amount of a Photolabile Compound which will be effective in the treatment, amelioration, reduction, elimination, inhibition, or prevention of a particular disease, condition, pathology, or disorder associated with the use and bioactivity of an
organic molecule can be determined by standard clinical techniques. An "effective amount" or a "pharmaceutically effective amount" of a Photolabile Compound of this invention refers to an amount effective for treating, ameliorating, reducing, abating, eliminating, preventing, a disease, condition, pathology, or disorder for which the compound is being used. In particular embodiments, an effective amount is an amount effective for making an organic molecule of the invention bioavailable to a subject. If another therapeutic agent is used in conjunction with the Photolabile Compounds, the effective amount of the therapeutic agent refers to an amount effective for providing the therapeutic effect of the therapeutic agent. The precise dose to be employed in the formulation will also depend on the route of administration, as well as an individual patient's circumstances, such as age, health and vital statistics of the patient, and the severity of the disease, condition, or disorder. Dosing should be decided according to the judgment of the medical practitioner based on an evaluation of the patient and considerations of a patient's physiologic situation and medical history. In addition, in vitro assays may optionally be used to assist in determining optimal dosage ranges. Effective doses can be extrapolated from dose-response curves derived from in vitro or in vivo animal model test systems.
[00175] As general guidance, the total effective amount of a Photolabile
Compound administered parenterally per dose will be in the range of about 1 μg/kg/day to 10 mg/kg/day of a subject's body weight, although, as noted above, this will be subject to discretion based on the subject's condition and the above-mentioned variables. A therapeutic dose can also be at least 0.01 mg/kg/day, or between about 0.01 and 1 mg/kg/day, with particular regard for human administration. If given continuously, a therapeutic is typically administered at a dose rate of about 1 μg/kg/hour to about 50 μg/kg/hour, either by 1 to 4 injections per day or by continuous subcutaneous infusions, e.g., using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur will likely vary depending on the desired effect. In some embodiments, suitable effective dosage amounts range from about 10 μg to about 2500 mg about every 4 hours, although the amounts are typically about 100 mg or less. In one embodiment, the effective dosage of a Photolabile Compound ranges from about 0.01 mg to about 100 mg about every 4 hours. In another
embodiment, the effective dosage of a compound of the invention ranges from about 0.020 mg to about 50 mg every 4 hours, and in another embodiment, about 0.025 mg to about 20 mg about every 4 hours. The effective dosage amounts refer to total amounts administered. Thus, if more than one of the Photolabile Compounds is administered, the effective dosage amounts correspond to the total amount administered.
[00176] In another embodiment, if a Photolabile Compound is contacted with a biological sample in vitro, an effective amount will typically range from about 0.01 μg/L to about 5 mg/L; in another embodiment from about 0.01 μg/L to about 2.5 mg/L; in another embodiment, from about 0.01 μg/L to about 0.5 mg/L; and in yet another embodiment, from about 0.01 μg/L to about 0.25 mg/L of a solution or suspension of a pharmaceutically acceptable carrier, diluent, or excipient. In an embodiment, the volume of solution or suspension is from about 1 μL to about 1 mL; in another embodiment, the volume of solution or suspension is about 200 μL.
[00177] . Examples of neoplastic or hyperproliferative diseases, disorders, pathologies, or conditions that can be treated, ameliorated, reduced, abated, eliminated, inhibited, prevented, and/or diagnosed using the Photolabile Compounds and photoreleased organic molecules include, but are not limited to, neoplasms (cancers or tumors) located in the colon, abdomen, bone, breast, digestive system, esophagus, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovaries, cervix, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thoracic areas, bladder, and urogenital system. Cancers that may be treatable using the Photolabile Compounds include follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer, or metastases thereof. Autoimmune diseases, disorders, or conditions may be treatable with the Photolabile Compounds and include multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Bechet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis, rheumatoid arthritis,
ischemic injury (e.g., caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (e.g., caused by alcohol), septic shock, cachexia and anorexia. Viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft versus host (GVH) disease, acute graft rejection, and chronic graft rejection may also be treatable with the Photolabile Compounds.
[00178] Additional diseases or conditions associated with abnormal and increased cell survival that may be treated, ameliorated, reduced, abated, eliminated, inhibited, prevented, and/or diagnosed using the Photolabile Compounds include, but are not limited to, progression and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia, including myeloblasts, promyelocytic, myelomonocytic, monocytic, and erythroleukemia) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.
[00179] In another embodiment, the Photolabile Compounds may be needed as therapeutics to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and the healing of dermal wounds. The Photolabile Compounds of the invention may be clinically useful in stimulating wound healing, including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment using steroids, radiation therapy, anti-neoplastic drugs and anti-metabolites.
[00180] Other diseases, disorders, or conditions that may be treated, ameliorated, reduced, abated, eliminated, inhibited, prevented, and/or diagnosed with the Photolabile Compounds include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Retinitis pigmentosa (RP), cerebellar degeneration and brain tumor or prior associated disease).
[00181 ] In one embodiment, diseases and conditions that are treatable using calcium channel blockers, e.g., 4AP, include without limitation, heart disease, hypertension, angina, chest pain, cardiovascular diseases, such as coronary artery disease, cardiomyopathies, valvular heart disease, renal disease, Peyronie's disease and neurological, neurophysiological, or neuromuscular diseases and conditions, e.g., amyotrophic lateral sclerosis (ALS), multiple sclerosis, and epilepsy.
[00182] In another embodiment, diseases that are treatable using NMDA receptor agonists or antagonists, e.g., TzGIy, include without limitation, neurological, neurodegenerative, or neurophysiological diseases, disorders, and conditions, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and dyskinesias. In another embodiment, neurological, neurodegenerative, and neurophysiological diseases, e.g., Parkinson's disease, Alzheimer's disease, etc., are treatable using Tz- AMPA.
[00183] In another embodiment, the present invention relates to kits comprising a Photolabile Compound and instructions for use. A kit may be used in a diagnostic, screening, or testing assay. A kit may also be a pharmaceutical pack, particularly for use in treating or preventing a disease, disorder, pathology, or condition. A kit for pharmaceutical use is typically sterile and contains a Photolabile Compound in an amount effective to treat or prevent a disease, disorder, pathology, or condition, and a pharmaceutically acceptable carrier, diluent, or excipient. The kit, or a pharmaceutical pack, can comprise one or more vessels or containers filled with an effective amount, e.g., unit dosage form, of one or more of the Photolabile Compounds or compositions of the invention, and a pharmaceutically acceptable carrier, diluent, or excipient. The kit, or pharmaceutical pack, can further comprise a label. In addition, the kit, or pharmaceutical pack, can also include a unit dosage form of another therapeutic agent, for example, a container containing an effective amount of the other therapeutic agent. The kit, or pharmaceutical pack, may further optionally contain a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, reflecting approval by the agency of manufacture, use or sale for human administration. The kit, or pharmaceutical pack, can also contain a device useful for administering the unit dosage forms. Examples of such devices include, without limitation, a syringe, a drip bag, a patch, an inhaler, and an enema bag or container.
EXAMPLES
[00184] The examples described below are provided to illustrate the present invention and are not included for the purpose of limiting the invention.
EXAMPLE 1
[00185] Synthesis of [Ru(bpy)2(4AP)2]CI2. 159 mg of Ru(bpy)2Cl2 , where bpy = 2,2'-bipyridine, were suspended in 7 mL of water at 85°C under N2. After dissolution, 66 mg of 4-aminopyridine ("4AP") were added, and the resultant solution was heated for about 20 minutes at about 50-800C or greater. A molar excess of NH4PF6, was added, and the resultant red solid was washed with water and dried. The red solid was dissolved in a minimal amount of acetone, and to the acetone solution
was added tetraethylammonium chloride, precipitating [Ru(bpy)2(4AP)2]Cl2 (79% yield).
EXAMPLE 2
[00186] Synthesis of [Ru(bpy)2(TzGly)2]Cl2. [Ru(bpy)2(TzGly)2]Cl2 was made according to the procedure used to make [Ru(bpy)2(4AP)2]Cl2 set forth in Example 1 , except that (RS)-(tetrazol-5-yl)glycine ("TzGIy") was used in place of 4AP.
EXAMPLE 3
[00187] Synthesis of [Ru(bpy)2(5HT)2]Cl2. [Ru(bpy)2(5HT)2]Cl2 is made according to the procedure used to make [Ru(bpy)2(4AP)2]Cl2 set forth in Example 1 , except that serotonin ("5HT") is used in place of 4AP.
EXAMPLE 4
[00188] Synthesis of [Ru(bpy)2(4AP)(PPh3)]Cl2. Ru(bpy)2Cl2 , where bpy =
2,2'-bipyridine, was suspended in water at a concentration of 10 mg/mL at 850C under N2. After dissolution, 1 equivalent of PPh3 was added, and the resultant solution was heated for about 60 minutes at about 50-800C or greater. 1.1 Equivalents of 4AP were subsequently added, and heating continued for an additional 30 minutes. A molar excess Of NH4PF6, was added, and the resultant orange solid was washed with water and dried. The orange was dissolved in a minimal amount of acetone, and to the acetone solution was added tetraethylammonium chloride, precipitating [Ru(bpy)2(4AP)(PPh3)]Cl2.
EXAMPLE 5
[00189] Synthesis of [Ru(bpy)2(TzGIy)(PPh3)] Cl2.
[Ru(bpy)2(TzGly)(PPh3)]Cl2 was made according to the procedure used to make [Ru(bpy)2(4AP)(PPh3)]Cl2 set forth in Example 4, except that TzGIy was used in place of 4AP.
EXAMPLE 6
[00190] Synthesis of [Ru(bpy)2(5HT)(PPh3)]Cl2. [Ru(bpy)2(5HT)(PPh3)]Cl2 is made according to the procedure used to make [Ru(bpy)2(4AP)(PPh3)]Cl2 set forth in Example 4, except that serotonin is used in place of 4AP.
EXAMPLE 7
[00191 ] Synthesis of [Ru(bpy)2(nicotine)(PPh3)]Cl2.
[Ru(bpy)2(nicotine)(PPh3)]Cb is made according to the procedure used to make [Ru(bpy)2(4AP)(PPh3)]Cl2 set forth in Example 4, except that nicotine is used in place of 4AP.
EXAMPLE 8
[00192] Synthesis of [Ru(bpy)2(TzGly)(py)]Cl2. [Ru(bpy)2(TzGly)(py)]Cl2, where py = pyridine, was made according to the procedure used to make [Ru(bpy)2(4AP)(PPh3)]Cl2 set forth in Example 4, except that TzGIy was used in place of 4AP and pyridine was used in place of PPh3.
EXAMPLE 9
[00193] Synthesis of [Ru(bpy)2(4AP)(py)]Cl2. [Ru(bpy)2(4AP)(py)]Cl2, where py = pyridine, is made according to the procedure used to make [Ru(bpy)2(4AP)(PPh3)]Cb set forth in Example 4, except that pyridine is used in place Of PPh3.
EXAMPLE 10
[00194] Synthesis of [Ru(bpy)2(5HT)(py)]Cl2. [Ru(bpy)2(5HT)(py)]Cl2, where py = pyridine, is made according to the procedure used to make [Ru(bpy)2(4AP)(PPh3)]Cl2 set forth in Example 4, except that 5HT is used in place of 4AP and pyridine is used in place of PPh3i
EXAMPLE 11
[00195] Synthesis of [Ru(bpy)2(nicotine)(py)]Cl2.
[Ru(bpy)2(nicotine)(py)]Cl2, where py = pyridine, is made according to the procedure
used to make [Ru(bpy)2(4AP)(PPh3)]Cl2 set forth in Example 4, except that nicotine is used in place of 4AP and pyridine is used in place of PPI13.
EXAMPLE 12
100196] Synthesis of Co(DMG)2(SHT)(Cl). CoCl2 was dissolved in a 1 : 1 v/v mixture of water/ethanol at a final concentration of about 0.2 M. Two equivalents of dimethylglyoxime ("DMG") were added, and the resultant mixture was allowed to stir under N2 until dissolution. One equivalent of 5HT was added, air was bubbled into the resultant mixture for 6 hours and Co(DMG)2(5HT)(Cl) precipitated. The precipitated product was filtered and washed.
EXAMPLE 13
[00197] Photorelease of 4AP from [Ru(bpy)2(4AP)2]Cl2. UV-vis spectra in water were obtained with an HP 8453 diode array spectrophotometer. RMN 1H spectra were obtained using a Bruker 500 MHz equipment. CV measurements were performed with a PAR 273 A potentiostat. Irradiation was effected by means of a pulsed Xe lamp, (pulse energy -0.5 J), with a low-pass filter at 480 nm. Irradiation using a 473 nm DPSS laser gave similar results.
[00198] [Ru(bpy)2(4 AP)2]Cl2 is very soluble in water and stable in the dark, while undergoing decomposition under irradiation with visible light in its metal-to- ligand charge transfer (MLCT) band, centered at 489 nm. (In CH3CN solution, the absorption band is red-shifted to 492 nm, consistent with the lower polarity of the solvent, despite a previous characterization that reported 450 nm. However, light exposure of a CH3CN solution of [Ru(bpy)2(4AP)2]Cl2 produced a yellow compound with absoφtion maximum at 450 nm. This may correspond to the previously misinterpreted assignments for this compound (D. Chun-Ying et al., 1999, J. Coord. Chem., 46:301-312), and the photoproduct is likely to be the complex [Ru(bpy)2(4AP)CH3CN]2+). Several ruthenium polypyridyl complexes present this behavior. (D. V. Pinnick et al., 1984, Inorg. Chem., 23: 1440-1445).
[00199] Although at pH 7 the spectrum of the irradiated complex is very similar to that of the original complex, a diminished shoulder at 470 nm becomes evident. To determine the nature of the photoreaction, NMR spectra were taken before
and after irradiation with visible light. FIG. 1 shows the signal assigned to the meta hydrogens [Ru(bpy)2(4AP)2]Cl2 (ml). After irradiation, this signal decreased, and two new signals appeared at lower fields: one corresponding to the free ligand (m3), and the other corresponding to the aquo-4AP complex (m2), indicating photorelease of the 4AP. These two latter signals integrated for 0.30 and 0.27 of the initial signal, which corresponds to a photoreaction of 60%.
[00200] The redox potential of the couple Ru11VRu" for [Ru(bpy)2(4 AP)2]Cl2 measured in water is E = 0.76 V versus Ag/AgCl, which is consistent with the higher basicity of 4AP compared with that of pyridine. Thus, the redox and the photochemistry of [Ru(bpy)2(4AP)2]Cl2 is in total agreement with results obtained corresponding to the Ru(bpy)2XY family, X and Y being monodentate ligands. (See, e.g., E.S. Dodsworth et al., 1986, Chem. Phys. Lett., 124:152-158). The photoactivity of these compounds has been explained in terms of a reaction pathway that involves the transition between the MLCT state to a lower-energy d-d state, which promotes ligand release. There is a direct correspondence between the energy of the MLCT transition and the quantum yield of the photoreaction. For [Ru(bpy)2(4AP)CH3CN] + , the photoreaction yield is about ΦPR = 0.4. Since [Ru(bpy)2(4AP)2]Cl2 presents a red- shifted band, a lower photoreaction yield is expected. An estimate based on early experiments leads to an estimate of ΦPR = 0.02 at 473 nm.
EXAMPLE 14
[00201 ] Neurophysiological Activity of 4AP Photoreleased from
[Ru(bpy)2(4AP)2]Cl2. A standard setup for intracellular voltage measurements was used, and the medicinal leech Hirudo medicinalis was used to demonstrate photoreleased 4AP's neurophysiological activity. Hirudo medicinalis has a central nerve cord with several ganglia, each one containing about 400 neurons arranged in a known pattern. (W.-R. Schlue et al., 1980, J. Exp. Biol, 82:23-34). An entire ganglion was mounted on a dish. The transmembrane potential for a single cell (a neuron) in the ganglion was recorded by inserting inside the neuron a glass micropipet with a micrometer-sized end, filled with saturated aqueous KCl that acts as a luggin bridge for an Ag/AgCl electrode. Another Ag/AgCl electrode was used as a reference. The signal was taken with an AM-System 1600 amplifier, and the entire setup was covered
with a Faraday cage. A 12 bit A/D acquisition card was used to digitize the data using an ad-hoc program written in QuickBasic.
[00202 ] Low Ca2+-high Mg2+ saline solution (NaCl, 102 mM; KCl, 4 mM;
CaCb: 1 mM; and MgCb: 10 mM; Tris base, pH 5.4 adjusted to 7.4) was perfused through the dish. [Ru(bpy)2(4AP)2]Cb and the free ligand 4AP were injected in the mainstream at controlled times. A pulsed Xe lamp located under the dish was used to irradiate the solution. UV light was removed using a band-pass filter at 500 nm. FIG. 2 shows the behavior of the membrane potential recorded at one of the Retzius (Rz) cells in the ganglion. The upper graph in FlG. 2 shows the raw data, presenting periods of rest potential and very fast spikes (action potentials), produced by the changes in membrane ion permeabilities. The lower graph shows the instantaneous spiking frequency at each time.
[00203] After impaling the cell with an electrode, many experiments were performed on the same cell to ensure reproducibility. After 5000 seconds, the cell showed low activity, as can be seen at the left of the graph. At t = 5200 s, ~ 100 μM Ru(bpy)3Cb was added to the saline solution, without significant changes in activity. 300 seconds later, at 5500 s, a light flash was directed to the ganglion. The sudden increase in the frequency of the action potentials is mainly due to the temperature pulse, but after a short time the activity decreased to the basal level. After washing by perfusion, further irradiation (t = 6000 s) with a pulse showed a very similar pattern. At t = 6250 s, -100 μM [Ru(bpy)2(4AP)2]Cb was added to the saline and the activity remained unchanged. However, after a new light flash (t = 6400 s), sudden activity was recorded and it remained high after 300 s. A second light pulse at 6750 s promoted an even higher activity, which decreased only after cleaning perfusion with pure saline.
[00204] A similar frequency increase occurred when free 4AP was perfused onto the ganglion, thus demonstrating that the release of 4AP causes this maintained frequency increase. Calibration of the cell activity using solutions of 4AP showed that in each irradiation, 10-15 μM of 4AP were released from [Ru(bpy)2(4AP)2]Cb during the previous experiments. Neither toxicity nor a deleterious effect was observed on the neuron during the experiments. These results show that a neuronal response can be
stimulated using [Ru(bpy)2(4AP)2]Cb, an illustrative Photolabile Compound, to photorelease an organic molecule having neurophysiological activity.
EXAMPLE 15
(00205) Photorelease of TzGIy from [Ru(bpy)2(TzGly)(py)]Cl2. The procedure for the photorelease of TzGIy from [Ru(bpy)2(TzGly)(py)]Cl2 is analogous to that used for photorelease of 4AP from [Ru(bpy)2(4AP)2]Cl2 described above in Example 13, except that the irradiation light spot was very localized (diameter < 1 micron). Irradiation of [Ru(bpy)2(TzGly)(py)]Cl2 at 470 nm photoreleased TzGIy.
EXAMPLE 16
[ 00206] Neurophysiological Activity of TzGIy Photoreleased from
[Ru(bpy)2(TzGIy)(py)]Cl2 The neurophysiological activity of photoreleased TzGIy was assessed by performing experiments similar to those as set forth above in Example 14. Accordingly, the standard setup for intracellular voltage measurements was used, and the medicinal leech Hirudo medicinalis was used to demonstrate photoreleased TzGly's neurophysiological activity in the leech ganglion.
EXAMPLE 17
[00207] Synthesis of [Ru(bpy)2(PMe3)Cl)PF6. 520 mg of [Ru(bpy)2Cl2] were dissolved in 2O mL of a 1 : 1 mixture of methanol and water and refluxed under N2. 1.2 mL of trimethylphosphine I M in THF (Aldrich, 324108) were added with a syringe. The reaction was followed by UV-Vis spectroscopy. In some cases, more phosphine solution was added. Once the UV-Vis spectrum is stable, methanol and excess phosphine are distilled under vacuum with a rotavap. The resulting aqueous solution is filtered to remove any solids, and precipitated with excess of KPFβ over ice. The dark orange solid is washed three times with cold water and dried.
EXAMPLE 18
[00208] Synthesis of [Ru(bpy)2(PMe3)GlutH2](PF6)2. 1 10 mg of
[Ru(bpy J2(PMe3)CI)PFo were dissolved in 2 mL of acetone. A suspension of 200 mg chloride-containing anionic exchange resin DOWEX 2x8 was added, and stirred during
10 minutes. The resulting [Ru(bpy)2(PMe3)Cl]Cl solution was filtered. 500 mg of monosodium glutamate and 4.4 mL of NaOH IM were added, and heated during 3 hours. 1 mL of saturated KPFO was added, and the resulting precipitate was discarded. The solution was cooled to 0 0C and acidified with HCl 5M to pH2. [Ru(bpy)2(PMe3)GlutH2](PF6)2 precipitates upon addition of excess of KPFO. The yelowish-orange solid is washed three times with cold water and dried.
EXAMPLE 19
[00209] Photorelease of Glutamate from [Ru(bpy)2(PMe3)GIutH2] (PF6)2.
[Ru(bpy)2(PMe3)GlutH2](PF6)2 exhibits a bright orange color and presents a high solubility in water at pH>6 (as the deprotonated species [Ru(bpy)2(PMe3)Glu]). Its aqueous solutions present a strong metal to ligand charge-transfer band (MLCT band) at 450 nm, characteristic of this family of Ru polypyridines. Cyclic voltammetry of the compound dissolved in acetonitrile (Figure 15) shows three redox processes at 0.98, 1.46 and 1.56 V vs. NHE, corresponding respectively to a Ru(III)/Ru(II) couple of the original complex, and those of the complexes bearing oxidation products of glutamate.
[00210] Figure 16 (top) shows the UV- Vis spectrum of the complex, at pH=7 during irradiation with a 450±20 nm LED. As the photoreaction proceeds, the generation of the aquo complex was recorded to reach completion in about 4 minutes. The presence of two isosbestic points as well as a factor analysis performed on the spectra indicate that just two colored species are present in the solution, according to what is expected in a single photoaquation process. The spectrum of the photoproduct was found identical to that of the complex [Ru(bpy)2(PMe3)(H2θ)]2 +, which can be synthesized by refluxing the chloro complex in water. At pH=l 1 a similar behavior was observed, although in this case the product is the hydroxo complex [Ru(bpy)2(PMe3)(OH)]+.
[0021 1 ] The inset in Figure 16 (top) shows the yield of free glutamate generated by the photolysis obtained from the analysis of the spectra. The irradiance of the light source was calibrated using the known efficiency of the photolysis of [Ru(bpy)(Py)2]2+. The amount of photoreleased glutamate was fitted using a two- parameter single-exponential function: y=a[l-exp(-bx)] and the quantum yield (φPC) was obtained as a*b, adopting a value of 0.13 at pH=7 and 0.10 at pH= 1 1.
[00212 ] In order to estimate the uncaging time, a flash photolysis experiment was performed on a basic aqueous solution of [Ru(bpy)2(PMe3)Glu] using the second harmonic of a Nd-YAG laser (532 nm, 10 ns pulse). The results are shown in Figure 16 (bottom). The photocleavage occurs within the first 50 ns, being the fastest reported caged compound, to our knowledge. The fact that a tens of nanoseconds are required to complete the glutamate uncaging reaction is compatible with the observation that the excited state lifetime measured for a similar compound containing pyridine instead of glutamate is in the range of 10- 100 ns.
[00213] The photoreaction was also followed by NMR spectroscopy. In the aromatic region of the I H-NMR spectrum of the complex (Figure 17) it is possible to distinguish 16 signals corresponding to the bpy protons, which are found duplicated because the obtained material is a roughly 1 : 1 mixture of diasteromeres, resulting from the coordination of L-glutamate with the racemic mixture of Λ and Δ Ru-bpy enantiomeres. No efforts were done to separate the diasteromeres and both the chemical and biological tests suggest a similar behavior.
[00214] The aliphatic region corresponding to the glutamate moiety is depicted in the upper trace of Figure 18, where -NH2 protons appear at 4.50, 4.12, 4.00 and 3.57 ppm. The presence of these signals in a D2O solution, evidencing the absence of isotopic exchange in the complex, clearly indicates that the coordination of glutamate is done via the amine nitrogen, hampering further protonation. This behavior differs from that of free glutamate which, under the same conditions, exchanges rapidly D+ for H+. After 2 months in D2O at room temperature, no exchange is seen, also demonstrating that the compound is indeed inert.
[00215] After photolysis, many new signals appear in the aromatic region which correspond to the aquo complexes. At the same time, the analysis of the aliphatic region (Figure 18, bottom trace) clearly evidences the appearance of free glutamate signals. Coordinated -NH2 signals diminish upon irradiation, and the characteristic signals of methylene protons of free glutamate appear at 3.50, 2.30 and 2.04 and 1.94 ppm.
[00216] Further addition of glutamate did not produce new signals, but only an intensity enhancement of the existent ones, which proves that the unique aliphatic photoproduct is glutamate.
[00217] Biocompatibility tests were performed to evaluate the potential toxicity of the complex. 350 μM [Ru(bpy)2(PMe3)Glu], a concentration used for two-photon uncaging experiments, was incubated with living neocortical pyramidal neurons in mouse brain slices, and carefully monitored the morphology and electrophysiological properties of the neurons using two-photon microscopy and whole-cell patch recordings. After 1 hour of incubation, no detectable effects were observed, and the neurons remained healthy. This indicates that the complex does not modify membrane integrity or has deleterious effect on living neurons.
[00218] All patent applications, published patent applications, issued and granted patents, texts, and literature references cited in this specification are hereby incorporated herein by reference in their entirety to more fully describe the state of the art to which the present invention pertains.
[00219] As various changes can be made in the above methods and compositions without departing from the scope and spirit of the invention as described, it is intended that all subject matter contained in the above description, shown in the accompanying drawings, or defined in the appended claims be interpreted as illustrative, and not in a limiting sense.
EXAMPLE 20
A Ruthenium-Rhodamine Complex as an Activatable Fluorescent Probe
[00220] This example describes a caged fluorescent probe based on a ruthenium-bipyridine core, bearing a modified rhodamine as an active derivative of a labeling molecule. This complex behaves as a caged fluorescent probe, increasing its fluorescence around 6-fold upon visible light excitation. Thus, this example demonstrates the advantages of Photolabile Compounds comprising a labeling molecule or an active derivative thereof in increasing fluorescence of fluorescent molecule or an active derivative thereof, such as, rhodamine B, rhodamine 6G, RhodB- MAPN, Rhod-6G-MAPN, RhodB-MAMePy and Rhod-6G-MAMePy.
[00221 ] All reagents were purchased from Sigma-Aldrich and used as received.
Ru(bpy)2Cl2 was synthesized according to the literature using water as solvent (Viala, C; Coudret, C. Inorg. Chim. Acta 2006, 359: 984-989). UV-vis spectra were taken with a HP8453 diode-array spectrometer. NMR spectra were obtained using a 500 MHz Bruker AM-500. Fluorescence emission measurements were made with a PTl Quantamaster spectrofluorometer, corrected for the instruments response function. Rhodamine B was used as fluorescence standard of emission quantum yield (φ = 0.31 in aqueous solutions). Quantum yield of the complex was obtained directly from the ratio of the spectral areas, which present the same shape.
[00222] The photouncaging quantum yield measurements were performed with a Nd:YAG diode pumped solid state laser doubled to 473 nm with a constant power of 6.3 mW. The light was collimated and sent through an optical path of 1 cm into a fluorescence glass cuvette, with stirring. Total irradiation energy was measured using a Coherent Fieldmaster FM light meter with a visible light photodiode model SR45.
[00223 ) Microscopy of leech (Hirudo medicinalis) ganglia was performed in a custom-made setup for photoelectrophisiology equipped with a micromanipulator used to impale the neuron body with the ~1 μm tip diameter capillaries, and a CCD webcam as a registering device. An isolated leech ganglion from a segment between 7 and 14 was pinned down in a sylgard-coated, 35 mm Petri dish. Retzius cells were identified by their position, size, and firing behavior. Intracellular recordings were obtained with ~ 20 MΩ sharp capillary microelectrodes, a Neuroprobe 1600 (A-M Systems) amplifier and a A/D signal acquisition board at 1 kHz sampling rate and custom-made software. For iontophoretical injection of the dye the microelectrode was filled with recording solution to which 1 mM caged fluorescent dye (chloride form) was added. Square, biphasic pulses of 1 nA, 2 Hz were applied for less that 5 min.
[00224] Images of thin spectrophotometric flow cells and FIA capillaries were performed using a Nikon TS-100 with a fluorescence adapter. A consumer-electronics type compact digital camera (Casio Exilim EX-FClOO) focusing through a normal eyepiece through a custom adapter were use to register the videos at ISO 800 sensitivity. Videos and image analysis were done using public access ImageJ software. Activation of fluorescence was performed with a 405 nm 6 mW laser diode was
controlled with a pulse generator using a fast Reed relay to provide 20 ms light pulses. The laser beam was focused at the cell plane and monitored with an inverted microscope (Nikon TSlOO w/fluorescence adapter).
[00225] Syntheses. Rhodamine B-Methylaminopropionitrileamide (RhodB-
MAPN). 550 mg of rhodamine B. HCl were dissolved into 10 mL of dry 1 ,2 dichloroethane. The system was purged with N2 and 300 μL of phosphorus oxychloride were added. The mixture was refluxed during 5 h. The solvents were distilled under a vacuum and the solid was immediately dissolved in dry acetonitrile. 500 μL of triethylamine and 108 μL of N-methylaminepropionitrile were added, and the mixture was refluxed during 12 h. The solvent was removed under a vacuum, redissolved in water, filtered to eliminate any solids and precipitated by addition of excess KPF^. The dark red solid was washed several times with distilled water and dried over silica gel. Exchange of Cl for PFO in order to have a water soluble ligand was performed by stirring overnight a 1 : 1 acetone-water solution of RhodB-MAPN. PFO with Dowex 22 anionic resin and lyophilizing the obtained solution. RhodB-MAPN chloride salt is somewhat hygroscopic and must be stored in a moisture free environment.
[00226] Overall yield: 55%. 1 H NMR (Acetone-d6): IH δ 1.37 (t, 12H), 2.37
(t, 2H), 3.16 (s, 3H), 3.53 (t, 2H), 3.80 (m, 8H), 6.98 (d, 2H), 7.20 (dd, 2H), 7.37 (dd, 2H), 7.62 (m, I H), 7.77 (m, I H), 7.82 (t, 2H).
[00227] (Ru(bpy)2(L)Cl]PF6. For L = Rhodamine B-
Methylaminopropionitrileamide.
[00228] Twenty mg of RuCbPy)2Cl2 were suspended in 2 mL of a 2: 1
EtOHΛvater mixture and the suspension was heated to 80 0C until total dissolution. The formation of the [Ru(bpy ^(H2O)Cl]+ complex was determined by its absorption band at 490 nm (in water). After formation of the chloro-aquo complex, two equivalents of the RhodB-MAPN chloride salt were added, and the reaction was followed by TLC using silica plates and a mixture of 1 :1 :1 water/EtOH/nBuOH as eluent. The solution was heated at 80 0C during about 2 h, until no further TLC changes were observed. All the following procedures were done in darkness. The solution was filtered to remove any insoluble particles and the solvent was removed under a vacuum. The obtained oil
was redissolved in 4 mL of a 3: 1 acetone:methanol mixture and was precipitated by addition of excess THF.
[00229] The THF fraction containing unreacted ligand was discarded, and the precipitate was washed several times with THF, redisolved in water and precipitated with saturated KPF6. Yield: 26%. NMR (Acetone-d6): I H δ 1.35 (m, 12H), 2.98 (t, 2H), 3.10 (s, 3H), 3.40-3.55 (dm, 2H), 3.80 (m, 8H), 6.97 (d, 2H), 7.20-7.40 (m, 6H), 7.60 (d, I H), 7.67 (t, I H), 7.70-7.85 (m, 4H), 7.88-7.98 (m, 4H), 8.17 (t, IH), 8.30 (t, 1 H), 8.56 (dd, 2H), 8.69 (d, I H), 8.72 (d, IH), 9.55 (d, I H), 10.08 (d,l H).
[ 00230 J For L = Vinylacetonitrile (VACN). Twenty mg of Ru(bpy)2Cl2 were suspended in 2 mL of 96% EtOH, and the suspension was heated at 80 0C until total dissolution. The formation of the [Ru(bpy)2(H2θ)Cl]+ complex was determined by its band at 490 nm in water. 1.5 equivalents of VACN diluted in 4 mL of EtOH were added and the mixture was kept at 80 0C during 2 h. The solvent was removed by distilling under a vacuum, and the residue was redissolved in 2 mL of water, centrifuged to remove any solid, and precipitated with saturated KPFO. Yield 66%.
[00231 ] NMR (Acetone-d6): I H δ 3.65 (d, 2H), 5.13 (d, 2H), 5.75 (m, IH),
7.29 (t, I H), 7.32 (t, IH), 7.70 (d, IH), 7.81 (t, I H), 7.92 (3t, 3H), 7.97 (d, I H), 8.20 (t, 1 H), 8.31 (t, 1 H), 8.56 (d, 1 H), 8.60 (d, 1 H), 8.69 (d, 1 H), 8.74 (d, 1 H), 9.53 (d, 1 H). 10.08 (d, I H).
[00232] Rhodamines are useful fluorophores, due to their emission quantum yield approaching unity and their high resistance to photobleaching. They are comprised of a xanthene moiety that provides the fluorescence and a benzoic acid which modulates their spectral properties. Scheme I A shows the structure of rhodamine B which was chosen as the starting point for this example.
Scheme 1. (A) Rhodamlne B; (B) RhodB-APN, In Its Fluorescent Form; (C) RhodB-APN, In Its Spyrolactame Nonfluorescent Form; (D) RhodB-MAPN
[00233 ] Ruthenium-bipyridyl complexes can easily be coordinated to donor nitrogens such as those of the aliphatic amines, pyridines, imines, and even nitriles, but not to those of anilines, not even primary ones. Diethylanilines of the rhodamine B do not form stable complexes with Ru centers and although carboxylates can be coordinated to Ru-bpy cores, such complexes are easily hydrolyzed in aqueous solutions at room temperature.
[00234] Given these properties, the chemical structure of rhodamine B was modified by adding a "sticky tail" in order to coordinate the fluorescent molecule to the metal center. In a first attempt to synthesize a modified rhodamine bearing a coordinating group, carboxilate was amidated with aminopropionitrile, using the Adamczyk procedure (Adamczyk, M. J. Bioorg. Med Chem Lett. 2000, 10: 1539— 1541). The obtained compound is RhodB-APN, indicated in scheme IB. However, although this ligand can be coordinated to Ru-bpy complexes through the nitrile, it undergoes isomerization to the cyclic spirolactame form at physiological pH (scheme 1C) becoming nonfluorescent. Rhodamine 6G can be modified similarly to the rhodamine B, described above.
[00235] A secondary amide cannot isomerize to the cyclic form, thus RhodB-
MAPN, obtained through an amidation of rhodamine B acid chloride with aminopropionitrile (Scheme I D) presents a very high, yellow fluorescence while its terminal nitrile allows its coordination to a Ru-bpy center.
[00236] The complex cis-[Ru(bpy)2(L)Cl]PF6> L ) RhodB-MAPN was obtained as a dark purple solid, slightly soluble in water and very soluble in acetone. Due to its very high molar absorptivity, its water solubility is high enough for most experimental situations. For the FIA imaging experiments it was used in this form. A much more soluble chloride salt, which is better for the biological experiments, was prepared by means of batch ion exchange with Dowex 22-Chloride resin in 1 : 1 acetone-water. The salt was used in biological experiments. The solutions of the complex present a weak yellowish fluorescence. Preliminary studies showed that the complex is light sensitive, increasing its fluorescence when irradiated in aqueous, ethanol or acetone solutions.
[00237] Figure 19 (top) shows the aliphatic region of the 1H NMR spectrum of the Ru complex bearing RhodB-MAPN as a ligand, showing the expected number of signals and integrations for a coordinate RhodB-MAPN. The double multiplet at 3.40- 3.55 ppm (labeled a') corresponds to the methylene group closest to the coordination point. The triplet at 2.98 ppm (b') and the singlet at 3.10 ppm (c') correspond to the other methylene and the N-methyl group respectively. Similar signals were obtained if just the aminonitrile tail is coordinated to the Ru-bpy core. After 5 min of irradiation inside the NMR tube using a 450 nm LED (middle trace), new signals appear at 2.37, 3.16, and 3.53 ppm, due to the release of the RhodB-MAPN ligand. These three signals exactly match with those of the free ligand (labeled a, c, and b, respectively, bottom trace). The four ethyl groups of RhodB-MAPN are not totally equivalent, and they are seen as a multiplet (-CH2-) or broad triplet (-CH3) and present little change after irradiation since they are far from the coordination center.
[00238] In the aromatic region the expected number of signals and integrations for a nonsymmetric cis complex bearing RhodB-MAPN were obtained. After photolysis, the signals from the free RhodB-MAPN at 6.98, 7.20, 7.37, 7.62, 7.77, and 7.82 appear at the same chemical shifts as those from aquo-complex [Ru(bpy)2(H2O)Cl]+.
[00239] Dilute aqueous solutions of [Ru(bpy)2(RhodB-MAPN)Cl]+ present weak fluorescence with a maximum at 592 nm (excitation 518 nm).
[00240] Figure 20 depicts the emission spectra of the complex during irradiation. The maximum and the shape of the initial emission spectrum is the same as
that of the free ligand RhodB-MAPN but the emission quantum yield is much lower, around φt = 0.04. Quantum yields are easily calculated integrating the spectral areas. After irradiation with a 473 nm laser, RhodB-MAPN is released and the solution increases its fluorescence up to 6 fold, to φt = 0.24. The inset shows the maxima of the spectra as a function of the irradiation time.
[00241 ] The quantum yield of rhodamine photorelease was calculated after the analysis of fluorescence emission data during photouncaging at 473 nm. A complete spectrum was obtained once per second. Absorption of light by the complex [Ru(bpy)2(RhodB-MAPN)Cl]+ yields the aquo complex [Ru(bpy)2(H2O)Cl]+ and free RhodB-MAPN. In each irradiation period the amount of aquo complex and free RhodB-MAPN generated is given by the following: on = δtlφw(l - l0"Abs71AbsR/Abs-r where δt is the irradiation period, I the light intensity in moles of photons per second, φpu is the quantum yield of photouncaging, AbsR is the absorbance of the photoactive species [Ru(bpy)2(RhodB-M APN)Cl]+ at 473 nm and Absγ is the total absorbance of the irradiated solution. By means of finite element calculation of the former equation a photouncaging quantum yield of φpu = 0.12 at 25 0C was calculated. This value is in good agreement with the reported quantum yields for similar complexes.
[00242] The origin of this quenching can be attributed to the presence of the nearby ruthenium-bipyridine moiety, which presents an MLCT transition which overlaps with that of the rhodamine emission. However, direct inspection of the absorption bands of this complex at such a wavelength range is impossible, due to the very high molar extinction of the fluorescent ligand (ca., 105 M"'cnϊ'), which obscures any absorption due to the metal center.
[00243 ] In order to measure this absorption, an analogous complex was synthesized using vinylacetonitrile (VACN) instead of RhodB-MAPN. It is recognized that the energy of the MLCT band of the Ru-bpy complexes are strongly dependent on the nature and basicity of the ligands near the Ru center but almost independent of the farther fragments. The complex [Ru(bpy)2(VACN)Cl]+ shows a typical MLCT band, which is centered around 460 nm and extends more than 100 nm to the low energy region, overlapping with the emission spectra of the rhodamine ligand. This absorption
is enough to explain the observed quenching. This analog complex photoreleases VACN with even a higher quantum yield of φpu = 0.21.
[00244] This example provides an activatable fluorescent probe with surprising sensitivity in the visible light region. It increases its intrinsic fluorescence up to 6-fold after blue light irradiation. This probe is physiologically friendly and can be injected into living cells - even excitable ones like neurons - with no sign of acute toxicity in short-term (- 2 h) experiments. The probe was used to image the laminar flow inside a thin spectrophotometric flow cell and to visualize the parabolic-shaped flow in a FIA capillary. This probe reveals not only the broadening of the plume, but also the memory effect due to accumulation of analyte near the walls, where the flow velocity approaches zero. In brief, the complex [Ru(bpy)2(RhodB-MAPN)Cl]Cl is a surprisingly effective tool to image any kind of systems where manipulation of fluorescence is required.
[00245] [Ru(bpy)2(Rhod6G-MAPN)Cl]Cl and [Ru(bpy)2(RhodB-
MAMePy)Cl] were made using the procedures described herein and exhibited results similar to those described herein for [Ru(bpy)2(RhodB-MAPN)Cl]Cl, thus illustrating the applicability of the light antenna concept to the genus of Photolabile Compounds of Formulas I, II, III, V, VI, VII and VIII described herein, wherein L2 comprises a labeling molecule or an active derivative thereof.
[00246] The same surprising properties demonstrated in this example for
[Ru(bpy)2(RhodB-MAPN)Cl]Cl are expected to apply to the Photolabile Compounds of Formulas I, II, III, V, VI, VII and VIII described herein, wherein L2 comprises a labeling molecule or an active derivative thereof.
Claims
1. A compound of Formula V :
V wherein: each L1 is independently an organic molecule having:
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl;
L2 is (R9)3P, (R9O)3P, or L1 and m is 2; or L2 is -CN and m is 1; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -C1-C18 alkyl, -C3-C8 cycloalkyl, or phenyl; wherein when L2 is P(phenyl)3 or a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of P(phenyl)2, each phenyl is independently substituted with -Ci-Ci8 alkyl, -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyl)- amino, -(Ci-Ci8 alkyl)-thio, -CO2Y, -C(=0)Y, -C(=0)NY2, -NH2, -NO2, -OH, or -SH, and
R1 to R4 are independently -H, -Ci-Ci8 alkyl; -NH25-(Ci-Ci8 alkyl)-O-(Ci-Ci8 alkyl), -OC(O)(Ci-Ci8 alkyl), -(Ci-Ci8 alkyl)-0H, aryl, -(Ci-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyl)- amino, -(Ci-Ci8 alkyl)-thio, -CO2Y, -C(=0)Y, -C(=0)NY2, -NO2, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups; wherein when L2 is not P(phenyl)3, R1 to R4 are independently -H, -(Ci-Ci8 alkyl)- OH, aryl, -(Ci-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyl)-amino, -(Ci-Ci8 alkyl)-thio, -CO2Y, -C(=0)Y, -C(=0)NY2, -NO2, -OH, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups, wherein at least one of R1 to R4 is not H;
X is Cl", F", Br ", I", PF6 ", CF3SO3 ", (Ci-Ci8 alkyl)-CO2 ", or (Ci-Ci8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-Ci8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
2. The compound of claim 1, wherein the organic molecule is L1 is 4-aminopyridine.
3. The compound of claim 1, wherein the organic molecule is (RS)-(tetrazol-5-yl) glycine.
4. The compound of claim 1, wherein the organic molecule is (tetrazol-5-yl) AMPA.
5. The compound of claim 1, wherein the organic molecule is nicotine or caffeine.
6. The compound of claim 1, wherein the organic molecule is serotonin, epinephrine, norepinephrine, or dopamine.
7. The compound of claim 1, wherein the organic molecule is adenosine 5'-diphosphate ADP, adenosine 5'-triphosphate ATP, adenosine 5'-monophosphate AMP, cyclic adenosine 5'-diphosphate ribose, or adenosine 3', 5'-cyclic monophosphate.
8. The compound of claim 1, wherein the organic molecule is aminobutyric acid or L- glutamic acid, or methyl-D-aspartic acid.
9. A method for releasing an organic molecule from a Photolabile Compound, comprising: exposing a compound of claim 1 to light under conditions sufficient to release the organic molecule.
10. The method of claim 9, wherein the light comprises a wavelength of about 300 to about 500 nm.
11. The method of claim 9, wherein the light comprises a wavelength of about 300 to about 360 nm.
12. The method of claim 9, wherein the light comprises a wavelength of about 450 to about 500 nm.
13. The method of claim 9, wherein L2 is L1.
14. The method of claim 9, wherein the light comprises visible light or infrared light.
15. The method of claim 9, wherein the exposing occurs at a temperature from about O0C to about 15O0C.
16. A method for making an organic molecule bioavailable to a subject, comprising:
(a) administering a compound of claim 1 to the subject; and
(b) exposing the compound to light under conditions sufficient to release the organic molecule from the compound, wherein the organic molecule has:
(i) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(ii) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru; (iii) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(iv) an -NH2 group whose nitrogen atom forms a bond with Ru;
(v) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(vi) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl; or
(vii) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl.
17. The method of claim 16, wherein the light is sunlight, photo-optic light, or laser light.
18. The method of claim 16, wherein the light is visible light or infrared light.
19. The method of claim 16, wherein the exposing occurs at the site of a tumor, cancer, or neoplasm.
20. The method of claim 16, wherein the exposing occurs at the site of a blood dyscrasia.
21. The method of claim 16, wherein the administering occurs intravenously, topically, intradermally, intramuscularly, transdermally, subcutaneously, intranasally, parenterally, intrathecally, vaginally, rectally, colorectally, orally, intracranially, retroorbitally, intrasternally, or by injection.
22. The method of claim 16, wherein the administering is via a transdermal patch.
23. A composition comprising a compound of claim 1 and a physiologically acceptable carrier, vehicle, diluent, or excipient.
24. A vessel containing a compound of claim 1.
25. The vessel of claim 24, further containing a biological sample.
26. The vessel of claim 25, wherein the biological sample is an organ, tissue, cell, or hair sample.
27. The vessel of claim 26, wherein the tissue is neuronal tissue.
28. The vessel of claim 26, wherein the cell is a neuronal cell.
29. The vessel of claim 26, wherein the tissue or cell is a tumor, cancer, or neoplastic tissue or cell.
30. The vessel of claim 25, wherein the biological sample is a body fluid sample.
31. The vessel of claim 30, wherein the body fluid sample is blood, serum, plasma, lymph, saliva, sputum, tears, semen, or urine.
32. A kit comprising a compound of claim 1 and instructions for use of the compound.
33. A method of treating disorders and diseases in a subject, comprising
(a) administering a therapeutically effective amount compound of claim 1 to the subject; and
(b) exposing the compound to light under conditions sufficient to release the organic molecule from the compound, wherein the organic molecule has:
(i) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(ii) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(iii) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(iv) an -NH2 group whose nitrogen atom forms a bond with Ru;
(v) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(vi) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl; or
(vii) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl.
34. The method of claim 33, wherein the disorders and diseases are neurological, neurophysiological, or neuromuscular diseases and conditions.
35. The method of claim 34, wherein the neurological, neurophysiological, or neuromuscular disease and condition is epilepsy.
36. The method of claim 34, wherein the neurological, neurophysiological, or neuromuscular disease and condition is multiple sclerosis.
37. The method of claim 34, wherein the disorder is diaphoresis.
38. The method of claim 34, wherein the disease is cancer.
39. A method for enhancing the solubility of an organic molecule, comprising complexing an organic molecule to a photolabile caging group to form a compound of claim 1; wherein exposing the compound to light under sufficient conditions releases the organic molecule from the compound, and wherein the organic molecule has:
(i) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(ii) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(iii) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(iv) an -NH2 group whose nitrogen atom forms a bond with Ru;
(v) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(vi) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl; or
(vii) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl.
40. A compound of Formula VI :
VI wherein: each L1 is independently an organic molecule having: (a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl;
L2 is P(phenyl)3, wherein each phenyl is independently substituted with -C1-C18 alkyl, -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyl)-amino, -(Ci-Ci8 alkyl)-thio, - CO2Y, -C(O)Y, -C(O)NY2, -NH2, -NO2, -OH, or -SH^or L2 is a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -Ci-Ci8 alkyl, -C3-C8 cycloalkyl, or phenyl;
R1 to R4 are independently -H, -Ci-Ci8 alkyl; -NH2, -(Ci-Ci8 alkyl)-O-(Ci-Ci8 alkyl), -OC(O)(Ci-Ci8 alkyl), -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyl)-amino, - (Ci-Ci8 alkyl)-thio, -CO2Y, -C(O)Y, -C(O)NY2, -NO2, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups;
X is Cl", F", Br ", I", PF6 ", CF3SO3 ", (Ci-Ci8 alkyl)-CO2 ", or (Ci-Ci8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-Ci8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
41. The compound of claim 40, wherein L2 is P(phenyl)3 and each phenyl is independently substituted at the 3 or 4 position.
42. The compound of claim 40, wherein L is P(phenyl)3 and at least one phenyl is substituted with -(Ci-Ci8 alkyl)-OH.
43. The compound of claim 40, wherein L2 is P(phenyl)3 and each phenyl is substituted with -(Ci-Ci8 alkyl)-OH.
44. The compound of claim 40, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -COOH.
45. The compound of claim 40, wherein L2 is P(phenyl)3 and each phenyl is substituted with -COOH.
46. The compound of claim 40, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -OH.
47. The compound of claim 40, wherein L2 is P(phenyl)3 and each phenyl is substituted with -OH.
48. The compound of claim 40, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -NH2.
49. The compound of claim 40, wherein L2 is P(phenyl)3 and each phenyl is substituted with -NH2.
50. The compound of claim 40, wherein L2 is P(phenyl)3 and at least one phenyl is substituted with -NO2.
51. The compound of claim 40, wherein L2 is P(phenyl)3 and each phenyl is substituted with -NO2.
52. A compound of Formula VII :
(a) a 5-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(b) a 6-membered monocyclic aromatic ring, one of the ring's members being a nitrogen atom that forms a bond with Ru;
(c) an 8-10-membered bicyclic ring, one of the bicyclic rings being aromatic and having a nitrogen atom member that forms a bond with Ru;
(d) an -NH2 group whose nitrogen atom forms a bond with Ru;
(e) a -COOH group, one of whose oxygen atoms forms a bond with Ru;
(f) a -PR2 group whose phosphorus atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl; or
(g) an -SR group whose sulfur atom forms a bond with Ru, wherein R is independently -H, -C1-C18 alkyl, or aryl;
L2 is (R9)3P, (R9O)3P, or L1, wherein each R5 is independently -Ci-Ci8 alkyl, -C3-C8 cycloalkyl, or phenyl, m is 2, and L2 is not P(phenyl)3; or L2 is -CN and m is l;_or L2 is a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L2 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -Ci-Ci8 alkyl, -C3-C8 cycloalkyl, or phenyl;
R1 to R4 are independently -H, -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyl)-amino, -(Ci-Ci8 alkyl)-thio, -CO2Y, -C(=0)Y, -C(K))NY2, -NO2, -OH, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups, wherein at least one of R1 to R4 is not H;
X is Cl", F", Br ", I", PF6 ", CF3SO3 ", (Ci-Ci8 alkyl)-CO2 ", or (Ci-Ci8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-Ci8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
53. The compound of claim 52, wherein L2 is P(methyl)(phenyl)2.
54. The compound of claim 52, wherein L2 is P(methyl)2(phenyl).
55. A compound of Formula VIII:
VIII wherein: each L1 is independently a labeling molecule or an active derivative thereof connected to Ru through the phosphorous atom of (R9)2P or (R9O)2P and m is 2; or L1 is a labeling molecule or an active derivative thereof connected to Ru through the nitrogen atom of: NHR9, N(R9)2, pyridyl, C(R9)=NH, C(R9)=NR9 cyclic aliphatic amine group or nitrile and m is 2; wherein each R9 is independently -Ci-Ci8 alkyl, -C3-C8 cycloalkyl, or phenyl;
L2 is Cl-, phosphine, OH2, or pyridine and m is 2; or L2 is -CN and m is 1;
R1 to R4 are independently -H, -C1-C18 alkyl; -NH2, -(Ci-Ci8 alkyl)-O-(CrC18 alkyl), -OC(O)(Ci-Ci8 alkyl), -(Ci-Ci8 alkyl)-OH, aryl, -(Ci-Ci8 alkyl)-oxy, -(Ci-Ci8 alkyl)-amino, - (Ci-Ci8 alkyl)-thio, -CO2Y, -C(=0)Y, -C(K))NY2, -NO2, or -SH, or R1 and R2 and/or R3 and R4 can combine to form a carbocyclic ring substituted by one or more oxo groups;
X is Cl", F", Br ", I", PF6 ", CF3SO3 ", (CrCi8 alkyl)-CO2 ", or (CrCi8 alkyl)-SO3 "; and
Y is selected from the group consisting of -H, -Ci-Ci8 alkyl, aryl, -(Ci-Ci8 alkyl)-aryl, -C3-C8 cycloalkyl, heteroaryl, and heterocyclyl.
56. The compound of claim 55, wherein the fluorescent molecule contains a -CN group whose nitrogen atom forms a bond with Ru.
57. The compound of claim 55, wherein the fluorescent molecule contains rhodamine.
58. The compound of claim 55, wherein the fluorescent molecule contains fluorescein.
59. The compound of claim 55, wherein the fluorescent molecule contains iodeosin.
60. A method for releasing a fluorescent molecule from a Photolabile Compound, comprising: exposing a compound of claim 55 to light under conditions sufficient to release the fluorescent molecule.
61. The method of claim 60, wherein the light comprises a wavelength of about 300 to about 500 nm.
62. The method of claim 60, wherein the light comprises a wavelength of about 300 to about 360 nm.
63. The method of claim 60, wherein the light comprises a wavelength of about 450 to about 500 nm.
64. The method of claim 60, wherein the light comprises visible light or infrared light.
65. The method of claim 60, wherein the exposing occurs at a temperature from about O0C to about 15O0C.
66. The method of any one of claims 1, 40, 52 or 55 wherein L2 is a labeling molecule or a derivative thereof.
67. The method of claim 66, wherein L2 is Rhodamine B-Methylaminopropionitrileamide (RhodB-MAPN), Rhodamine 6G-Methylaminopropionitrileamide (Rhod6G-MAPN), RhodB-MAMePy, Rhod6G-MAMePy or a salt therof.
68. A compound selected from the group consisting of: [Ru(bpy)2(RhodB-MAPN)Cl]Cl, [Ru(bpy)2(Rhod6G-MAPN)Cl]Cl, [Ru(bpy)2(RhodB-MAMePy)Cl]Cl.
69. A compound selected from the group consisting of: [Ru(bpy)2(RhodB-MAPN)Cl]Z, [Ru(bpy)2(Rhod6G-MAPN)Cl]Z, [Ru(bpy)2(RhodB-MAMePy)Cl]Z, wherein Z is an anion.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10792793A EP2445917A4 (en) | 2009-06-26 | 2010-06-28 | Photolabile compounds |
JP2012517826A JP5902618B2 (en) | 2009-06-26 | 2010-06-28 | Photolabile compound |
US13/336,643 US9744236B2 (en) | 2009-06-26 | 2011-12-23 | Photolabile compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22092209P | 2009-06-26 | 2009-06-26 | |
US61/220,922 | 2009-06-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/336,643 Continuation-In-Part US9744236B2 (en) | 2009-06-26 | 2011-12-23 | Photolabile compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010151879A1 true WO2010151879A1 (en) | 2010-12-29 |
WO2010151879A9 WO2010151879A9 (en) | 2011-03-24 |
Family
ID=43386928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/040220 WO2010151879A1 (en) | 2009-06-26 | 2010-06-28 | Photolabile compounds |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2445917A4 (en) |
JP (2) | JP5902618B2 (en) |
WO (1) | WO2010151879A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096836A1 (en) * | 2011-12-23 | 2013-06-27 | The Trustees Of Columbia University In The City Of New York | Photolabile compounds |
CN103648644A (en) * | 2011-06-06 | 2014-03-19 | 尤米科尔股份公司及两合公司 | New complexes of ruthenium, method for their preparation, and their application in olefin metathesis reactions |
US9273032B2 (en) | 2003-12-29 | 2016-03-01 | The Trustees Of Columbia University In The City Of New York | Photolabile compounds |
CN112300779A (en) * | 2019-07-31 | 2021-02-02 | 华南师范大学 | Polymerization-enhanced electrochemical luminescence probe and preparation method and application thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5902618B2 (en) * | 2009-06-26 | 2016-04-13 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Photolabile compound |
JP2016504930A (en) * | 2012-12-19 | 2016-02-18 | ユニバーシティー オブ サザン カリフォルニア | Photoactivatable molecules that photoinducedly modulate the activity of electroexcitable cells and uses thereof |
US11703800B2 (en) | 2018-03-21 | 2023-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for temporal and spatial multiplexing of spatial light modulators and systems for same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0414730B1 (en) * | 1988-03-31 | 1999-12-15 | Randell L. Mills | Chemical Compounds and pharmaceutical compositions capable of releasing a drug |
US6750357B1 (en) * | 1999-06-25 | 2004-06-15 | Syngen, Inc. | Rhodamine-based fluorophores useful as labeling reagents |
US20080176940A1 (en) * | 2003-12-29 | 2008-07-24 | The Trustees Of Columbia University In The City Of New York | Photolabile Compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5902618B2 (en) * | 2009-06-26 | 2016-04-13 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Photolabile compound |
-
2010
- 2010-06-28 JP JP2012517826A patent/JP5902618B2/en not_active Expired - Fee Related
- 2010-06-28 WO PCT/US2010/040220 patent/WO2010151879A1/en active Application Filing
- 2010-06-28 EP EP10792793A patent/EP2445917A4/en not_active Withdrawn
-
2015
- 2015-11-24 JP JP2015229061A patent/JP2016041746A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0414730B1 (en) * | 1988-03-31 | 1999-12-15 | Randell L. Mills | Chemical Compounds and pharmaceutical compositions capable of releasing a drug |
US6750357B1 (en) * | 1999-06-25 | 2004-06-15 | Syngen, Inc. | Rhodamine-based fluorophores useful as labeling reagents |
US20080176940A1 (en) * | 2003-12-29 | 2008-07-24 | The Trustees Of Columbia University In The City Of New York | Photolabile Compounds |
Non-Patent Citations (2)
Title |
---|
"PubChem lodeosin", 26 March 2005 (2005-03-26), XP008149173, Retrieved from the Internet <URL:http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=458734&loc=es_rss#Synonyms> [retrieved on 20100818] * |
See also references of EP2445917A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273032B2 (en) | 2003-12-29 | 2016-03-01 | The Trustees Of Columbia University In The City Of New York | Photolabile compounds |
US9688708B2 (en) | 2003-12-29 | 2017-06-27 | The Trustees Of Columbia University In The City Of New York | Photolabile compounds |
US9744236B2 (en) | 2009-06-26 | 2017-08-29 | The Trustees Of Columbia University In The City Of New York | Photolabile compounds |
CN103648644A (en) * | 2011-06-06 | 2014-03-19 | 尤米科尔股份公司及两合公司 | New complexes of ruthenium, method for their preparation, and their application in olefin metathesis reactions |
WO2013096836A1 (en) * | 2011-12-23 | 2013-06-27 | The Trustees Of Columbia University In The City Of New York | Photolabile compounds |
CN112300779A (en) * | 2019-07-31 | 2021-02-02 | 华南师范大学 | Polymerization-enhanced electrochemical luminescence probe and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2012531443A (en) | 2012-12-10 |
JP5902618B2 (en) | 2016-04-13 |
EP2445917A4 (en) | 2013-01-02 |
WO2010151879A9 (en) | 2011-03-24 |
EP2445917A1 (en) | 2012-05-02 |
JP2016041746A (en) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9744236B2 (en) | Photolabile compounds | |
US9688708B2 (en) | Photolabile compounds | |
JP2016041746A (en) | Photolabile compound | |
You et al. | Phosphorescent sensor for biological mobile zinc | |
US11912999B2 (en) | Aptamer conjugates with N-heterocyclic carbene metal complexes for targeted drug delivery | |
CN101948488B (en) | Ruthenium-selenium coordination compound and application thereof in preparing fluorescent probe and antineoplastic medicine | |
Bashiri et al. | Potent antiproliferative active agents: novel bis Schiff bases and bis spiro β-lactams bearing isatin tethered with butylene and phenylene as spacer and DNA/BSA binding behavior as well as studying molecular docking | |
WO2008031017A9 (en) | Supramolecular metallic complexes exhibiting both dna binding and photocleavage | |
CN106572991A (en) | Texaphyrin-PT(IV) conjugates and compositions for use in overcoming platinum resistance | |
CN110467633B (en) | Main group metal complex and preparation method and application thereof | |
US20050249669A1 (en) | Quadruplex stabilizer | |
CN114940685B (en) | Visual fluorescent anti-tumor drug and application thereof in anti-tumor field | |
CN103965175A (en) | 4-(substituted phenylamino)quinazoline compounds, and preparation method and application thereof | |
Churusova et al. | Pincer–dipeptide and pseudodipeptide conjugates: Synthesis and bioactivity studies | |
Dewangan et al. | Unsymmetrically bi-functionalized 1, 1′-ferrocenyl bi-hydrazone and hydrazone-cyanovinyl molecules as fluorescent “on–off” sensor: Synthesis, cytotoxicity and cancer cell imaging behavior | |
Neumann et al. | Rhenium fac-Tricarbonyl Bisimine Chalcogenide Complexes: Synthesis, Photophysical Studies, and Confocal and Time-Resolved Cell Microscopy | |
CN116096372A (en) | EGFR inhibitor, preparation method and pharmaceutical application thereof | |
Russo et al. | Light in a Heartbeat: Bond Scission by a Single Photon above 800 nm | |
US8173620B2 (en) | BHQ-caged nucleotide probes photolysable by two-photon excitation | |
EP3801643A1 (en) | Near-ir activatable fluorescent small molecules with dual modes of cytotoxicity | |
CN115073439B (en) | Pyrimidine compound and medical application thereof | |
CZ160999A3 (en) | Novel knoevenagel condensation products, processes of their preparation and their use | |
US20220306665A1 (en) | Reagent for measuring oxygen concentration in cell and tissue | |
Chen et al. | Cationic cyclometalated platinum (II) complexes of metformin with self-assembly and AIE behavior as nuclear and mitochondrial targeted anticancer theragnostic agents | |
Mvelase | Syntheses of (pyridyl) pyrazine carboxamide palladium (II) complexes, their DNA/BSA interactions, and cytotoxicity studies. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10792793 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012517826 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010792793 Country of ref document: EP |